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CHAPTER 1
General introduction
8  |  CHAPTER 1
Stem CellS
Bovine non-identical twins that share the same placenta and circulation before birth, can keep 
producing a pool of blood cells that are a genetic mix of themselves as well as their brother’s.1, 2 
Although not immediately recognized as such, it was as early as 1945 that this observation by 
Owen already suggested that the bone marrow hosted cells from early developmental origin 
that could produce more specialized progeny (blood cells) for a prolonged period through-
out life. How else would it be possible that one of the twins produced cells that genetically 
“belonged” to his twin brother while the two had lost physical connection long ago? Despite 
these early suggestions, it took nearly 20 years before Mc Culloch and Till discovered a portion 
of bone marrow cells that could renew themselves extensively without losing their ability to 
produce a variety of other organ-specific cells.3, 4 These two characteristics (self-renewal and 
differentiation capacity into more specialized cell types) have now been widely accepted as 
the requirements for calling a cell a “stem cell”. As one can imagine, these characteristics auto-
matically pose such cells as ideal candidates for both cellular and organ replacement therapies. 
However, before going into the therapeutic possibilities, it is important to gain some insight into 
different classes of stem cells. The most widely used classification of stem cells is based upon 
their origin and separates two groups of cells: “Embryonic stem cells (ESC)” and “adult stem cells”.
Four to 5 days after fertilization, the early stage embryo consists of around 150 cells called the 
blastocyst. ESC from the inner mass of this blastocyst can be isolated and expanded indefini-
tely under strict culture circumstances and supported by a feeder layer of mouse embryonic 
fibroblasts.5 The unique property of these cells lies within the capacity to develop into all three 
germ layers: Endo-, ecto-, and mesoderm, a phenomenon best described as pluripotency. Af-
ter making the first transition to these germ layers, the cells become more restricted in their 
developmental potential and differentiate within germ layer boundaries to more specialized 
cell types, resembling the natural process of organogenesis. 
On the other hand, adult or somatic stem cells are cells that have already differentiated further 
down the path of development. Although still capable of differentiating into multiple speci-
alized cell types, these cells are restricted by germ layer boundaries and as such have already 
been programmed to become and replace cells specific to their biological environment or 
function. Because of this limitation, adult stem cells are referred to as being multi- but not 
pluripotent. Adult stem cells reside in the adult body in various places where they play a role 
in tissue homeostasis and repair, but are usually low in number and difficult to isolate and ex-
pand. One least imaginative example of tissue-specific stem cells is epidermal stem cells that 
reside in the skin where they are responsible for the fast turnover and accelerated production 
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RegeneRative mediCine
Because of the above described properties of pluri- and multipotency, stem cells have con-
tributed significantly to the field of “regenerative medicine”. As the name already suggests, 
this discipline aims to heal disease by regeneration of damaged tissue. Adult stem cells carry 
this property by nature, as these cells are biologically destined to repair, for example, skin6, 
gut7, and liver8, or to replace blood cells9 throughout life. However, there is a range of disea-
ses where endogenous repair fails including diabetes, Parkinson’s, or coronary and peripheral 
artery disease. In this respect, it may prove beneficial to isolate, expand, and transplant adult 
stem cells to induce increased healing capacity. This approach carries great advantage because 
the cells are isolated from the patient and are thus not rejected through immunogenicity. It 
has even been reported that mesenchymal stem cells, which can be isolated from the bone 
marrow, may alleviate immune reaction.10 However, most adult stem cells can prove difficult 
to isolate and expand, and may not be able to restore a complete spectrum of different cells 
needed for functional recovery. Moreover, these transplanted cells may not be able to survive 
in the diseased, often hostile environment after transplantation. Lastly, the cells may not inte-
grate into the host tissue and as such cannot contribute to functional improvement.
Conversely, ESCs can be expanded in culture rapidly thus providing a possible “off-the-shelf” 
therapeutic. However, these cells must be directed into the desired cell type before transplan-
tation to prevent uncontrolled differentiation and subsequent malignant potential if residual 
undifferentiated cells are present. In this respect, success has been achieved by driving ESCs 
towards brain and skin derivates as well as pancreatic cells or muscle, bone and cardiac li-
neages.11 However, one major challenge remains eliminating undesired cell types as well as 
undifferentiated cells. A second hurdle is that, similar to organ transplants, the cells are from 
a different genetic background and may provoke immunorejection. Despite these problems 
and considerable ethical debate about the derivation of these cells, a clinical trial using ESC-
derived oligodendrocyte precursor cells to treat spinal cord injury has just been initiated.12
Stem Cell tReatment foR CaRdiovaSCulaR diSeaSe
Annually, more people die from cardiovascular diseases (CVDs) than from any other cause, re-
presenting 30% of all global deaths (http://www.who.int, factsheet 317). Thus, despite a wide 
variety of treatments ranging from medication to heart transplantation, there clearly remains a 
great need for new therapeutic approaches. In 2001, Orlic and colleagues reported that trans-
plantation of bone marrow stem cells in the damaged mouse heart not only yielded an impro-
vement in function, but also new cardiomyocytes (cardiac muscle cells) that originated directly 
from the transplanted cells.13 For reasons described above, the observation that bone marrow 
cells were capable of differentiation into cardiomyocytes was heavily discussed and refuted 
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by, among others14, our laboratory.15 Despite these conflicting reports, it was Orlic’s study that 
raised tremendous enthusiasm for stem cell therapy for heart disease and subsequent ultra-
rapid initiation of clinical trials using bone marrow cells. Similarly, clinical trials with bone mar-
row cells for treatment of peripheral artery occlusive disease were initiated.16 In the meantime, 
experimental studies showed promise for other adult stem cell types as well, including skeletal 
myoblasts17, mesenchymal stem cells18, and adipose-derived stromal cells.19 While outcomes 
from these studies were generally promising, questions remained about the mechanism of 
action and the cellular behavior following cell transplantation. Unfortunately, there was few 
available data on the in vivo cellular kinetics thus leaving an unknown gap of what happened 
to the cells once they were transplanted into the animal.
In vIvo moleCulaR imaging of Stem Cell kinetiCS
To study the mechanism by which stem cells might or might not preserve function after trans-
plantation, it is of great importance to gain insight into cellular behavior. Usually, this is ap-
proached by labeling cells with conventional reporter genes such as Green Fluorescent Protein 
(GFP, which is isolated from luminescent jelly fish).20 However, to image GFP, extrinsic excitation 
light is needed, which produces significant background signal and has poor tissue penetration. 
This makes GFP unsuitable for reliable in vivo imaging of stem cells, and therefore GFP-labeled 
cells are typically identified histologically. Unfortunately, this requires the isolation of the tar-
get tissue and thus provides only a single time point rather than following a series of events 
in real time. In order to reliably investigate the behavior of transplanted stem cells, however, 
one must be able to track the cells longitudinally over time, whilst keeping the animal alive. To 
establish this goal, our group has developed novel molecular imaging techniques.21 
 Molecular imaging is defined as the in vivo characterization of cellular and molecular proces-
ses.22 The backbone of reporter gene-based molecular imaging technique is the design of a 
suitable reporter construct. This construct carries a reporter gene linked to a promoter that can 
be inducible, constitutive, or tissue specific. The construct can be introduced into the target 
tissue by molecular biology techniques using either viral or nonviral approaches. Transcription 
of DNA and translation of mRNA lead to the production of reporter protein. After adminis-
tration of a reporter probe, this probe reacts with the reporter protein, giving rise to signals 
that are detectable by a charged-coupled device (CCD) camera, positron emission tomography 
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Figure 1. Examples of reporter gene and probe imaging. (a) Enzyme-based bioluminescence imaging. 
Expression of the firefly luciferase (Fluc) reporter gene leads to the firefly luciferase reporter enzyme, which 
catalyzes the reporter probe (D-luciferin) that results in a photochemical reaction. This yields low levels of pho-
tons that can be detected, collected, and quantified by a CCD camera. (b) Enzyme-based PET imaging. Expres-
sion of the herpes simplex virus type 1 thymidine kinase (HSV1-tk) reporter gene leads to the thymidine kinase 
reporter enzyme (HSV1-TK), which phosphorylates and traps the reporter probe (F-18 FHBG) intracellularly. 
Radioactive decay of F-18 isotopes can be detected via PET. (c) Receptor-based PET imaging. F-18 FESP is 
a reporter probe that interacts with D2R to result in probe trapping on or in cells expressing the D2R gene. 
(d) Receptor-based MRI imaging. Overexpression of engineered transferrin receptors (TfR) results in increased 
cell uptake of the transferrin–monocrystalline iron oxide nanoparticles (Tf-MION). These changes result in a 
detectable contrast change on MRI. Reprinted with permission from Wu et al.24
Recent studies from our group have shown that it is possible to monitor experimental stem 
cell transplantation by bioluminescence imaging (BLI).25, 26 By introducing the Firefly Luciferase 
gene into the isolated cells, these donor cells can be imaged after transplantation in a naïve 
host. The Luciferase gene produces Luciferase protein, which will react with D-Luciferin (the 
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probe that is injected into the recipient animal before every imaging session) to produce a 
donor cell-specific signal that will be detected by the CCD camera. This approach potentially 
carries four major advantages: (1) It is in vivo, thus keeping the animal alive and permitting re-
peated imaging over time; (2) Luciferase protein will only be produced by donor cells that are 
alive, thus providing insight into cell viability; (3) D-Luciferin is systemically distributed while 
the CCD camera can image the whole animal, thereby monitoring signal from donor cells in-
dependent of cell location; and (4) There is no need of extrinsic excitation light, keeping back-
ground signals within acceptable limits. Following these advantages, this technique would be 
specifically suited to answer basic questions regarding cellular behavior after (embryonic and 
adult) stem cell transplantation in small animal models of cardiovascular disease. 
Stem Cell theRapy foR CaRdiovaSCulaR diSeaSeS: anSweRing baSiC 
queStionS RegaRding Cell behavioR
The scope of this thesis is to utilize molecular imaging techniques to address for the first time 
some basic but critical issues of both embryonic and adult stem cell therapy. Specifically, these 
issues involve in vivo cell survival, proliferation, migration, and misbehavior. 
The initial part of this thesis describes the advantages and drawbacks of embryonic stem cell 
(ESC) transplantation. In Chapter 2, the effects of undifferentiated mouse ESC transplantation 
into the infarcted heart are described. Different in vivo modalities were used to assess short-
term functional effects while histology tested the true regenerative capacity of these cells by 
means of staining for GFP and cardiomyocyte-specific markers. Moreover, non-invasive BLI and 
gross histology were performed to follow the fate of donor cells, and to image possible migra-
tion or misbehavior. Following this study, Chapter 3 was designed to test some important cha-
racteristics of ESC-derived teratoma formation. Specifically, it tested the possibility that these 
cells can migrate through the body and form teratomas in distant locations after intramyo-
cardial transplantation. Moreover, the potent teratogenic potential of undifferentiated mESC 
was visualized by testing how many undifferentiated cells are sufficient to provoke teratoma 
formation. The importance of these kinds of studies was acknowledged in a comment by Rao.27 
Chapter 4 provides an overview of the potential of guided in vitro ESC differentiation and the 
wide variety of therapeutic possibilities. While giving insight into the basics of molecular ima-
ging, it provides an introduction to the drawbacks of ESC. Getting more into detail, Chapter 
5 focuses on ESC-derived cardiomyocytes. It describes the clinical hurdles concerning diffe-
rentiation efficiency, purification, integration, and immune rejection of embryonic stem cell-
derived cardiomyocytes. Moreover, it outlines the role that molecular imaging can and should 
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After discussing the hurdles for clinical translation of ESC, the second part of this thesis focuses 
on the applicability of adult stem cells in cardiovascular diseases. Chapter 6 focuses on non-inva-
sive molecular imaging of different clinically utilized adult stem cell types. This was the first study 
to directly compare mononuclear cells from the bone marrow, skeletal myoblasts, mesenchymal 
stem cells, and fibroblasts in a mouse model of heart failure and revealed the survival of these 
cells in the ischemic environment of the infarcted heart. Moreover, it clarified which cell type 
resulted in superior functional preservation and if any of these cell types formed cardiomyocytes. 
An alternative kind of mesenchymal stem cells can be isolated from the fat (adipose-derived 
stromal cells). These were compared to the “traditional” mesenchymal stem cell population 
from the bone marrow as described in Chapter 7. The in vitro morphological and growth cha-
racteristics of both cell types were analyzed. Thereafter, the cells were transplanted into the 
infarcted mouse myocardium and cell survival was monitored by in vivo BLI, while cardiac func-
tion was monitored by echocardiography. The echocardiography data was validated by pres-
sure-volume loop measurements followed by histological analysis. Additional experiments 
using in vivo BLI examined the possibility that immunogenicity of GFP or the sex mismatch 
model used were of significant influence on donor cell survival in this study. This study was 
featured on the cover of Transplantation.
In Chapter 8, a novel small animal imaging modality to assess cardiac function is introduced. 
By comparison to traditional modalities such as echocardiography and catheter-based hemo-
dynamic measurements, novel Micro-CT was tested for its ability to reliably and precisely as-
sessing cardiac geometry and ventricular function of the infarcted mouse heart in an in vivo, 
three-dimensional fashion.
Next, Chapter 9 makes the transition from cardiac studies to the field of stem cell therapy for 
peripheral artery occlusive disease. Using a mouse model of hind limb ischemia, different mo-
nonuclear cell transplantation techniques were tested while the patterns of cell survival and 
migration were visualized in live animals using molecular imaging. The results from this study 
reveal the patterns of cell survival and homing to the affected area after intramuscular and in-
travenous transplantation, respectively. Moreover, the effect on paw perfusion was monitored 
by Laser Doppler Perfusion Imaging (LDPI). 
Finalizing this thesis, Chapter 10 summarizes and discusses the most important findings and 
implications from the research conducted, and brings forward my opinion on the future di-
rections of stem cell therapy for cardiovascular diseases. A synopsis in Dutch is provided in 
Chapter 11. 
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CHAPTER 2
Multimodal evaluation of in vivo 
magnetic resonance imaging of myocardial 
restoration by mouse embryonic stem cells
Stephen L. Hendry III*, Koen E.A. van der Bogt*, Ahmad Y. Sheikh, 
Takayasu Arai, Scott J. Dylla, Micha Drukker, Michael V. McConnell, 
Ingo Kutschka, Grant Hoyt, Feng Cao, Irving L. Weissman, 
Andrew J. Connolly, Marc P. Pelletier, Joseph C. Wu, 
Robert C. Robbins and Phillip C. Yang
Journal of Thoracic and Cardiovascular Surgery 
2008 Oct;136(4):1028-1037.
*Both authors contributed equally to this study
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abStRaCt
Objective: Mouse embryonic stem cells (mESC) have demonstrated the potential to restore 
the infarcted myocardium following an acute myocardial infarction (AMI). Although the under-
lying mechanism remains controversial, MRI has provided reliable in vivo assessment of func-
tional recovery following cell transplantation. Multi-modality comparison of the restorative 
effects of mESC and mouse embryonic fibroblasts (mEF) was performed to validate MRI data 
and provide mechanistic insight. 
Methods: SCID beige mice (n=55) underwent coronary artery ligation followed by injection of 
2.5x105 mESC, 2.5x105 mEF, or normal saline (NS). In vivo MRI of myocardial restoration by mESC 
was evaluated by: 1) in vivo pressure volume (PV) loops, 2) in vivo bioluminescence imaging 
(BLI), and 3) ex vivo TaqMan PCR (TM-PCR) and immunohistology. 
Results: In vivo MRI indicated significant improvement of LVEF at 1 week in the mESC group. 
This finding was validated with: (1) PV loop analysis demonstrating significantly improved sys-
tolic and diastolic functions, (2) BLI and TM-PCR showing superior post-transplant survival of 
mESC, (3) immunohistology identifying cardiac phenotype within the engrafted mESC, and (4) 
TM-PCR measuring increased expression of angiogenic and anti-apoptotic genes, and decre-
ased expression of anti-fibrotic genes. 
Conclusion: This study validates in vivo MRI as an effective modality to evaluate the restorative 
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intRoduCtion
Cellular therapy is rapidly emerging as a potential therapeutic option following an acute myo-
cardial infarction (AMI).1 Although studies have shown that transplantation of stem cells de-
rived from different lineages have provided significant functional recovery in the setting of 
AMI, the exact mechanisms of cell-mediated restoration have not been established.2 There are 
several theories regarding the possible mechanisms underlying myocardial restoration follo-
wing cell therapy: 1) augmentation of the infarct region’s elasticity preserving regional systolic 
and diastolic functions; 2) contractility of engrafted cells improving systolic function; 3) an-
giogenesis enhancing regional myocardial perfusion; and 4) paracrine effects modulating the 
progression of cardiac remodeling.3-6 
In vivo MRI has demonstrated improved cardiac function following transplantation of stem 
cells in both pre-clinical and clinical investigations.1, 7-11 These findings have led to questions 
regarding the validity of such data, however, and more importantly, the potential mechanisms 
underlying myocardial restoration. This investigation addresses these issues by validating in 
vivo MRI evaluation of myocardial restoration through a systematic comparison of the resto-
rative potential of “non-specific” mouse embryonic fibroblasts (mEF) to the more biologically 
active, self-renewing, pluripotent mouse embryonic stem cells (mESC) in a murine model of 
AMI. This is the first study to validate in vivo MRI at a functional level, and to conduct a mul-
timodality evaluation of physiologic, cellular, and molecular mechanisms of mESC-mediated 
myocardial restoration. 
methodS
Cell culture. Undifferentiated D3-derived mESC (ATCC, Manassas, VA) were cultured in DMEM 
(Invitrogen, Carlsbad, CA) with 15% fetal calf serum (FCS, Hyclone, Logan, UT), 100 mg/mL 
penicillin-streptomycin, 1mM sodium pyruvate, 2mM L-glutamine, NEAA, 0.1mM b mercapto-
ethanol (Invitrogen, Carlsbad, CA) and 106 u/mL leukemia inhibitory factor (Chemicon Inter-
national, Temecula, CA). Fresh mouse embryonic fibroblasts (mEF) were prepared from 13-day 
embryos, whose carcasses were minced and passed 10 times through a 21-gauge needle. Cells 
were seeded in 10 cm culture dishes and were propagated for two passages in DMEM with 
10% FCS and 100 mg/mL penicillin-streptomycin solution. Both mESC and mEF were transfec-
ted with a lentiviral vector carrying a cytomegalovirus promoter driving both a firefly luciferase 
(fluc) reporter gene and green fluorescent protein (GFP). Cells underwent FACS sorting for GFP 
and single clone selection; the clone was adapted to feeder-free conditions. Prior to injection, 
the cells were trypsinized (0.25% trypsin/0.02% EDTA) washed with DMEM containing 10% se-
rum. Following centrifugation, the cells were washed with PBS, centrifuged and resuspended 
in PBS for injection one hour after trypsinization. 
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Experimental animals. Animal care and interventions were provided in accordance with the 
Laboratory Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (National 
Institutes of Health, publication 78-23, revised 1978). Immunotolerant SCID-beige female mice 
(8-12 weeks, Charles River, Wilmington, MA) were anesthetized in an isoflorane inhalational 
chamber and endotracheally intubated with a 20 gauge angiocath (Ethicon Endo-Surgery, Inc. 
Cincinnati, OH). Ventilation was maintained with a Harvard rodent ventilator. Myocardial in-
farction was created by ligation of the mid-left anterior descending (LAD) artery through a 
left thoracotomy. The mice were randomized into three groups: 1) LAD ligation with normal 
saline (NS) injection (n=10), 2) LAD ligation with mESC injection (n=25), or 3) LAD ligation with 
mEF injection (n=20). The infarct region was injected with 25mL using a Hamilton syringe con-
taining 250,000 mESC, mEF, or NS. Cell suspensions contained rhodamine beads (6 x 105) to 
ensure injection accuracy. Following chest tube placement, the chest was closed in 2 layers 
with 5-0 vicryl. 
In vivo MRI. One week after transplantation, cardiac MRI was obtained using a Unity Inova con-
sole (Varian, Inc., Palo Alto, CA) controlling a 4.7T, 15cm horizontal bore magnet (Oxford Instru-
ments, Ltd., Oxford, UK) with GE Techron Gradients (12G/cm) and a volume coil with a diame-
ter of 3.5cm (Varian, Inc., Palo Alto, CA). The ECG gating was optimized using 2 subcutaneous 
precordial leads with respiratory motion and body temperature monitors (SA Instruments, Inc., 
Stony Brook, NY). LV function was evaluated using ECG-triggered cine sequence (TE 2.8-ms, TR 
160-ms, FA 60°, FOV 3.0cm2, matrix 128×128, slice gap 0-mm, slice thickness 1.0-mm, 8 NEX, 
and 12 cardiac phases). The imaging plane was localized using double-oblique acquisition. 
The data were analyzed using MR Vision software (Winchester, MA). LV ejection fraction (LVEF), 
end-diastolic (LVED), and end-systolic (LVES) volumes were calculated by tracing the endocar-
dial borders in end-systole and -diastole.  
Pressure-volume (PV) loop analysis. One week after transplantation, ventricular perfor-
mance was assessed by PV loop analysis using a 1.4 F conductance catheter (Millar Instruments, 
Houston, TX) prior to euthanasia. The closed chest technique was utilized which consisted of 
a midline neck incision to access the left external jugular vein with PE10 tubing (Intramedic-
Becton Dickinson). The right carotid was cannulated with the Millar catheter and advanced 
through the aortic valve into the LV. The PV relations were measured at baseline and during 
inferior vena cava occlusion. The measurements of segmental conductance were recorded 
which allowed extrapolation of the left ventricular volume. When coupled with pressure, the 
generation of ventricular PV relationships allowed precise hemodynamic characterization of ven-
tricular systolic and diastolic function and loading conditions.12 These data were analyzed using 
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In vitro firefly luciferase (fluc) assay. On the day of operation, parallel sets of cells from the 
same plates as the injected cells were trypsinized, resuspended in PBS and divided into a 6-well 
plate in different concentrations. After administration of D-luciferin (Xenogen, California, USA, 
4.5ug/mL), peak signal expressed as photons per second per centimeter square per steridian 
(p/s/cm2/sr) was measured using a charged coupled device (CCD) camera (Xenogen, California, 
USA).
In vivo optical bioluminescence imaging (BLI). Optical BLI was performed using 8 x 5 minute 
acquisition scans on a CCD camera (IVIS 50, Xenogen, California, USA). Recipient mice were 
anesthetized and placed in the imaging chamber. After acquisition of a baseline image, mice 
were intraperitoneally injected with D-luciferin (Xenogen, USA, 400 mg/kg body weight). Peak 
signal (p/s/cm2/sr) from a fixed region of interest (ROI) was evaluated using the Living Image 
2.50 software (Xenogen, USA). 
Ex vivo TaqMan PCR (TM-PCR) for cell survival and expression of genes of interest. Since 
the transplanted cells were derived from male mice and were transplanted into female reci-
pients, the surviving mESC in the explanted hearts could be quantified using TM- PCR to track 
the SRY locus found on the Y chromosome. Whole explanted hearts were minced and homo-
genized in DNAzol (Invitrogen, Carlsbad, CA). RNA was extracted from the mice myocardium 
after treatment with TRIzol reagent (Invitrogen, Carlsbad, CA). Taqman PCR was performed 
using SuperScript II RT-PCR kit (Invitrogen, Carlsbad, CA). To assess the expression of several 
genes of interest, relative quantitation of mouse primers was performed for: matrix metal-
loproteinase (MMP)-1β, -2, -9, -14, tumor necrosis factor (TNF)-α, vascular endothelial growth 
factor (VEGF)-A, procollagen-2α1, transforming growth factor (TGF)-β, angiotensin converting 
enzyme (ACE), insulin-like growth factor (IGF) 1, Flk-1, and NFkβ-1 (Applied Biosystems, Foster 
City, CA). The fluorogenic probes contained a 5’-FAM report dye and 3’-BHQ1 quencher dye. 
TaqMan 18S Ribosomal RNA (Applied Biosystems, Foster City, CA) was used as control gene. 
RT-PCR reactions were conducted in iCylcer IQ Real-Time Detection Systems (Bio-Rad, Hercu-
les, CA). 
Histological analysis. Hearts were flushed with NS and subsequently placed in 2% parafor-
maldehyde for 2 hours at room temperature followed by 12-24 hours in 30% sucrose at 4°C. 
The tissue was embedded in Optical Cutting Temperature (OCT) Compound (Tissue-Tek. Sak-
ura Finetek USA Inc., Torrance, CA) and snap frozen on dry ice. Five-micron sections were cut 
in both the proximal and apical regions of the infarct zone. Slides were stained for H&E, GFP 
(anti-green fluorescent protein, rabbit IgG fraction, anti-GFP Alexa Fluor 488 conjugate, 1:200, 
Molecular Probes, Inc.), Troponin I (H-170 rabbit polyclonal IgG for cardiac muscle, 1:100, Santa 
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Cruz Biotech, Santa Cruz, CA), and Connexin 43 (rabbit polyclonal, 1:100, Sigma). Stained tis-
sue was examined by Leica DMRB fluorescent microscope and a Zeiss LSM 510 two-photon 
confocal laser scanning microscope. Cell engraftment was confirmed by identification of GFP 
expression under fluorescent microscopy. Colocalization of troponin, alpha sarcomeric actin, 
and connexin 43 with GFP was visualized with streptavidin-conjugated to Alexa Fluor Red 555 
(Invitrogen Molecular Probes, Carlsbad, CA).
Statistical analysis. Descriptive statistics included mean and standard error. Comparison 
between groups was performed using students’ t-test for independent and normally distri-
buted data variables using SPSS 11.0. For comparison between multiple groups, ANOVA with 
Bonferroni correction was utilized. Significance was assumed when p<0.05.
ReSultS
Quantitation of left ventricular ejection fraction (LVEF) by in vivo MRI. As seen in figure 
1a and b, MRI indicated that AMI led to significant reduction in LVEF at 1 week in all groups 
compared to sham operated, normal hearts [60.9±1.4% (n=5)] (p<0.01), illustrating the effecti-
veness of this murine AMI model. A significant improvement of LVEF in the mESC-treated [40.2 
±2.0% (n=23)] group was seen versus mEF- [29.4 ± 1.5% (n=17)] and NS-treated [26.4 ± 1.8% 
(n=6)] (p<0.05) groups. No significant improvement was observed in the mEF- versus NS-tre-
ated group. Measurements of LV end-diastolic and –systolic volumes are included in Table 1.
Measurement of maximal elastance (EMax) and end systolic elastance (Ees) by pressure-
volume (PV) loop analysis. As seen in figure 1c, PV loop analysis demonstrated significantly 
compromised Emax (mmHg/mL) in the mEF- [9.95 ± 1.4 (n=4)] and NS-treated [5.8 ± 1.2 (n=4)] 
groups compared to normal hearts [22.6 ± 2.5 (n=5)] (p<0.05) at 1 week. However, a preserved 
Emax (mmHg/mL) was noticeable in the mESC-treated group [18.4 ± 3.5 (n=4)], which was sig-
nificantly higher than the mEF- and NS-treated groups (p<0.05). No significant improvement 
was observed in Emax in the mEF- versus the NS-treated group. The Ees data paralleled these 
findings with a significant decrease in the NS-treated [4.1 ± 0.7 (n=4)] group versus normal 
hearts [12.5 ± 1.2 (n=5)] (p<0.05) and a significant preservation of Ees in the mESC-treated [8.8 
± 1.5 (n=4)] versus the mEF- and NS-treated groups (p<0.05). No significant improvement was 
observed in Ees in the mEF- versus NS-treated group. As shown in figure 1d, the left ventricular 
volumes measured by PV-loop in the mEF and NS groups demonstrate negative remodeling, 
while mESC treated hearts showed the least dilatation. The improved systolic and diastolic 
functions measured by the PV loops provide physiologic confirmation of in vivo MRI data, as 
left ventricular volumes measured by MRI and PV loop correlate (figure 1e).  For further results 
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  Normal mESC mEF NS
MRI        
LVEF (%) 60.9 ± 1.4 40.2 ±2.0 29.4 ± 1.5 26.4 ± 1.8
LVED volume (mL) 4.23 ± 0.5 4.53 ± 0.6 5.74 ± 0.6 8.32 ± 0.7
LVES volume (mL) 1.63 ± 0.2 2.67 ± 0.2 4.09 ± 0.3 6.14 ± 0.5
PV-Loop        
Heart rate (bpm) 277.25 ± 10.60 302.75 ± 26.93 319.25 ± 16.45 260.00 ± 22.51
End-systolic 
Volume (uL)
26.72 ± 0.49 21.65 ± 4.82 40.56 ± 8.67 45.82 ± 8.89
End-diastolic 
Volume (uL)
29.29 ± 0.47 24.00 ± 5.56 43.15 ± 9.21 49.40 ± 9.67
End-systolic 
Pressure (mmHg)
83.86 ± 9.17 † 85.92 ± 5.91 † 71.40 ± 6.55 49.84 ± 5.35
End-diastolic 
Pressure (mmHg)
5.15 ± 1.21 19.14 ± 7.01 6.50 ± 0.54 8.21 ± 1.64
Arterial Elastance 
(Ea) (mmHg/uL)
29.34 ± 9.50 37.50 ± 11.56 22.04 ± 3.88 10.62 ± 3.35
dPdt max 
(mmHg/sec)
4100.50 ± 412.10 3867.50 ± 751.61 3108.75 ± 293.20 2157.00 ± 358.83
dPdt min 
(mmHg/sec)
-2993.25 ± 138.66 † -2779.75 ± 144.06 † -2397.75 ± 107.80 -1578.50 ± 304.29
Tau_w (msec) 15.01 ± 1.32 21.38 ± 4.32 15.13 ± 1.16 12.75 ± 3.89
Maximal Power 
(mWatts)




9.21 ± 1.19 18.88 ± 6.13 † 5.87 ± 0.76 3.69 ± 1.25
Table 1. Steady-state hemodynamic measurements by MRI and PV-loop. † indicates p<0.05 vs. NS (†), no 
symbols indicate p=NS (ANOVA).
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Figure 1. Functional outcomes after mESC and mEF transplantation. (a) Representative MR images of each 
group (normal, mESC, mEF, and NS) shown in end-diastole and end-systole at one week after LAD ligation and 
cell transplantation. The mESC-treated group demonstrated increased LVEF with visual confirmation from the 
MR images. (b) One week after LAD ligation and cell transplantation, MRI indicated significant improvement 
in the left ventricular ejection fraction (LVEF) in the mESC versus mEF and NS groups. ** Indicate p<0.01 vs. all 
groups, * represents p<0.05 vs. MEF and NS (ANOVA). (c) One week after LAD ligation and cell transplantation, 
PV loop analysis demonstrated compromised Emax (mmHg/μL) in the mEF and NS groups compared to normal 
hearts. A preserved Emax (mmHg/μL) was noticeable in the mESC group, which was significantly higher than 
the NS group. No significant improvement was observed in Emax in the mEF group versus the NS group. The 
Ees data show significant decrease in the NS group versus normal hearts and a significant preservation of Ees in 
the mESC group versus the NS group. No significant improvement was observed in the mEF group versus NS. * 
Indicates p<0.05 vs. mEF and NS, † indicates p<0.05 vs. NS (n>4/ group, ANOVA). (d) PV loop measurements of 
left ventricular volumes in end-systole (Ves) and end-diastole (Ved) show a decreased ventricular dilatation in 
the mESC group (p=NS). (e) Scatter plot of average left ventricular volumes in each group measured by PV loop 
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Determination of transplanted cell survival by in vivo BLI and ex vivo TaqMan PCR. Stable 
mESC and mEF transfection with GFP and firefly luciferase (fluc) generated mESC-GFP+-fluc+ 
and mEF-GFP+-fluc+ cell lines. The cells were selected and tested for fluc signal by biolumines-
cence imaging (BLI). Expression of fluc signal correlated robustly with cell number (r2=0.99 and 
r2=0.95, respectively, figure 2a-c). Thus, BLI was validated as a tool to monitor cell viability 
quantitatively as the signal intensity reflected the number of viable cells in vitro. Following 
transplantation of the transfected cells, BLI signal from the mESC-treated group decreased un-
til post operative day (POD) 2. At POD 8 and 14, there was a significant (p<0.01) increase in 
signal due to the rapid division of the undifferentiated mESC (figure 3a-b); probably commen-
cing teratoma formation as already shown in our earlier work.13 However, in the mEF-treated 
group, signal increased until POD 2 but decreased thereafter, suggesting cell death (figure 
3a-b). Ex vivo TaqMan PCR (TM-PCR) results indicated significantly lower cycle numbers over 
time in the mESC-treated group compared to the increasing cycle numbers in the mEF-treated 
group (figure 3c), which is representative of higher number of viable male donor cells in the 
mESC group.14 Thus, ex vivo TM-PCR correlated well with the BLI results (figure 3d). This finding 
supports in vivo MRI data in which cell survival, a major biological property, is significantly en-
hanced in order for the transplanted mESC to remain biologically active to restore the injured 
myocardium.
Figure 2. In vitro Firefly Luciferase (fluc) signal correlates with cell number. (a, b) Bioluminescence (BLI) 
image showing increasing fluc signal with increasing cell number in mouse embryonic stem cells (mESC, a) and 
embryonic fibroblasts (mEF, b). Bars represent maximum radiance (p/s/cm2/sr). (c) Correlation plot showing ro-
bust correlation of fluc signal and cell number for mESC and mEF (r2=0.99 and r2=0.95, respectively).
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Figure 3. Transplanted Cell Survival by in vivo Bioluminescence and ex vivo TaqMan PCR. (a) Representa-
tive BLI images of mESC survival, tracked longitudinally at post-operative day (POD) 0, 2, 8, and 14. The survival 
decreases from POD 0 to POD 2 after which there is a notable increase at POD 8 and 14 due to rapid division. 
Color bars represent maximum radiance (p/s/cm2/sr). (b) Normalized plot indicating significant (p<0.01) mESC 
proliferation starting on POD 2 and gradual cell death in the mEF group starting on POD 2 (n>4/group). Y-axis 
shows the log10 percentage of the average BLI signal on POD 0. * Indicates p<0.01 vs. mESC on POD 0, 2, and all 
mEF time points (ANOVA). (c) Ex vivo TaqMan PCR for SRY gene representing the male mESC survival at POD 0, 
2, 8, and 14 which demonstrates a similar trend as seen in the in vivo BLI (n>4/group). * Indicates p<0.05 vs. mEF, 
** indicate p<0.01 vs. mEF (ANOVA). (d) Correlation plot showing correlation (r2=0.86 and r2=0.87 for mESC and 
mEF, respectively) between in vivo BLI and ex vivo TaqMan PCR.
Gene expression profiling by TM-PCR for matrix metalloproteinase (MMP)-1β, -2, -9, -14, 
tumor necrosis factor (TNF)-a, vascular endothelial growth factor (VEGF)-A, procollagen-
2a1, insulin-like growth factor (IGF) 1, transforming growth factor (TGF) -b, angiotensin 
converting enzyme (ACE), Flk-1, and NFkβ-1. Relative quantitation of mRNA expression of 
12 genes (4 mice/group) using RT-PCR demonstrated significant increase of TNF-a in the mESC-
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tively, p<0.01). Significant up-regulation of VEGF-A was also observed in mESC-treated group 
compared to the mEF and NS-treated groups (104% vs. 13% and 42%, respectively, p<0.01). On 
the other hand, mESC-treated mice demonstrated a trend towards down-regulation of MMP-
1β and procollagen-2α1 expression when compared to NS-treated groups (p>0.05). The mRNA 
expressions of the remainder of genes; IGF1, NFkβ-1, MMP-2, -9, -14, TGFb, ACE, and Flk-1 did not 
demonstrate significant difference among mESC- mEF- and NS-treated groups. The gene expres-
sion profiles of TNF-α, which may have had an enhanced anti-apoptotic effects, and VEGF-A, 
consistent with proangiogenic effects, were demonstrated in the mESC-treated group (figure 4).
Figure 4. Relative quantitation of TNF-α and VEGF-A expression. Relative quantitation of mRNA expression on 
POD 7, normalized to the percentage of expression in normal, sham-operated hearts. A significant upregulation is 
noticeable in the mESC group. ** indicate p<0.01 vs. all groups, * indicates p<0.01 vs. mEF and NS (ANOVA). 
Immunohistology of mESC cardiomyocyte differentiation. As seen in figure 5 (a-d), cross-
sectional images of H&E stained hearts demonstrate thinning of myocardial tissue and dilata-
tion of LV chamber after LAD ligation. However, in the mESC treated mice, restoration of the 
LV wall mass and reduction of LV dilatation are seen. Co-localization of GFP with troponin and 
α-sarcomeric actin in isolated cells demonstrated potential differentiation of the mESC into 
cardiomyocytes as shown in figure 5 (e-h). Colocalization of GFP with Connexin 43 suggest the 
formation of gap junctions as represented in figure 5i. 
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Figure 5. Histopathology of Anti-remodeling Effect and Cardiomyocyte Differentiation after mESC trans-
plantation on POD 7. (a-d) Cross-sectional representative images of H&E stained (a) normal heart, (b) LAD liga-
tion control, demonstrating thinning and dilatation of the ventricular wall, (c) mEF treated heart and (d) mESC 
treated heart demonstrating the restoration of the LV wall mass. (e) Confocal microscopy picture showing GFP 
positive stained mESC. (f ) Confocal microscopy picture showing same cells as 5D expressing troponin. The 7-mi-
cron clustered round structures probably represent non-specifically stained red blood cells. (g) Overlay of 5D-E, 
showing co-localization of GFP with troponin, suggestive for a mESC-derived cardiomyocyte. Note that the non-
specifically colored blood cells locate inside a GFP-stained blood vessel (white arrow), suggesting mESC- de-
rived neovasculogenesis. (h) Image showing co-localization of GFP-positive mESC with alpha sarcomeric actin. 
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diSCuSSion
Cardiomyocyte death or dysfunction following an acute myocardial infarction (AMI) results in 
pathological remodeling of the left ventricle with eventual sequela of heart failure. Despite 
recent reports of the regenerative potential of cell-based therapies in the injured myocardium, 
a definitive mechanism of the enhanced myocardial function has not been elucidated. In the 
present study, we have provided independent support for in vivo MRI data by PV-loop and 
established the fundamental biological importance of cell survival, cell differentiation, and pa-
racrine effects as potential mechanisms of mESC underlying myocardial restoration. The inves-
tigation focused on the immediate effects of cell transplantation post-AMI because teratoma 
formation would have likely interfered with reliable measurements during longer follow-up15, 
as greatly increased mESC BLI signal on POD 14 confirmed. Our data demonstrated significant-
ly improved LVEF measured by in vivo MRI, the most commonly utilized clinical end-point. This 
finding has been confirmed by end-systolic and maximal elastance values as measured by PV 
loop indicating improved systolic and diastolic functions as early as one week following mESC 
treatment. The improvement of diastolic function can be attributed to the augmentation of 
the infarct region’s elasticity and recovery in the overall maximal elastance in the mESC-treated 
group. Moreover, we found a correlation between left ventricular volumes as measured by MRI 
and PV-loop.
These findings challenge the current notion that myocardial function is improved irrespective 
of cell type.16, 17 The preservation of cardiac performance following cell transplantation cannot 
be attributed merely to the physical scaffolding effect but also must arise from the biological 
properties of the transplanted cells. During myocardial ischemia, the ischemic region develops 
diastolic and subsequent systolic abnormality.18 Studies have confirmed the Frank-Starling re-
lationship in which contractile function is preserved with reduction in ventricular volume.19 
In fact, our PV-loop results indicate a reduction in ventricular volume in the mESC group. This 
reduction involves complex yet fundamental biological processes. First, the prolonged survival 
kinetics of mESC can offer a longer lasting scaffolding effect, which may help to explain both 
the reduction in pathological remodeling and sustained restoration. More importantly, how-
ever, the persistence of viable mESC generates biologically active stimuli to salvage the injured 
myocytes. Thus, this enhanced survival of mESC enables a second potential mechanistic expla-
nation for in vivo MRI findings of myocardial restoration: paracrine effect. The results from ex 
vivo TM-PCR demonstrate that the potential anti-apoptotic cytokine, TNF-a, was significantly 
upregulated in the mESC-treated group. TNF-α has been shown to have negative inotropic 
effects, to induce resistance to hypoxic stress in cardiomyocytes, and to play a role in the re-
cruitment of stem cells.20-23 It must be stated, however, that the increased TNF-a expression 
could also be attributable to a greater mass effect of mESC, with a subsequent greater endoge-
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nous inflammatory reaction, a greater mESC-induced monocyte influx, or teratoma formation 
leading to endogenous TNF-a production. In addition, the observed up-regulation of VEGF-A 
in this study may promote angiogenesis to attenuate the ischemic insult to recover the inju-
red cardiomyocytes. Finally, non-significant trends towards down-regulation of matrix metal-
loproteinase-1 (MMP-1) and procollagen 2α-1 have also been detected, which may contribute 
to decreased cardiac matrix remodeling in failing hearts.24 Surprisingly, we did not observe 
upregulation of MMP-2 and -9. This may have been because the absence of T-cells in the SCID 
mice, on which MMP-2 and -9 expressions have been shown to depend.25 Taken together, these 
TM-PCR results suggest that multiple mechanisms underlie the restoration by mESC.
The pluripotency of mESC may lead to regeneration of cardiac tissue after cardiomyogenic 
differentiation.26 In order to contract synchronously with host cardiomyocytes, newly formed 
mESC-derived cardiomyocytes must undergo electromechanical coupling through the forma-
tion of gap junctions in vivo with the host myocardium.26, 27 This study provides possible 
evidence that donor mESC are capable of engrafting within the host myocardium and differen-
tiating into cardiomyocytes. While these findings are encouraging, it must be noted that this 
was a low-frequency event, making it less likely that the observed functional improvement can 
be attributed to robust cardiac regeneration by mESC-derived cardiomyocytes. 
There are several limitations of this study. First of all, in order to investigate the acute effect of 
cell survival, we chose to compare fast-growing, undifferentiated mESC and less active mEF. 
This gave us the opportunity to study the relationship between cardiac function and cell survi-
val in a relatively short period of one week. However, it must be stated that eventual teratoma 
formation, as suggested by our BLI findings on POD 14 and consistent with the literature13, 15, 
28, would likely hamper long term restoration of cardiac function. Secondly, this study does not 
provide insight in acute post-operative infarct size, which may have been dependent upon cell 
type. All operations, however, were conducted by the same experienced micro-surgeon that 
was blinded to the study. Moreover, after one week, all operated groups had a significant com-
promised LVEF on MRI, which lead to the assumption that infarct size had been comparable in 
all study groups. Third, we focused on validating the most important MRI data, namely LVED 
and LVES. Wall thickness, which could have correlated with cell survival, was not measured 
since we did not anticipate regenerative changes in the immediate period after AMI. Other stu-
dies are currently underway to address the regenerative changes by measuring wall thickness.
In conclusion, this is the first study to provide a fundamental functional and biological evalu-
ation of in vivo MRI in mESC therapy. This study has shown that mESC are superior to mEF in 
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the cells must at the very least survive to restore the myocardium is confirmed as the enhanced 
survival of mESC is attributed as one of the key factors in myocardial restoration. Improved 
survival of transplanted cells may not only offer a physical scaffolding mechanism but, more 
importantly, biological support by generating sustained paracrine effects after injury. We have 
also observed that mESC retain the ability to differentiate into cardiomyocytes, albeit at low 
frequency. Unfortunately, although the pluripotency and robust proliferation are among the 
major advantages of embryonic stem cells, these characteristics also contribute to teratoma 
formation13, 15, which, for the present, prevents clinical translation. Further research regarding 
directed differentiation of mESC into cardiomyocytes may lead to a safe regenerative therapy 
for myocardial disease in the future. 
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abStRaCt
Pluripotent embryonic stem cells (ESCs) have the potential to form teratomas composed of 
derivatives from all three germ layers in animal models. This tumorigenic potential prevents 
clinical translation of ESC research. In order to understand the biology and physiology of te-
ratoma formation, we investigated the influence of undifferentiated ESC number, migration, 
and long-term follow up after transplantation. Murine ESCs were stably transduced with a 
self-inactivating (SIN) lentiviral vector with a constitutive ubiquitin promoter driving a double 
fusion (DF) reporter gene that consists of firefly luciferase and enhanced green fluorescent pro-
tein (Fluc-eGFP). To assess effects of cell numbers, varying numbers of ES-DF cells (1, 10, 100, 
1000, and 10000) were injected subcutaneously into the dorsal regions of adult nude mice. To 
assess cell migration, 1x106 ES-DF cells were injected intramyocardially into adult Sv129 mice 
and leakage to other extra-cardiac sites was monitored. To assess effects of long-term engraft-
ment, 1x104 ES-DF cells were injected intramyocardially into adult nude rats and cell survival 
response was monitored for 10 months. Our results show that ES-DF cells caused extra-cardiac 
teratoma in both immunocompetent and immunodeficient hosts; the lowest number of undif-
ferentiated ESCs capable of causing teratoma was 500 to 1000; and long-term engraftment 
could be visualized for >300 days. Collectively, these results illustrate the potent tumorigenic 
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intRoduCtion
Embryonic stem cells (ESCs) can divide for unlimited generations without losing their ability to dif-
ferentiate into cells of all three germ layers: ectoderm, mesoderm, and endoderm.1 This pluripo-
tency has given ESCs a major advantage over adult stem cells, which are generally tissue-specific 
and whose plasticity is more limited. Therefore, ESCs have great potential as future treatments for a 
wide variety of diseases, including cardiovascular2, neurodegenerative3, and endocrine4 disorders. 
Ironically, the pluripotency and fast growth kinetics of ESCs also underlie their major disadvanta-
ge, as these characteristics can easily turn into undefined growth in vivo, giving rise to teratoma. 
Teratoma is a complex tumor consisting of cell lines from different germ layers which are known 
to develop after ESC transplantation in animal models.5, 6 Therefore, prior to future clinical trans-
lation of ESC-based therapy, basic characteristics of teratoma formation must be elucidated. 
Previous studies have shown that the tumorigenic potential of ESCs seems to decrease with 
increasing purity of pre-differentiated target cell populations, such as cardiomyocytes7 or 
oligodendrocyte progenitor cells.3 However, the maximum number of contaminant undiffe-
rentiated ESCs in these pre-differentiated populations for safe non-tumorigenic application 
remains unknown. Secondly, it has been shown recently that the tumorigenic potential of ESCs 
is dependent upon the site of transplantation.8 Whether it is also possible that transplanted 
ESCs can form teratoma in distant graft sites need to be examined. Lastly, as teratoma forma-
tion usually presents around two to four weeks after transplantation2, 8, the long-term fate of 
transplanted, undifferentiated cells has never been investigated. By studying these issues, this 
study aims to evaluate the in vivo tumorigenic characteristics of ESCs. 
methodS
Culture of undifferentiated ESCs. The murine ES-D3 cell line was derived originally from 
Sv129 mice and obtained commercially from ATCC (Manassas, VA). Undifferentiated cells were 
maintained with 1000 IU/mL leukemia inhibitory factor (Chemicon, ESGRO, ESG1107) and mu-
rine embryonic fibroblasts (MEFs) feeder layer inactivated by 10 ug/mL mitomycin C (Sigma). 
Murine ESCs were cultured on 0.1% gelatin-coated plastic dishes in ES medium containing Dul-
becco Modified Eagle Medium (DMEM) supplemented with 15% fetal calf serum, 0.1 mmol/L 
β-mercaptoethanol, 2 mmol/L glutamine, and 0.1 mmol/L nonessential amino acids (Gibco) as 
described previously.9 Culture medium was changed every day. Murine ESCs were passaged 
every 1 or 2 days. Images were obtained using a ZEISS Axiovert microscropy (Sutter Instru-
ment).
Lentiviral transduction of ESCs with a double fusion (DF) reporter gene. The self-inactiva-
ting (SIN) lentiviral vector was constructed by deleting 133 bp in the U3 region of the 3’ LTR, 
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including the TATA box and binding sites for transcription factors Sp1 and NF-kappaB as first 
described by Miyoshi et al..10 The deletion is transferred to the 5’ LTR after reverse transcription 
and integration in infected cells, resulting in the transcriptional inactivation of the LTR in the 
proviruses. For the DF construct, pFUG-DF containing Fluc-eGFP was co-transfected into 293T 
cells with HIV-1 packaging vector (δ8.9) and vesicular stomatitis virus G glycoprotein-pseu-
dotyped envelop vector (pVSVG) as described.11 Lentivirus supernatant was concentrated by 
sediment centrifugation using a SW29 rotor at 50,000g for two hours. The concentrated virus 
was titered on 293T cells. ESCs were transduced at a multiplicity of infection (MOI) of 10. The 
infectivity was determined by eGFP expression as analyzed on FACScan (Becton Dickinson, 
San Jose, CA). These ESCs underwent a total of 3 rounds of FACS to increase the percentage of 
GFP+ to >95%. Note the sorter cannot guarantee 100% positive cells because of the setting, 
compensation, autofluorescence, and false positives. These stably transduced ESCs (termed 
ES-DF cells) are then used for subsequent in vitro studies and in vivo imaging as described next.
Effect of reporter genes on ESC proliferation. The control non-transduced ESCs and stably 
transduced ESCs (ES-DF cells) were plated uniformly in 96-well plates at a density of 5,000 cells 
per well. The CyQuant cell proliferation assay (Molecular Probes, Eugene, OR) was measured 
using a microplate spectrofluorometer (Gemini EM, Sunnyvale, CA) at 24, 48, and 72 hour time 
points. Eight samples were assayed and averaged. 
Intramyocardial transplantation of ESCs into mice and rats. All animal study protocols were 
approved by the Stanford Animal Research Committee. Adult immunocompetent Sv129 mice 
(20-25g) and nude athymic rats (200-250g) underwent aseptic lateral thoracotomy. Briefly, ani-
mals received isoflurane (2% for mice, 3% for rats) for general anesthesia, banamine (2.5 mg/
kg) for pain relief, and normal saline (0.2-2 ml) for volume replacement. Harvested ES-DF cells 
(after 3 rounds of FACS to increase eGFP+ cells to ∼95-98%) were kept on ice for <30 minutes for 
optimal viability prior to injection into the mouse or rat myocardium. Sv129 mice (n=10) were 
injected intramyocardially with 1x106 ES-DF cells in 50 µl PBS. Nude athymic rats (n=5) were in-
jected intramyocardially with lower numbers of cells (1x104 ES-DF cells in 50 µl PBS) purposely 
to allow long-term study. Control animals (n=5 in each group) received non-transduced ESCs 
in equal numbers. All animals recovered uneventfully and underwent subsequent BLI.
Subcutaneous transplantation of varying numbers of ES-DF cells into mice. Adult nude 
mice (20-25g) received isoflurane (2%) for general anesthesia. Harvested ES-DF cells were kept 
on ice for <30 minutes for optimal viability. Mice (n=10) were injected subcutaneously within 
dorsal regions with 1, 10, 100, 1000 or 10,000 of ES-DF cells accompanied by 99999, 99990, 
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San Jose, CA). The final total cell number was 100,000 in each site. Afterwards, animals under-
went longitudinal BLI as described below. 
Optical bioluminescence imaging (BLI) of mESC transplantation. BLI was performed using the 
Xenogen In Vivo Imaging System (IVIS, Xenogen, Alameda, CA), which is an ultra-sensitive charged 
coupled device (CCD) camera.12 Animals received isoflurane (2% for mice, 3% for rats) for gene-
ral anesthesia. After intraperitoneal injection of the reporter probe D-Luciferin (250 mg/kg body 
weight), animals were imaged for 30 min using 1-min acquisition intervals repetitively for the study 
period. The gray-scale photographic images and BLI color images were analyzed using the Igor 
image analysis software (Wavemetrics, Lake Oswego, OR) and overlaid using the LivingImage soft-
ware (Xenogen, Alameda, CA). Region of interest (ROI) were drawn over the signals and BLI was 
quantified in units of maximum photons per second per centimeter square per steridian (p/s/cm2/
sr) as described.2
Postmortem immunohistochemical staining. After completion of study periods, animals 
were sacrificed according to protocols approved by the Stanford Animal Research Committee. 
Explanted subcutaneous teratomas were routinely processed for hematoxylin and eosin (H&E). 
Slides were interpreted by an expert pathologist (A.J.C) blinded to the study.
Data analysis. Data are given as mean ± SD. For statistical analysis, the two-tailed Student’s 
t–test was used. Differences were considered significant at P<0.05. 
 
ReSultS
Lentiviral transduction and characterization of murine ES-DF cells. The DF construct con-
sists of Fluc and eGFP reporter genes linked by a 14-amino acid long linker (LENSHASAGYQAST) 
as shown in figure 1a. After 48 hours of transduction, there was no change in morphology of 
ESCs (figure 1b) and the percentage of eGFP was quantified as 21±4 based on the average 
of three FACS scans (figure 1c). In order to obtain more purified GFP(+) cells, the cells were 
passaged 4 to 5 times and sorted three time during a 2 week period. After the third sort, the 
percentage of ESCs expressing eGFP was typically 95±3. These stably transduced ESCs (ES-DF) 
were used for further in vitro and in vivo analysis. To ensure that the construct and the lentivi-
ral transduction did not favorably influence tumorigenic potential, we examined the growth 
kinetics of control non-transduced ESCs and ES-DF in vitro. Both control ESCs and ES-DF cells 
showed no significant differences in proliferation rate (P=NS) (figure 1d). Taken together, these 
data suggest that lentiviral transduction is a robust method to introduce reporter genes into 
ESCs without significantly affecting their self-renewal and pluripotency characteristics.
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Figure 1. Stable lentiviral transduction of murine embryonic stem cells (ESCs) with a double fusion (DF) 
reporter gene. (a) Schematic overview of the lentiviral DF reporter construct with firefly luciferase (Fluc) and 
enhanced green fluorescent protein (eGFP). These reporter genes were cloned into a self-inactivating (SIN) 
lentiviral vector (LV) driven by an ubiquitin promoter (pUB). (b) Morphology of the transduced ES-DF cells, 
which clearly showed green fluorescence (left: brightfield, right: fluorescence). (c) Flow cytometry plots showing 
non-transduced control ESCs do not express GFP (left). After lentiviral transduction, the transduction efficiency 
is ∼21±4% after the first round (middle) and ∼95±3% after the third round of sorting (right). (d) CyQuant cell 
proliferation assay showing that lentiviral transduction and DF reporter gene expression did not significantly 
affect growth of ES-DF cells compared to control non-transduced ESCs.
Minimal number of undifferentiated murine ESCs causing teratoma formation. At pre-
sent, it is not feasible to select or grow 100% pure ESC-derived progenitor cells.13, 14 Thus, it is 
likely that at the time of therapeutic transplantation, mixed cell populations may still contain 
some undifferentiated ESCs. Therefore, we set out to determine the lowest threshold of un-
differentiated ESC contaminant that can still cause teratoma formation. In order to do so, we 
first investigated the minimal reproducible cell number that can be imaged in vitro. The results 
from in vitro BLI indicated that 10,000 ES-DF cells were easily noticeable (figure 2a). Marginal 
signal from 1000 ES-DF cells led us to hypothesize that it is possible to image as low as 500 to 
1000 cells in vivo if they are located within a compact region. Indeed, 7 days after subcutane-
ous transplantation of 500 to 1000 ES-DF cells, which were kept localized to the same region 
by Matrigel, faint signals were noticeable on BLI in vivo (figure 2b). Moreover, these 500 to 
1000 ES-DF cells induced tumor growth over a time period of 3 months, which was confirmed 
by histology (figure 2c). By contrast, no such tumorigenic transformation was observed after 
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Figure 2. Potential for different numbers of undifferentiated ESCs to form teratomas in vivo. (a) In vitro BLI 
shows the ability to image different numbers of ESCs, with a lower threshold of around 1000 ESCs. (b) Different 
numbers of undifferentiated ESCs, as marked on the picture, were then subcutaneously transplanted into nude 
mice and accompanied by irradiated non-proliferating mouse embryonic fibroblasts to achieve a total cell num-
ber of 100,000 in 20 µl Matrigel. BLI imaging for 3 months revealed teratoma formation with only 500 to 1000 
ESCs. (c) Postmortem H&E staining confirmed teratoma formation in the 500 to 1000 ESCs group: (I) lower power 
field of mesenchymal and gland cell differentiation; (II) gland cells; and (III) cartilage formation (arrow).
ESC survival and migration after intramyocardial injection. Previous studies have shown 
that transplantation of undifferentiated murine ESCs into immunodeficient mice leads to te-
ratoma formation using conventional histological techniques.15 However, these histological 
techniques do not allow for in vivo longitudinal tracking of tumorigenicity. To demonstrate the 
importance of following cell fate in a whole-body living animal system, we injected 1x106 ES-DF 
cells intramyocardially into immunocompetent syngeneic Sv129 mice. Cell survival was moni-
tored longitudinally for about 35 days. Figure 3a shows a representative Sv129 mouse whereby 
BLI revealed teratoma formation. Quantitative analysis showed cardiac bioluminescence sig-
nals increased from 1.3x106±1.0x105 at day 2 to 1.9x107±1.3x106 at day 7 to 5.4x107±4.7x106 
at day 14 and to 4.2x108±3.7x107 p/s/cm2/sr at day 35. As early as 4 days after intramyocardial 
delivery, a strong BLI signal was present within the chest region. Moreover, a separate focal 
signal within the long femur bone marrow was noticeable, which is likely due to leakage from 
the intramyocardial injection and seeding peripherally. At day 35, all mice were too weak for 
further follow-up and had to be euthanized. During necropsy, the organs were explanted and 
imaged immediately. Ex vivo bioluminescence signals were found in the heart, spine, humerus, 
femur, submandible (figure 3b).
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Animals injected with control non-transduced ESCs showed no bioluminescence signals as 
expected (data not shown). Finally, histological examination with H&E staining also confirmed 
presence of teratoma formation in the heart, femur, and submandible (figure 4). Interestingly, 
only a small amount of intramyocardially transplanted ES-DF cells expressed the cardiac-spe-
cific marker troponin T, suggesting that the in vivo differentiation of ESCs into cardiomyocytes 








Figure 3. Noninvasive bioluminescence imaging of ESC survival, proliferation, and teratoma formation 
in Sv129 mice. (a) One million ES-DF cells were injected intramyocardially into immunocompetent syngeneic 
Sv129 mice hearts. Imaging of the same representative animal over 5 weeks showed a progressive increase in 
intra-cardiac and extra-cardiac signals. (b) Ex vivo imaging of explanted organs from the same sacrificed animal 
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Figure 4. Postmortem histology confirms teratoma formation. (a) Representative H&E staining of a section of 
heart showing (I) teratoma (lower power field) with (II) epithelium (arrow), cartilage (#), and osteoid (*) formation 
inside (higher power field). Few numbers of the transplanted ES-DF cell population were found to differentiate 
into cardiomyocytes as assessed by double-staining of GFP and cardiac troponin T (cTNT) (III, IV). (b) Teratoma 
formation was also observed in extra-cardiac organs: (I) H&E staining showing submandibular teratoma forma-
tion (lower power field) and (II) typical gland (arrow), cartilage (*), and epidermis (#) development (high power 
field of I). Concordantly, teratoma formation was observed (III) in the femur bone with multiple cell lineages 
including (IV) gland cells (arrow). 
Long-term tracking of ESC fate by BLI. In order to investigate whether lower cell number 
would have a different outcome, we decided to inject a smaller number (∼10,000) of ES-DF 
cells and follow the animals for a longer period. Since the smaller size of mice was only able to 
bear teratoma formation for up to 5 weeks, we switched to the larger size rats. This also allowed 
us to test the influence of different animal species. After intramyocardial injection of 10,000 ES-
DF cells, nude rats were followed by BLI longitudinally (figure 5a, 5b). After 10 months, animals 
were sacrificed and hearts were explanted for visual inspection of gross morphology. Histolo-
gical sectioning of all hearts confirmed differentiation into all three germ layers (figure 5c). 
These results indicate that, even after deliberate local delivery into the left ventricular mass, 
the process is still associated with extra-cardiac leakage and seeding to other organs. 
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Figure 5. Long term noninvasive tracking of ESC survival kinetics in nude rats. (a) In vivo visualization of 
ESC growth and migration until 10 months after transplantation into the hearts of nude rats. (b) Growth curve of 
transplanted ES-DF cells in vivo. Y-axis shows BLI signal from a fixed region of interest (p/s/cm2/sr) over the heart, 
while the X-axis represents time after transplantation (months). (c) Gross (I) in situ and (II) ex vivo picture of the 
heart from figure 5a containing a visible teratoma. H&E staining of slides from the explanted heart confirms (III) 
clear-edged teratoma formation within the cardiac tissue (lower magnification), including (IV) bone formation.
diSCuSSion
ESCs hold great promise in regenerative medicine. However, several critical obstacles need to 
be resolved before ESCs can play a role in clinical medicine. Among these are the immunogeni-
city of ESCs, and perhaps more importantly from the safety standpoint, the tumorigenic ability 
of ESCs.6, 16 This study has shown that molecular imaging is a reliable tool for long-term in vivo 
imaging of ESCs. Our major findings are as follows: (a) reporter genes do not affect ES cell vi-
ability and proliferation; (b) as low as 500-1000 undifferentiated ESCs are capable of inducing 
teratoma formation; and (c) ESCs are capable of causing teratomas in both intra-cardiac and 
extra-cardiac sites after local intramyocardial delivery.
Although the risk of teratoma formation may be reduced by prolonged cell differentiation be-
fore its engraftment, in reality pre-differentiated ESCs or ESC-derived precursor cells might still 
form teratoma after transplantation into animals.17 Recently, Harkany et al. observed teratoma 
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sent further evidence that even 500 to 1000 murine ESCs were sufficient to induce teratoma 
formation, while less than 100 ESCs were not. In contrast, Nussbaum et al. have shown that 
50,000 intramyocardially injected murine ESCs were not noticeable in the heart and spleen and 
did not form teratoma after 3 weeks.16 Several factors might underlie the discrepancy between 
the findings. First of all, to mimic cell contamination, we have transplanted different numbers 
of ESCs accompanied by MEFs to achieve a total cell number of 100,000 cells. The MEFs might 
have contributed to better ESC engraftment, survival, and subsequent teratoma formation. Se-
condly, using conventional histological staining, Nussbaum et al. investigated teratoma forma-
tion at the site of transplantation (myocardium) and at one distant location (spleen), with both 
locations free of ESCs.16 This was in concordance with a recent report, whereby teratomas were 
induced in the kidney capsule of immunodeficient mice but without any human ESC activity 
in the spleen after 8 weeks as well.19 By contrast, using more sensitive in vivo whole body mo-
lecular imaging, which was validated by immediate ex vivo imaging of explanted organs, we 
did observe profound activity at other distant locations, such as the submandible and femur, 
suggesting ESC leakage during transplantation and subsequent engraftment and proliferation 
into teratoma. Taken together, these findings suggest longitudinal noninvasive imaging may 
give more valuable insight into teratoma formation and migration compared to conventional 
histology. 
Previously, we had demonstrated the feasibility of using triple fusion reporter gene to track the 
fate of transplanted murine ESCs in living subjects by fluorescence, bioluminescence and posi-
tron emission tomography (PET) modalities.2 This was followed by another study showing that 
not only does the herpes simplex virus thymidine kinase (HSV-tk) PET reporter gene can be used 
to monitor ESC engraftment, it also serves useful purpose as a suicide gene to ablate ESC mis-
behavior.20 In the current study, we further expanded on these initial observations by using a 
SIN lentiviral vector with ubiquitin promoter driving the bioluminescence (Fluc) and fluorescence 
(eGFP) to address the influence of undifferentiated ESC number, migration, and long-term follow 
up after transplantation. The human immunodeficiency virus type 1 (HIV-1)-based lentiviral vec-
tor has been shown to be an excellent tool for stable and efficient gene transfer to mouse21 and 
human ESCs.22 The enhanced safety of the self-inactivating (SIN) lentivirus is achieved by (a) using 
a three-plasmid expression system which consists of packaging, envelop, and vector constructs23, 
(b) by eliminating accessory genes (vif, vpr, vpu, and nef) from the packaging construct without 
losing the ability to transducer nondividing cells24, and (c) by deleting the viral enhancer and pro-
moter sequences from the long terminal repeat (LTR) sequence10. The double fusion construct we 
employed consists of two optical reporter genes (Fluc-eGFP) separated by a 14-amino acid linker. 
The Fluc enzyme catalyzes the oxidation of the D-luciferin (ATP and oxygen dependent) reporter 
probe into oxyluciferin, which emits low energy photons (2-3 eV) at 560 nm wavelength that can 
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be detected by an ultra-sensitive CCD camera12. By contrast, GFP does not require a substrate (or 
reporter probe) such as D-luciferin but rather relies on excitation wavelength in the visible light 
range of 395-600 nm. Wild-type GFP emits green (509 nm) light when excited by violet (395 nm) 
light. The variant eGFP has a shifted excitation spectrum to longer wavelength (488 nm) and has 
increased brightness (35-fold).25 Thus, by using the double fusion reporter gene construct, we 
were able to perform FACS to isolate stably transduced ESCs (via eGFP) and track their fate in 
living animals (via Fluc) at a rapid and high-throughput fashion.26
In this study, we were able to reliably monitor the fate of 10,000 transplanted ESCs in the heart 
for a period as long as 10 months in living animals. The clinical relevance of these findings 
is profound. As an example, current clinical trials involving bone marrow stem cells for the 
infarcted heart report injecting a mean cell number of 6.8x107 to 2.36x108.27-29 Assuming that 
the same cell numbers of human ESC-derived cardiac cells are used as treatment in the future, 
then ∼500 undifferentiated ESCs (enough to give rise to teratomas in this study) as contami-
nant would represent a total population of less than 0.001%. Yet current selection methods 
for pre-differentiated ESC-derived cardiomyocytes typically yield a maximum purity of 70% 
for human ESCs30 and 90% for murine ESCs.14 This scenario highlights the tedious and careful 
clinical protocols that need to be devised to avoid contaminants. 
Several limitations of the study need to be raised. First, we have focused on murine rather than 
human ESCs. While murine and human ESCs have been compared for their gene expression 
pattern31, there is a lack of comparison studies on teratoma formation. In the future, the same 
issue of minimal human ESCs that can cause teratoma formation will need to be addressed. 
Second, ESCs tend to differentiate at an earlier stage when implanted subcutaneously (compa-
red to intra-hepatic transplantation) as described by Cooke and colleagues8. In this respect, the 
well vascularized, growth factor-rich, and perhaps immune-privileged porous structure in the 
liver may help to maintain ESCs in undifferentiated state.8 Thus, it is plausible that when trans-
planted in the liver, the minimal cell number needed for teratoma formation might be even 
lower than the 500 to 1,000 cells found on subcutaneous study in the present study. Third, we 
used nude mice while others have relied on severe combined immunodeficient (SCID) mice. 
Nude mice (lacking furs) are easier to image but have more natural killer (NK) cell activity as 
compared to SCID mice32, which could also contribute to transplanted cell death by NK cell-
mediated cytotoxicity.33 Moreover, decreased tumor engraftment and higher regression rates 
of several tumor cell lines have been observed in nude mice as compared to increased tumor 
growth and larger tumor mass in SCID mice.34, 35 These observations suggest that the actual cell 
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In summary, we have provided important insight into the influence of ESC number, cell migra-
tion, and engraftment period on teratoma formation. These findings are an additional stimulus 
for further research on this topic. Therefore, our ongoing work is focusing on optimizing in 
vitro differentiating systems to acquire purer populations for transplantation, in vivo imaging 
of stem cell behavior, and how to control teratoma formation after transplantation. All these 
issues need thorough understanding in order for ESCs to play the prominent role they are ex-
pected to play in clinical treatments.
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abStRaCt
Human embryonic stem cells (hESCs) are capable of differentiation into every cell type of the 
human being. They are under extensive investigation for their regenerative potential in a vari-
ety of debilitating diseases. However, the field of hESC research is still in its infancy, as there are 
several critical issues that need to be resolved before clinical translation. Two major concerns 
are the ability of undifferentiated hESCs to form teratomas and the possibility of a provoked 
immune reaction after transplantation of hESCs into a new host. Therefore, it is imperative to 
develop non-invasive imaging modalities that allow for longitudinal, repetitive, and quanti-
tative assessment of transplanted cell survival, proliferation, and migration in vivo. Reporter 
gene-based molecular imaging offers these characteristics and has great potential in the field 
of stem cell therapy. Moreover, it has recently been shown that reporter gene imaging can 
be combined with therapeutic strategies. Here, we provide an outline of the current status of 
hESC research and discuss the concerns of tumorigenicity and immunogenicity. Furthermore, 
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intRoduCtion
Adult stem cells have great promise as potential treatments for a variety of intractable disea-
ses. However, these cells are generally limited in their plasticity. Therefore, it would be ideal 
to obtain or create a cell line that is truly able to differentiate into every cell of the body. The 
first such cell line was derived in the 1960’s and originated from teratomas that developed 
spontaneously in male mice of the 129 strain. These “embryonal carcinoma” (EC) cells were 
capable of teratoma formation after transplantation of single cells into a new host,1 confirming 
their ability to differentiate into progeny of all three germ layers (ectoderm, mesoderm and 
endoderm)--a phenomenon known as ‘pluripotency’.2 Further research led to the first isolation 
of murine embryonic stem cells (mESCs) in 1981 from the epiblast of blastocyst-stage mouse 
embryos,3, 4 followed by the establishment of the first human embryonic stem cell (hESC)-line 
in 1998.2 To date, there are more than 300 hESC lines, but only 22 hESC lines are commercially 
available and registered in the “NIH Human Embryonic Stem Cell Registry”.5
Although most studies using hESCs in disease models show auspicious results, there are se-
veral concerns about hESC transplantation. First, the pluripotent character of hESCs is some-
what a double-edged sword. They are an attractive candidate for cell based therapies, but their 
pluripotency can also lead to risk of teratoma formation after transplantation. Second, since 
it is presently impossible to transplant hESCs syngeneically, the possibility that hESCs might 
provoke an immune reaction following allogeneic transplantation must be considered. This 
review will discuss these issues and how molecular imaging can help resolve them.
deRivation, maintenanCe, and diffeRentiation
Traditionally, hESCs are isolated from the inner cell mass of the human blastocyst, or as recently 
shown, can be derived from single blastomeres.6 The isolated cells can be expanded in vitro, 
with an average doubling time of 30-35 h.7 However, strict homeostatic culture conditions and 
the addition of inhibiting compounds are necessary to keep the hESCs in an undifferentiated 
state, a condition required for maintaining a normal karyotype and an unlimited capacity for 
self-renewal. This is possible by growing hESCs on a cellular feeder layer. Inactivated murine 
embryonic fibroblasts prove to be an effective feeder layer for the undifferentiated growth of 
hESCs because they secrete differentiation-inhibiting factors.8 Due to the risk of cross-species 
retroviral infection, however, this is an unattractive option in the long term. Recently, several 
reports have described the culture of hESCs in animal-free conditions, using human feeder 
cells consisting of foreskin,9 pure human fibroblast populations,10 or uterine endometrial cells 
and serum-free medium.11 Generally, these undifferentiated hESCs express transcription fac-
tors OCT-3/4, Sox-2, and NANOG; surface markers CD9, CD133, and SSEA-3/4; proteoglycans 
TRA-1-60/81 and TRA-2-54; and enzyme alkaline phosphatases and telomerase.12, 13
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Following withdrawal of inhibitory factors, hESCs will aggregate into three-dimensional clus-
ters of cells in an early stage of differentiation, thereby losing pluripotency. These clusters, 
named Embryoid Bodies (EBs),14 form the first step of further differentiation into any type of 
progeny. Within the EBs, a microenvironment exists in which various signals will promote diffe-
rentiation into all three germ layers. Although differentiation generally occurs spontaneously, 
much effort currently focuses on stimulating directed differentiation to achieve sufficiently 
large populations for clinical use. The generation of pure, differentiated cultures is indispen-
sable for developing cell based therapies, and will help us better understand cellular develop-
mental processes and test pharmacological strategies.
Differentiation into Mesoderm Lineages
While reports have been published of hESCs differentiating into various mesodermal lineages, 
including kidney, muscle, bone and blood cells,15 it is cardiomyogenesis that has received the 
most attention. Cardiomyogenesis typically manifests as a beating area within the EBs around 
5 days after EB-formation, the surface of which increases gradually with time.16 Kehat and col-
leagues were the first to show that hESC-derived cardiomyocytes within these beating EBs 
actually resemble the structural and functional properties of early stage human cardiomyocy-
tes.16 Since then, several other methods have been tested to improve the efficiency of in vitro 
differentiation of hESCs into cardiomyocytes with moderate success.17-19 
Differentiation into Ectoderm Lineages
Using different growth factors and stimulating environments, hESCs can also be driven to dif-
ferentiate into brain, skin, and adrenal derivates.15 The potential of hESC-derived cultures for 
the treatment of neurodegenerative disorders is under intensive investigation. While many 
groups have described neuronal differentiation within the EB,20-22 factor-induced neuronal dif-
ferentiation seems to be limited to the addition of retinoic acid (RA) and nerve growth factor 
(betaNGF),21 or the use of serum-free, conditioned medium.23 The coculture of hESCs with mu-
rine skull bone marrow-derived stromal cells also seems to induce neuronal differentiation.24
Differentiation into Endoderm Lineages
From the beginning, hESCs were shown to be capable of differentiating in vitro into liver and 
pancreatic cells when exposed to a variety of growth factors.15 The creation of insulin-secreting 
pancreatic cell populations has generated much interest, as this might ultimately provide a 
cell-based therapy for patients with type I diabetes.25 However, the identification of insulin-
producing cells has proven to be difficult and susceptible to artifacts.26 Thus, the in vitro pan-
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In summary, although much is being done to improve the efficacy of in vitro differentiation 
systems, little is known about the cellular interactions that occur during natural differentiation. 
Most of the in vitro differentiation methods are to some extent dependent on EB formation. 
The process of in vitro EB formation mimics the natural transcriptional pathways occurring in 
the developing embryo, leading not only to the differentiation into the desired cell type, but 
also to the production of undesired cells. The most dangerous example of the latter is undif-
ferentiated hESCs that retain the ability to form teratomas. Until we understand the precise 
pathways of pluripotent differentiation, the acquisition of desired, transplantable cell types 
can only rely on stimulating known pathways and the pre-transplantation selection of the de-
sired cell type. 
teRatoma foRmation
At present no selection method exists that can yield a 100% pure population, which is a major 
obstacle for clinical translation. When transplanted in immunodeficient mice, hESCs form te-
ratomas consisting of human tissues from all germ layers.2, 28 The formation and composition 
of teratomas seem to be influenced by several factors, including graft site,29 transplanted cell 
number, and developmental phase of the host,24 as described next.
One factor influencing hESC-based teratoma formation is the site of transplantation, which af-
fects both growth and composition of the tumor. As recently shown by Cooke and colleagues, 
teratomas rising from hESCs will grow faster and contain more undifferentiated cells when 
transplanted in the liver of nude mice, as compared to subcutaneous transplantation.29 It is of 
major interest why hESCs differentiate at the subcutaneous site but remain undifferentiated in 
the liver. The authors hypothesize that this was due to the well vascularized, growth factor-rich, 
immune-privileged porous structure in the liver.29 These findings are not only a stimulant for 
further research on graft site and teratoma formation, but also indicate the importance of in 
vivo experiments, as there may be factors present in the liver that could help maintain hESCs in 
an undifferentiated state in vitro.
Another factor influencing teratoma formation is the number of undifferentiated hESCs that 
are viable after transplantation. As discussed earlier, transplantation of pure undifferentia-
ted hESC inevitably leads to teratoma formation.2, 28 Interestingly, transplantation of selected 
hESC-derived cells in a more developed phase will not automatically lead to teratomas, even 
when this population is not 100% pure.30 However, there are no extant studies that assess the 
minimal cell number needed for teratoma formation, or stated otherwise, the maximum per-
centage of contamination with undifferentiated hESC. Our laboratory is actively investigating 
these issues.
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Recently, Muotri and colleagues have studied undifferentiated hESC after in utero transplanta-
tion into the lateral brain ventricle of day-14 mouse embryos.24 The results showed that hESCs 
integrated into the brain, giving rise to neuronal and glial lineages, but not to teratomas. These 
findings suggest that hESCs are susceptible to environmental cues that can modulate its dif-
ferentiation and tumorigenic potential, as was suggested in earlier studies with hESCs in chick 
embryos.31 
Taken together, these observations and questions are not only a stimulant for further research 
on teratoma biology, but also indicate the importance of developing novel imaging tech- 
niques to track their growth in vivo longitudinally, repetitively, and quantitatively. 
immunogeniCity
Another hurdle facing clinical transplantation of hESCs is the potential immunologic barrier. 
The immune response generated after transplantation is directed towards alloantigens, which 
are antigens presented on the cell surface that are considered non-self by the recipient im- 
mune system.32 The major system of alloantigens responsible for cell incompatibility is the ma-
jor histocompatibility complex (MHC). In humans, MHC-I molecules are expressed on the surf-
ace of virtually all nucleated cells and present antigens to CD8+ cytotoxic T cells, while MHC-II 
molecules are normally more restricted to antigen presenting cells such as dendritic cells and 
macrophages, and are selectively recognized by CD4+ helper T cells.33
It has been shown that hESCs express low levels of MHC-I in their undifferentiated state.34, 35 
In one study, the MHC-I expression increased two to four-fold when the cells were induced to 
spontaneously differentiate to EB, and an eight to ten-fold when induced to differentiate into 
teratomas.34 In contrast, a different group observed MHC-I downregulation after differentiation 
induced with retinoic acid or on Matrigel or in extended cultures.35 In both studies, MHC-I ex-
pression was strongly upregulated after treatment of the cells with interferon-γ, a potent MHC 
expression-inducing cytokine known to be released during the course of an immune response. 
MHC-II antigens were not expressed on hESCs or hESC derivatives.34 The latter finding confirms 
that, in contrast to tissue allografts, hESC transplants are devoid of highly immunogenic ma-
ture dendritic cells, or any other type of specialized antigen presenting cells. Thus, the trans-
planted cells may not express MHC-II molecules required for effective priming of alloreactive 
CD4+ T cells through direct recognition. 
Previously, our group tested allogeneic undifferentiated mESCs for their ability to trigger al-
loimmune response in a murine model of myocardial infarction.36 We found progressive intra-
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cells) and innate (macrophages and granulocytes) immunity. Cellular infiltration progressed 
from mild infiltration at two weeks to vigorous infiltration at four weeks, leading to rejection of 
the mESC allograft. Moreover, we found an accelerated immune response against mESCs that 
had differentiated in vivo for 2 weeks, suggesting that mESC immunogenicity increases upon 
their differentiation.36
Although it was previously reported that hESCs failed to elicit immune responses during the 
first 48 hours after intramuscular injection of immunocompetent mice,37 a recent report using 
a similar model found hESCs to be completely eliminated at 1 month post-transplantation.38 
Thus, questions regarding the exact character and intensity of immune responses towards al-
logeneic hESCs and their derivatives remain. Solutions that reduce or eliminate the potential 
immunological response to transplanted allogeneic hESCs are urgently needed. Possible stra-
tegies to minimize rejection of hESC transplants have been extensively reviewed elsewhere.39, 
40 Examples of these strategies include: (1) forming HLA isotyped hESC-line banks; (2) creating 
a universal donor cell by genetic modification; (3) inducing tolerance by hematopoietic chi-
merism; or (4) generating isogeneic hESC lines by somatic nuclear transfer. To optimize these 
techniques in the future, it is crucial to develop sensitive and reliable imaging methods for 
monitoring the viability of transplanted cells in vivo. 
moleCulaR imaging
To date, most studies on stem cell therapy have relied on conventional reporter genes such as 
GFP41 and b-galactosidase (lacZ) to monitor cell survival and differentiation. However,   these 
reporter genes cannot be used to reliably track in vivo characteristics of transplanted cells 
due to poor tissue penetration and the need for extrinsic excitation light, which produces an 
unacceptable amount of background signal. Instead, GFP-labeled cells are typically identified 
histologically, which provides only a single snapshot representation rather than a complete 
picture of cell survival over time. To solve these shortcomings, our group has been developing 
reporter gene-based molecular imaging techniques.42 
Molecular imaging can be broadly defined as the in vivo characterization of cellular and mo-
lecular processes.43 The backbone of reporter gene-based molecular imaging technique is 
the design of a suitable reporter construct. This construct carries a reporter gene linked to 
a promoter/enhancer, which can be inducible, constitutive, or tissue specific. The construct 
can be introduced into the target tissue by molecular biology techniques using either viral or 
non-viral techniques. Transcription of DNA and translation of mRNA lead to the production of 
reporter protein. After administration of a reporter probe, the reporter protein reacts with the 
reporter probe, giving rise to signals that are detectable by a charged-coupled device (CCD) 
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camera, positron emission tomography (PET), single photon emission computed tomography 
(SPECT), or magnetic resonance imaging (MRI) (figure 1). For thorough review, please refer to 
other relevant articles.43, 44 
Figure 1. Schematic overview of molecular imaging. Outline of a vector containing a DNA reporter construct 
with the reporter gene(s) driven by a promoter of choice. Transcription and translation lead to production of 
mRNA and reporter protein, respectively. After administration of a reporter probe systemically, the reporter 
probe will be catalyzed by specific cells that have the reporter proteins. This amplification process can be de-
tected by a sensitive imaging device. Examples of reporter genes and their specific reporter probes are listed 
per imaging modality. Abbreviations: Fluc, Firefly luciferase; PET, positron emission tomography; HSV-ttk, herpes 
simplex virus truncated thymidine kinase; [18F]-FHBG, 9-(4-[18F]-fluoro-3hydroxymethylbutyl) guanine; SPECT, 
single photon emission computed tomography; hNIS, human sodium/iodide symporter; MRI, magnetic reso-
nance imaging; CCD, charged coupled device; BLI, bioluminescence imaging.
Imaging ESC Transplantation, Tumorigenicity, and Immunogenicity 
A major advantage of reporter gene imaging is the incorporation of the reporter construct into 
the cellular DNA. This ensures that the reporter gene will only be expressed by living cells and will 
be passed on equally to the cell’s progeny. Thus, this imaging modality can provide significant 
insight into cell viability and proliferation. As discussed earlier, monitoring cell viability is a criti-
cal requirement to assess immunogenicity, as a provoked immune reaction can kill transplanted 
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tential of undifferentiated hESCs. Moreover, the ability to image the whole-body will allow us to 
track cell migration in other organs. This is a major advantage when compared to tissue biopsies 
using GFP-labeled cells.
In addition, multiple reporter genes can also be introduced into the same cell for multimodality 
imaging. Recently, our group has tested the efficacy of mESC with a self-inactivating lentiviral 
vector carrying triple-fusion (TF) construct containing firefly luciferase (Fluc), monomeric red 
fluorescent protein (mRFP), and herpes simplex virus truncated thymidine kinase (HSV-ttk).45 
The mRFP in the construct facilitates the imaging of single cells by fluorescence microscopy 
and allows for the isolation of a stable clone population by fluorescence activated cell sorter 
(FACS). The Fluc can be used to perform high throughput bioluminescence imaging (BLI) for 
assessment of cell survival, proliferation and migration at relatively low costs. Finally, the HSV-
ttk allows for deep-tissue PET imaging of gene expression in small animals45, 46 as well as in 
patients.47, 48 After transplantation into the hearts of athymic nude rats, mESCs could be succes-
sfully followed for 4 weeks using BLI and PET imaging. Between week 2 and 4, both BLI and PET 
reporter gene signals increased rapidly, indicating teratoma formation. This was confirmed by 
histological analysis.45 
Because of the risk of teratoma formation, it would be ideal to have an in vivo imaging moda-
lity in combination with a fail-safe suicide-gene mechanism. Using the antiviral drug ganci-
clovir, which is toxic against cells expressing HSV-ttk, Cao and colleagues were able to ablate 
teratoma formation and follow this progress non-invasively.49 This study reveals the excellent 
potential of reporter gene imaging for future use with hESC transplantation. In fact, prelimi-
nary studies in our lab suggest that as low as 100 undifferentiated hESCs (H9 line) can cause 
teratoma formation after subcutaneous injection (figure 2). Whether lower cell numbers (e.g. 
1, 10, 50), other graft sites (e.g. intramuscular, intravenous), or different cell lines (e.g., federally 
and non-federally approved) have similar kinetics of teratoma formation will need to be deter-
mined carefully in the future.
Finally, a very critical question with regard to reporter genes is whether they will affect ESC 
differentiation and hamper efforts for clinical applications. A previous study from our lab has 
shown that the TF reporter genes affect <2% of total genes of mESC using transcriptional pro-
filing analysis.50 A more recent follow up study using proteomic analysis show that there were 
no significant differences between control mESCs versus mESCs with reporter genes.51 Impor-
tantly, reporter probes such as D-Luciferin (for Fluc) and [18F]-FHBG (for HSV-ttk) had no ad-
verse effects on mESC viability and proliferation as well.45 Ongoing studies are evaluating the 
effects of reporter gene expression and reporter probes on various hESC cell lines.
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Figure 2. In vivo bioluminescence imaging of teratoma formation after transplantation of 100 hESCs. (a) 
Bioluminescence image showing longitudinal follow up after transplantation of 100 hESCs stably expressing a 
double fusion reporter gene (Fluc-GFP). Faint imaging signals were seen as early as 2 hrs after transplant, which 
became progressively stronger over 2 weeks. Histology at 8 weeks confirmed teratoma formation. Note one of 
the hESC transplanted sites did not successfully engraft (arrow) as there were no detectable signals by 2 weeks. 
(b) Histology from a representative explanted teratoma showing hESCs that have differentiated into Histology 
from a representative explanted teratoma showing hESCs that have differentiated into derivates from different 
germ layers. (I) squamous cell differentiation with keratin pearl; (II) respiratory epithelium with ciliated columnar 
and mucin producing goblet cells; (III) osteoid (non-mineralized bone) formation; (IV) cartilage formation; (V) 
gland cells; and (VI) rosette consistent with neuroectodermal differentiation (400x magnification).
ConCluSion
Clearly, the capacity of hESCs to differentiate into almost all human cell types highlights their 
promising role in regenerative therapies for the treatment of heart disease, Parkinson’s disease, 
leukemia, diabetes, and other degenerative disorders. But the pluripotency of hESCs may also 
pose major risks such as teratoma formation. Likewise, hESCs might not be immunoprivileged 
and could trigger host immune responses, leading to decreased cell survival or acute rejection. 
These are issues that can become significant barriers to future clinical application of hESC-
based therapies. To meet these challenges, researchers must gain a better understanding of 
the in vivo behavior of transplanted hESCs. This review outlines the burgeoning application of 
molecular imaging to track transplanted hESCs in vivo. Continuing research merging molecular 
imaging and hESC biology will likely lead to significant advances in the future, both scientifi-
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abStRaCt
Over the past few years, human embryonic stem cells (hESCs) have gained popularity as a po-
tentially ideal cell candidate for tissue regeneration. In particular, hESCs are capable of cardiac 
lineage-specific differentiation and confer improvement of cardiac function following trans-
plantation into animal models. Although such data are encouraging, there remain significant 
hurdles before safe and successful translation of hESC-based treatment into clinical therapy, 
including the inability to assess cells following transplant. To this end, molecular imaging has 
proven a reliable methodology for tracking the long-term fate of transplanted cells. Imaging 
reporter genes introduced into the cells prior to transplantation enable non-invasive and lon-
gitudinal studies of cell viability, location, and behavior in vivo. Therefore, molecular imaging 
is expected to play an increasing role in characterizing the biology and physiology of hESC-
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intRoduCtion
Coronary artery disease remains the leading cause of death in the Western world.1 As the hu-
man heart is not capable of regenerating the great numbers of cardiac cells that are lost after 
myocardial infarction, impaired cardiac function is the inevitable result of ischemic disease. 
Recently, three randomized clinical trails reported either clinically marginal2, 3 or no4 signifi-
cant benefit following adult bone marrow cell transplantation for patients suffering from acute 
and/or chronic ischemic heart disease. These reports add to a growing body of evidence that 
adult-derived stem cells have limited capacity to aid renewal and regeneration of damaged 
organs and structures. By contrast, hESCs show greater promise, as they are capable of self-
renewal and differentiation. hESCs were first isolated by Thompson and colleagues in 1998.5 
They are derived from the inner cell mass of the human blastocyst and can be kept in an undif-
ferentiated, self-renewing state when cultured in the presence of inhibitory compounds, such 
as mouse embryonic fibroblast feeder layer cells. Compared to adult stem cells harvested from 
the bone marrow, hESCs have the advantage of being pluripotent, which provides them with 
the ability to differentiate into virtually all cells of the human body. For cardiac applications, 
hESCs have the ability to differentiate into cardiac cell lineages.6, 7 These hESC-derived cardiac 
cells have structural and functional properties of human cardiomyocytes and can integrate 
with host myocardium after transplantation into rats8 and pigs.9 However, in order to critically 
evaluate and optimize hESC-based therapy for the heart, new methodologies for assessing the 
viability, location, and behavior of transplanted cells are needed. This article aims to provide a 
concise overview of the major hurdles that need to be addressed before hESC-derived cardiac 
cell transplantation can become a clinical reality. This is followed by an outline of potential of 
molecular imaging tools that may help to overcome these challenges in the future.
huRdleS foR CliniCal tRanSlation
Although substantial progress has been made in recent years towards improving culture con-
ditions, differentiation strategies, and potential hESC-based cardiac regeneration, several un-
resolved issues exist between the laboratory and bedside that still need to be bridged (figure 
1). This article will cover some of the major areas of concern regarding hESC-derived cardiac 
cell transplantation, including: (1) optimization of in vitro differentiation into cardiac cells; (2) 
purification of cardiac cells to minimize post-transplant cellular misbehavior such as teratoma 
formation; (3) in vivo integration and function with host myocardium; and (4) evaluation of 
post-transplant immune rejection and cell death. 
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Figure 1. Human embryonic stem cells: from laboratory to bedside. Areas of concern in derivation, culture, 
differentiation, purification, delivery, integration, and survival are outlined. 
In vitro differentiation to cardiomyocytes
Following removal of the inhibitory feeder layer cells, hESCs can aggregate into clusters of cells 
known as embryoid bodies (EBs). Within these EBs, various signals are activated to promote 
differentiation of cells into all three germ layers, including mesoderm-derived cardiac cells (fi-
gure 2). Formation of cardiomyocytes usually starts 5 days after EB-formation, presenting as a 
beating area within the EB. Moreover, the hESC-derived cardiac cells within these beating areas 
actually resemble the structural and functional properties of early stage human cardiomyocy-
tes.6 Unfortunately, the rate of spontaneous differentiation of hESCs into cardiac cells is low. 
Typically ∼8% of the EBs grown in suspension undergo differentiation into beating clusters, 
and ∼30% of the cells contained in these clusters are actual cardiomyocytes.6
Mouse ESCs (mESCs) were originally isolated in 198110, and subsequent studies have focused 
on different strategies to induce cardiac-specific differentiation of mESCs in vitro. Retinoic acid 
was one of the first agents described that significantly increase the percentage of cardiomyo-
cytes arising from ESCs.11 Similar effects have been described for oxytocin12, dynorphin B13, 
nitric oxide14, and ascorbic acid.15 However, the efficacy of these compounds can be dose-
dependent and bound to a specific time period in embryonic development.11 Other groups 
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ding transforming growth factor-β216, basic fibroblast growth factor, and bone-morphogene-
tic protein-2.17 Interestingly, findings from mESC studies do not appear to translate to hESC 
research. Thus far, only 5-aza-2’-deoxycytidine7, combination of activin A and BMP-418, and co-
culture with murine END-2 visceral endoderm-like cells19 have been shown to enhance cardio-
myogenesis in hESC cultures.
Figure 2. Undifferentiated hESCs (H9 cell line) grow indefinitely in culture on mouse embryonic fibroblast 
feeder layer cells (upper left panel). Following withdrawal of inhibitory feeder cells, hESCs can aggregate into 
EBs (upper right panel). Formation of cardiac cells usually starts 5 days after differentiation, initially presenting 
as a beating cluster within the EB. After isolation of EBs and further enrichment by Percoll gradient separation, 
these hESC-derived cardiac cells (lower panels) express cardiac lineage specific makers as shown by immunof-
luorescent staining of GFP-labeled cells with skeletal muscle alpha actin (a-Actin), connexin-43 (Cx-43), cardiac 
troponin T (cTnT), and Myosin Enhancer Factor 2c (MEF2c) (all in red; counterstaining with DAPI, blue).
Purification of hESC-derived cardiac cells
Once ESCs are successfully induced to adopt cardiac fate, it becomes yet another challenge to 
isolate and further purify such subpopulations while avoiding contamination by undifferenti-
ated, pluripotent ESCs. Following transplantation, undifferentiated ESCs could cause teratoma 
formation, which are complex tumors comprised of cellular or oganoid components reminis-
cent of normal derivatives from the three germ layers.20 This indicates the need to achieve 
a highly, if not completely, pure population of cardiomyocytes prior to transplantation. Cur-
rently, selection methods for ESC-derived cardiac cells include Percoll density gradient-based 
isolation, which can enrich up to ∼70% pure cardiac cell population for hESC7 and ∼90% for 
mESC.21 An alternative strategy for cardiac cell purification combines genetic engineering and 
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molecular biology techniques. Klug et al. utilized a fusion gene consisting of an alpha-cardiac 
myosin heavy chain (α-MHC) promoter that drives expression of aminoglycoside phospho-
transferase, which is an enzyme that confers resistance to the antibiotic geneticin (G418). Once 
the transgenic mESCs differentiate into cardiac cells, activation of the cardiac specific a-MHC 
promoter leads to expression of aminoglycoside phosphotransferase and allows these cells to 
survive against treatment with G418. The resultant surviving cells represent 99% pure cardio-
myocyte population22. Similarly, Muller et al. reported transfection of mESCs with a fusion gene 
of of myosin light chain-2v (MLC-2v) linked to enhanced green fluorescent protein (eGFP). In 
this case, mESC-derived cardiac cells expressed eGFP that enabled fluorescent-activated cell 
sorting (FACS) and collection of cardiomyocyte population (97% pure).23
In vivo integration and function of ESC-derived cardiac cells
Data from rodent models evaluating the fate of mESC transplantation into the heart have 
demonstrated mixed results. Early reports by Min et al. evaluating transplantation of mESC-
derived beating cells into immunocompetent rat myocardium showed long-term (up to 32 
weeks) cell survival, improvement of cardiac function, and improved angiogenesis in the in-
farct zone24, 25. Most notably, no adverse sequelae such as graft rejection, arrythmogenesis, or 
teratoma formation were observed. By contrast, two more recent studies demonstrated that 
mESCs transplanted into hearts of both immunocompetent mice20 and athymic nude rats26 
formed teratomas by as early as 3 to 4 weeks following transplantation. At present, there are 
few published studies testing the efficacy of hESC-derived cardiac cell transplantation for car-
diac repair. Kehat et al. showed promising results by injecting hESC-derived cardiac cells into 
swine heart with complete atrioventricular block.9 They demonstrated electromechanical and 
structural coupling of the transplanted cells with the host myocardium. Xue et al. also showed 
functional integration and active pacing of hESC-derived cardiac cells following transfer into 
healthy myocardium of guinea pigs.27 Furthermore, Laflamme et al. demonstrated that hESC-
derived cardiac cells transplanted into athymic rat hearts successfully engrafted, proliferated, 
and expressed several cardiomyocyte markers.8 Notably, none of these studies reported cellu-
lar misbehavior or teratoma formation. It is also not clear what percentage of these transplan-
ted cells actually survived after transplantation
Immune rejection of allogeneic hESC transplantation
Several factors threaten hESC-derived cardiac cell survival following delivery into a new host, 
which, if properly modulated, might prevent the drastic post-transplant death of donor cells 
presently observed. One such major factor is cellular rejection based on immunological in-
compatibility. Theoretically, hESCs represent an immune-privileged cell population, since em-
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ternal host.28 However, the understanding the immunogenicity of hESCs and their derivatives 
remains a challenge.
It has been shown that mESCs do not express major histocompatibility complex (MHC) an-
tigens, the major system of alloantigens responsible for cell incompatibility.29 Furthermore, 
mESCs can inhibit T-lymphocyte proliferation in vitro and establish multi-lineage mixed chi-
merism in vivo.30 However, when allogeneic undifferentiated mESCs were transplanted into a 
murine model of myocardial infarction, our group found progressive intra-graft infiltration of 
inflammatory cells mediating both adaptive (T cells, B cells, and dendritic cells) and innate (ma-
crophages and granulocytes) immunity, leading to rejection of the mESC allograft20. In contrast 
to mESCs, hESCs express low levels of MHC-I antigens.31, 32 Drukker et al. observed that MHC-I 
expression increased two to four-fold when cells were induced to spontaneously differentiate 
to EBs31, and eight to ten-fold when cells differentiated into teratomas. In contrast, Draper et 
al. reported MHC-I downregulation upon hESC differentiation towards EB.32 Thus, questions 
regarding the character and intensity of immune responses towards allogeneic hESC-derived 
cardiac cells still remain. Solutions that reduce or eliminate the potential immunological res-
ponse are needed, including: (1) forming MHC isotyped hESC-line banks; (2) creating a univer-
sal donor cell by genetic modification; (3) inducing tolerance by hematopoietic chimerism; (4) 
generating isogeneic hESC lines by somatic nuclear transfer; (5) and/or using immunosuppres-
sive medication. Details of these strategies to minimize rejection of hESC-derived transplants 
have been extensively reviewed by others.33, 34
imaging heSC-deRived CaRdiaC CellS
non-invasive cell tracking
As outlined earlier, hESC-derived cardiac cell transplantation is potentially feasible, but there 
are several aspects that require improvement. For clinical translation to occur, it is essential 
that tools be developed for longitudinal tracking and evaluation of transplanted cell viability 
and behavior. Traditionally, cell therapy studies have relied upon conventional reporter genes 
such as GFP and b-galactosidase (LacZ) to monitor cell survival and differentiation. However, 
visualizing GFP and LacZ cells requires postmortem tissue analysis, which provides only a sin-
gle snapshot representation of cell fate, not a complete picture over time. Moreover, sampling 
error inherent in ex vivo analysis requires large numbers of animals be sacrificed to develop a 
realistic picture of longitudinal survival kinetics.
Another technique for measuring the efficacy of cell therapy is to assess secondary endpoints. 
Cardiac contractility can be monitored by conventional methodologies such as echocardio-
graphy or magnetic resonance imaging (MRI). Cardiac perfusion can be assessed using posi-
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tron emission tomography (PET) or single-photon emission computed tomography (SPECT). 
However, these data cannot be correlated to the biological state of the cells, as the cells them-
selves can neither be visualized nor assayed in the living subject. Aiming to provide insight into 
the location and survival of transplanted cells, recent studies have reported labeling mESCs 
with magnetic iron particles and following them by MRI.35 Although these iron particles are 
robust and facilitate repeated imaging over time, they do not reliably provide insight into cell 
proliferation and viability, due to the disparate passing of the particles from parent to daugh-
ter cells and the ability of non-specific immune cells (e.g., macrophages) to engulf particles, 
respectively.
Molecular imaging: direct vs. indirect approach
Ideally, a non-invasive method for in vivo tracking of hESC-derived cardiac cells should be ca-
pable of providing insight into the following processes: (1) localization and migration of the 
cells, (2) cell survival and proliferation kinetics, and (3) cell differentiation or de-differentiation 
patterns. Molecular imaging of reporter genes offers potential promise in meeting these goals. 
Molecular imaging can be broadly defined as the visualization of molecular and cellular pro-
cesses in the living subject. For in vivo molecular imaging to work, two basic elements are 
required: a molecular probe that detects a quantifiable signal based on the presence of gene, 
RNA, or protein, and a method to monitor these probes in vivo.36 In general, molecular imaging 
can be divided into two categories: (a) direct imaging of probe-target interaction or (b) indirect 
imaging based on reporter gene and reporter probe.
The most commonly used direct cardiac imaging modality utilizes 18F-fluorodeoxyglucose 
([18F]-FDG), a glucose analog which can cross intact membranes into living cells and is phos-
phorylated by the endogenous enzyme, hexokinase, trapping the probe inside the cell. The 
phosphorylated [18F] will undergo positron annihilation to give off two 511 keV photon sig-
nals that can be detected by PET, providing a measurement of cell or tissue viability37 This 
approach has recently been shown feasible for imaging clinical cardiac cell therapy. Hofmann 
et al. labeled autologous bone marrow cells with [18F]-FDG from nine patients suffering from 
acute myocardial infarction.38 The [18F]-FDG labeled cells were injected into either the infarct-
related coronary artery or the antecubital vein five to ten days following coronary stenting. PET 
imaging was performed 50 to 75 minutes after the procedure and successfully detected the 
transplanted cell population in all patients, with higher signals in the intra-coronary group. Al-
though PET is a valuable tool to monitor the location of cells shortly after transplant, the short 
half-life of the [18F]-FDG radiotracer (∼110 minutes) does not permit long-term follow-up of cell 
survival and/or migration. Furthermore, [18F]-FDG is not passed on to daughter cells during cell 
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The concept behind indirect molecular imaging is an expansion upon basic reporter gene tech-
nology whereby a promoter or enhancer region of interest is linked to the imaging reporter 
gene. The nature of the promoter can be inducible, constitutive, or tissue specific. The con-
struct can be introduced into the target cell using either viral or non-viral techniques. Once 
incorporated, the reporter gene produces the reporter protein which then interacts with the 
introduced reporter probe, producing an analytic signal that can be detected by the detec-
tor system. Depending on the reporter gene used, available imaging modalities include PET, 
SPECT, MRI or a charged-coupled device (CCD) camera.39 The two most widely used reporter 
gene imaging systems are firefly luciferase (Fluc)-based optical bioluminescence imaging and 
herpes simplex virus thymidine kinase (HSV-tk)-based PET imaging. For bioluminescence ima-
ging, the Fluc reporter protein catalyzes the D-Luciferin reporter probe to produce low-energy 
photons (2-3 eV) that can be captured by an ultra-sensitive CCD camera. The reporter probe 
can be administered before every imaging session, allowing for multiple imaging acquisitions 
over time. For PET imaging, the HSV-tk reporter protein phosphorylates radiolabeled thymi-
dine analogue 9-(4-[18F]fluoro-3-(hydroxymethylbutyl)guanine ([18F]-FHBG) reporter probe, 
which emits high-energy photons (511 keV) that can be detected by PET. The reporter gene 
technique has been used to assay survival and localization of transplanted rat embryonic car-
diomyoblasts40 and more recently of mESCs.26
Reporter gene imaging of ESCs and ESC-derived cardiac cells
Regarding transplantation of hESC-derived cardiac cell transplantation, reporter gene imaging 
can be used to monitor critical events. First, since the reporter gene can be integrated into the 
DNA of transplanted cells, its expression is limited to only living cells, and thus facilitates as-
sessment of cell survival. Second, the reporter gene can be passed onto daughter cells, thus 
providing insight into cell proliferation. This is an important feature given the tumorigenic po-
tential of undifferentiated ESCs discussed earlier. Third, it is possible to introduce several repor-
ter genes into the same cell, facilitating a multi-modality imaging approach. Recently, Cao et 
al. tested the efficacy of mESC with a self-inactivating lentiviral vector carrying the triple-fusion 
(TF) construct that consists of firefly luciferase (Fluc), red fluorescence protein (mRFP), and her-
pes simplex virus truncated thymidine kinase (HSV-ttk).26 The mRFP facilitates imaging of sin-
gle cells by fluorescence microscopy and allows for the isolation of a stable clone population 
by FACS. The Fluc allows for bioluminescence imaging for assessment of cell survival, prolifera-
tion, and migration in small animals. Finally, the HSV-ttk affords the ability to use PET imaging 
in small and large animals, as well as humans. Following transplantation into the hearts of 
athymic nude rats, mESC survival, migration, and proliferation was monitored for 4 weeks by 
bioluminescence and PET imaging. PET imaging, both with [18F]-FHBG to image cells and [18F]-
FDG to image myocardial viability, proved to be a very sensitive tool to assess the tomographic 
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location of mESC engraftment (figure 3). However, reporter gene signals increased rapidly 
within 4 weeks due to teratoma formation. Histologic samples obtained from both intra- and 
extra-cardiac sites revealed spontaneous differentiation of the mESC into all three germ layers. 
In a subsequent study, our group also demonstrated the ability of an anti-viral drug to selec-
tively target teratomas expressing the HSV-ttk reporter gene.41 Thus, in addition to its use for 
monitoring cell fate, the reporter gene also serves as an inducible suicide gene that facilitates 
selective cellular ablation. This could be an important tool in controlling cellular misbehavior 
and/or teratoma formation of transplanted hESC-derived cells.
 
Figure 3. Positron emission tomography imaging of transplanted mESCs in the myocardium. Two weeks 
after mESC transplantation, nude rats underwent [18F]-FHBG reporter probe imaging (top row) followed by [18F]-
FDG myocardial viability imaging (middle row). Fusion of [18F]-FHBG and [18F]-FDG images (bottom row) shows 
the exact anatomic location of transplanted mESC (arrow) at the anterolateral wall in horizontal, coronal, and 
sagittal views. (Reproduced with permission from Cao et al.26) 
Recently, our group has successfully transduced hESCs (H9 line) with a lentiviral vector contai-
ning a double fusion (DF) reporter gene that consists of Fluc and eGFP. Cardiac cells derived 
from hESCs using EB formation and Percoll gradient enrichment constitutively express Fluc 
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deficient (SCID) mice, these cells can be monitored by bioluminescence imaging for >3 months 
(Cao et al., unpublished data). By contrast, injection of undifferentiated hESCs caused teratoma 
formation during the same period (figure 4). Taken together, these results highlight the valua-
ble role of molecular imaging for following the developmental fate of transplanted hESCs and 
their derivates.
Figure 4. Comparison of undifferentiated hESCs versus hESC-derived cardiac cell survival and behavior in 
vivo. Both hESC (top row) and hESC-derived cardiac cells (bottom row) were transplantated into ischemic myo-
cardium of SCID mice. Bioluminescence imaging during the first three weeks following transplantation reveals 
acute donor cell death followed by stable survival of hESC-derived cardiac cells. In contrast, undifferentiated hE-
SCs proliferate uncontrollably in the heart as well as other seeded organs (arrows) to cause teratoma formation. 
Finally, a critical question with regard to reporter genes is whether the might influence the 
biology and physiology of the stem cells. In the study by Cao et al., the TF construct had no 
influence on mESC morphology, viability, proliferation, and differentiation capacity in vitro.26 
Likewise, both the bioluminescence (D-luciferin) and PET ([18F]-FHBG) reporter probes had no 
adverse effects on mESC behavior. In two recent studies, the TF reporter genes affected <2% 
of the total mESC genome using transcriptional profiling analysis42 and caused no significant 
differences in protein expression quantified by proteomic analysis.43 Ongoing studies are also 
evaluating the effects of reporter gene and reporter probe on hESCs as well.
78  |   PART I: EMBRYONIC STEM CELLS - CHAPTER 5 DRAwBACKS OF hESC-DERIVED CARDIOMYOCYTE TRANSPLANTATION   |  79
ConCluSion
The last several years have produced revolutionary advancemences in exploring the capabi-
lities of stem cells for treatment of cardiovascular disease. In particular, initial animal results 
involving hESC-derived cardiac cells appear promising for improving cardiac function after 
ischemic injury. Nonetheless, we are still years away from safely translating these initial obser-
vations into therapy for humans. There are several issues within the field that require improve-
ment, especially those related to in vitro differentiation and purification, as well as in vivo inte-
gration and survival of the transplanted cells. As the field of hESC-derived cell transplantation 
emerges, there will be an urgent need for reliable methodologies to track and assess behavior 
of the cells following transfer into the injured heart. Molecular imaging serves these needs and 
will likely play a prominent role in future hESC research.
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ABSTRACT
introduction: A comparative analysis of the efficacy of different cell candidates for the treat-
ment of heart disease remains to be described. This study is designed to evaluate the thera-
peutic efficacy of 4 cell types in a murine model of myocardial infarction. 
methods: Bone marrow mononuclear cells (MN), mesenchymal stem cells (MSC), skeletal 
myoblasts (SkMb) and fibroblasts (Fibro) were isolated from male L2G transgenic mice (FVB 
background) that constitutively express firefly luciferase (Fluc) and green fluorescence protein 
(GFP). Cells were characterized by flow cytometry, bioluminescence imaging (BLI), and lumino-
metry. Female FVB mice (n=60) underwent LAD ligation and were randomized into 5 groups to 
intramyocardially receive one cell type (5 x 105) or PBS as control. Cell survival was measured in 
vivo by BLI and ex vivo by TaqMan PCR at week 6. Cardiac function was assessed by echocardio-
graphy and invasive hemodynamic measurements were made at week 6. 
Results: Fluc expression correlated with the cell number in all groups (r2>0.93). In vivo BLI re-
vealed acute donor cell death of MSC, SkMb, and Fibro within 3 weeks after transplantation. By 
contrast, cardiac signals were still present after 6 weeks in the MN group, as confirmed by Taq-
Man PCR (P<0.01). Echocardiography showed significant preservation of fractional shortening 
in the MN group compared to controls (P<0.05). Measurements of left ventricular end-systolic/
diastolic volumes revealed that the least amount of ventricular dilatation occurred in the MN 
group (P<0.05). Histology confirmed the presence of MN, although there was no evidence of 
transdifferentiation by donor MN into cardiomyocytes.
Conclusion: This is the first study to directly compare a variety of cell candidates for myocar-
dial therapy. Compared to MSC, SkMB, and Fibro, our results suggest that MN cells exhibit a 
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INTRODUCTION
Coronary artery disease is the number one cause of morbidity and mortality in the US. Despite 
a wide range of therapeutic approaches, heart failure remains the leading cause of death in 
the Western world.1 Recently, cell therapy has generated much enthusiasm as a novel potential 
treatment for ischemic heart disease. Numerous animal studies, each evaluating a particular 
class of cells for its regenerative potential in the infarcted heart, have been conducted.2 Further-
more, the administration of skeletal myoblasts (SkMb)3, bone marrow-derived mononuclear 
cells (MN)4-6 and mesenchymal stem cells (MSC)7 as a therapy for end-stage heart disease has 
already been translated from bench top to bedside. Although the majority of experimental 
studies have shown encouraging results, clinical outcomes are divergent, which highlights the 
present imperfect understanding of the in vivo behavior and the mechanism(s) of action of the 
cells.8 Moreover, differences in cell type and dose, study design, patient population, and timing 
of cell transplant hamper inter-study comparisons. 
Recently, molecular imaging has proven to be a valuable tool to track cells on an in vivo and 
quantitative bases in mice.9 As opposed to post-mortem histology, molecular imaging is non-
invasive and facilitates repetitive imaging, thereby providing unprecedented insight into cell 
position and count. These characteristics make molecular imaging an extremely useful method 
to monitor cell survival, proliferation, migration, and even misbehavior.10 In order to under-
stand which cell type will generate optimal therapeutic responses, we evaluated the efficacy 
of various therapeutic stem cell candidates in a uniform, controlled murine model of ischemic 
heart failure. Results gathered from this head-to-head comparison study should yield valuable 
information regarding the optimal cell type for cardiac regenerative therapy.
METHODS
Transgenic l2G animals expressing fluc-GfP. All animal study protocols were approved by 
the Stanford Animal Research Committee. The donor group consisted of 8-week old male L2G 
mice (n=10), which were bred on FVB background and ubiquitously express green fluorescent 
protein (GFP) and firefly luciferase (Fluc) reporter genes driven by a β-actin promoter as previ-
ously described.11 Recipient animals (n=70) consisted of syngeneic, female FVB mice (8 weeks 
old, Jackson Laboratories, Bar Harbor, ME, USA). To compare the efficacy of different adult stem 
cell types, animals were randomized into 5 recipient groups (n=12/group): (1) bone marrow 
derived mononuclear cells (MN), (2) skeletal myoblasts (SkMb), (3) bone marrow derived mes-
enchymal cells (MSC), (4) fibroblasts (Fibro), and (5) saline (PBS). To compare the effects of myo-
cardial milieus on MN survival, animals were randomized into 2 recipient groups (n=5/group): 
(1) injection at the infarct site and (2) injection at the peri-infarct site.
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Preparation of fibroblasts (fibro). Donor mice were euthanized by cervical dislocation after 
anesthesia with 5% isoflurane, and were placed in 70% ethanol for 5 minutes. For the isolation 
of Fibro, skin biopsies were taken from the tail and ears, minced, and incubated overnight in 
collagenase type II (400 U/mL, Gibco-Invitrogen, Carlsbad, CA, USA,), dissolved in DMEM (Gib-
co, NY, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS, Hyclone, Lo-
gan, UT, USA), 1% antibiotics/antimycotic solution (penicillin/streptomycin, Gibco-Invitrogen, 
Carlsbad, CA, USA) at 37°C and 5% CO2 in air.
12 The next day, cells were dislodged from digested 
tissue by repeated pipetting and were passed through 70 µm sterile netting into sterile 14-ml 
centrifuge tubes. The samples were centrifuged for 5 minutes at 1200 rpm, and the cell pellet 
was resuspended in DMEM, 20% FBS, 1% penicillin/streptomycin to be plated in a 25 cm2 tissue 
flask at 37°C/5%CO2.
Preparation of skeletal myoblasts (skmb). After the skin was isolated, the muscles were 
dissected from the legs, minced, and placed in a Dispase solution (grade II, 2.4U/mL, Gibco-
Invitrogen, Carlsbad, CA, USA) for 45 minutes under regular pipetting. The suspension was fil-
tered through a 70 μm nylon mesh and was centrifuged at 1200 rpm for 5 minutes. The cell 
pellet was resuspended into 45% DMEM/45% Ham’s F10 medium (Gibco-Invitrogen, Carlsbad, 
CA, USA), supplemented with 10% FBS and 1% penicillin/streptomycin and plated in 25 cm2 
collagen-coated tissue flasks. When confluent, cells were dislodged and passaged using PBS. 
Cells were grown for 5 passages, after which they were transferred into DMEM, 10% FBS, and 
1% penicillin/streptomycin medium supplemented with 2.5 ng/mL Basic Fibroblast Growth 
Factor (Gibco-Invitrogen, Carlsbad, CA, USA) to achieve confluent SkMb cultures.13
Preparation of bone marrow mononuclear cells (mn) and mesenchymal stem cells (msC). 
Finally, the long bones were explanted, washed, and flushed with PBS using a 25-gauge needle 
to collect bone marrow. After passing through a 70 μm strainer, the isolate was centrifuged at 
1200 rpm for 5 minutes, washed, and resuspended into DMEM, 20% FBS, and 1% penicillin/ 
streptomycin medium to grow MSC. All plated cells were allowed to grow for 6 passages before 
transplantation to avoid contamination with other cell types. To acquire the MN fraction, the 
bone marrow isolate was centrifuged for 40 minutes at 1600 rpm using a 14 mL tube with 3 
mL Ficoll-Paque Premium (GE Healthcare, Piscataway, NJ, USA) gradient and 4 mL cell/saline 
suspension. MN were prepared freshly before application.
Characterization of stem cells by flow cytometry. Cells were incubated in 2% FBS/PBS at 
4°C for 30 min with 1 μL monoclonal FITC-conjugated antibodies against CD34, CD45, C-kit, 
CD11b, and CD90 (BD, San Jose, CA, USA), and processed through a FACSCalibur system (BD, 
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In vitro firefly luciferase (fluc) assays. Cells were dislodged from culture flasks (SkMb, MSC 
and Fibro) or processed directly after isolation (MN) to be resuspended in PBS. Cell suspensions 
were divided into a 6-well plate in known concentrations. After administration of D-Luciferin 
(Xenogen, Alameda, CA, USA, 4.5ug/mL), peak signal expressed as photons per second per 
centimeter square per steridian (photons/s/cm2/sr) was measured using a charged coupled 
device (CCD) camera (IVS200, Xenogen, Alameda, CA, USA) as described.14 Same amounts of 
dislodged cells were lysed using 200 µL of 10X Passive Lysis Buffer (Promega, Madison, WI, USA) 
and centrifuged at maximum speed for 2 minutes at 4°C. For every sample, 20 µL supernatant 
was added to 100 µL Luciferase Assay Reagent (LAR-II, Promega, Madison, WI, USA) and lumi-
nosity in relative light units (RLU) was measured on a TD-20/20n luminometer (Turner Biosys-
tems, Sunnyvale, CA, USA). All samples were conducted in triplets. 
surgical model for myocardial infarction. Female FVB mice (8 weeks old) were intubated 
with a 20-gauge angiocath (Ethicon Endo-Surgery, Inc. Cincinnati, OH) and placed under ge-
neral anesthesia with isoflurane (2%). Myocardial infarction (MI) was created by ligation of the 
mid-left anterior descending (LAD) artery with 8-0 ethilon suture through a left anterolateral 
thoracotomy as described.15 Ten minutes afterwards, the infarct region was confirmed by myo-
cardial blanching. Injections were made at 2 sites near the peri-infarct zone (medial and la-
teral zones) with a total volume of 50 μL containing 5x105 cells or PBS respective of group 
randomization using a Hamilton syringe with a 29-gauge needle. All surgical procedures were 
performed in a blinded fashion by one micro-surgeon (G.H.) with several years of experience 
on this model. 
In vivo optical bioluminescence imaging (bli). BLI was performed using the IVIS 200 
(Xenogen, Alameda, CA, USA) system. Recipient mice were anesthetized with isoflurane, 
shaved, and placed in the imaging chamber. After acquisition of a baseline image, mice were 
intraperitoneally injected with D-Luciferin (400 mg/kg body weight). Mice were imaged on day 
2, 4, 7, and weekly until sacrifice at week 6. Peak signals (photons/s/cm2/sr) from a fixed region 
of interest (ROI) were evaluated as described.11 
Echocardiography to assess left ventricular fractional shortening (lvfs). Echocardiograp-
hy studies were performed 4 and 6 weeks post-operation. Three independent two-dimensi-
onal transversal-targeted M-mode traces were obtained at the level of the papillary muscles 
using a 14.7-MHz transducer on a Sequoia C512 Echocardiography system (Siemens, Malvern, 
PA, USA). Using the enclosed software, left ventricular end-diastolic and end-systolic posterior 
and anterior dimensions were measured by a blinded investigator (A.Y.S.) and processed to 
calculate left ventricular fractional shortening (LVFS).
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measurement of hemodynamics with pressure-volume loops. Invasive, steady-state he-
modynamic measurements were conducted by closed-chest pressure-volume (PV) loop ana-
lysis prior to sacrifice at week 6. The animal was placed under general anesthesia as described 
above. After midline neck incision, a 1.4-F conductance catheter (Millar Instruments, Houston, 
TX, USA) was retrogradally advanced through the right carotid artery into the left ventricle. The 
measurements of segmental conductance were recorded which allowed extrapolation of the 
left ventricular volume, which was coupled with pressure. These data were analyzed in a blin-
ded fashion using PVAN 3.4 Software (Millar Instruments, Houston, TX, USA) and Chart/Scope 
Software (AD Instruments, Colorado Springs, CO, USA). 
Ex vivo Taqman PCR. In our protocol, the transplanted cells were derived from male mice and 
were transplanted into female recipients, which facilitate quantification of male cells in the ex-
planted female hearts by tracking the Sry locus found on the Y chromosome. After the invasive 
hemodynamic measurements at week 6, animals were sacrificed and hearts were randomly se-
lected for explantation, followed by mincing and homogenization in 2 mL DNAzol (Invitrogen, 
Carlsbad, CA, USA). DNA was isolated according to the manufacturer’s protocol. The DNA was 
quantified on a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) 
and 500 ng DNA was processed for TaqMan PCR using primers specific for the Sry locus. RT-PCR 
reactions were conducted in iCylcer IQ Real-Time Detection Systems (Bio-Rad, Hercules, CA, 
USA). Detection levels were compared to a standard curve to assess the number of viable cells 
per sample. All samples were conducted in triplets.
 
Postmortem histology. Hearts (n=3/group at week 2) were flushed with saline and placed 
in 2% paraformaldehyde for 2 hours at room temperature followed by 12-24 hours in 30% 
sucrose at 4°C. The tissue was embedded in Optical Cutting Temperature (OCT) Compound 
(Tissue-Tek. Sakura Finetek USA Inc., Torrance, CA) and snap frozen on dry ice. Five-micron sec-
tions were cut in both the proximal and apical regions of the infarct zone. Slides were stained 
for GFP (anti-green fluorescent protein, rabbit IgG fraction, anti-GFP Alexa Fluor 488 conjugate, 
1:200, Molecular Probes, Inc.), troponin I (H-170 rabbit polyclonal IgG for cardiac muscle, 1:100, 
Santa Cruz Biotech, Santa Cruz, CA), and connexin 43 (rabbit polyclonal, 1:100, Sigma). Sections 
were counterstained with 4,6-diamidino-2-phenylindole (DAPI). Stained tissue was examined 
by Leica DMRB fluorescent microscope and a Zeiss LSM 510 two-photon confocal laser scan-
ning microscope. Cell engraftment was confirmed by identification of GFP expression under 
fluorescent microscopy. Colocalization of troponin, alpha sarcomeric actin, and connexin 43 
with GFP was visualized with streptavidin-conjugated to Alexa Fluor Red 555 (Invitrogen Mo-
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statistical analysis. Statistics were calculated using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). 
Descriptive statistics included mean and standard error. Comparison between groups was 
performed using a one-way between groups ANOVA, or one-way repeated measures ANOVA 
when compared over time, and significance was assumed according to the Bonferroni-Holm’s 
procedure. 
statement of Responsibility: The authors had full access to and take full responsibility for the 
integrity of the data. All authors have read and accept the manuscript as written.
Conflict of interest Disclosures: None.
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RESULTS
Cell characterization. The MN population consisted of CD34+, CD45+ and CD11b+, represen-
ting portions of hematopoietic cells as well as macrophages, granulocytes, and natural killer 
cells (figure 1a).16 After 6 passages of MSC, flow cytometry results showed absence of CD34, 
CD45 and C-kit markers (figure 1b), indicating depletion of hematopoeitic cells within the 
MSC. Moreover, these cells expressed the MSC markers CD90 and CD106, with negative expres-
sion of CD105 (data not shown). Myoblast cultures steadily differentiated into myotubes under 
high confluence or after prolonged culture without replating (figure 2c-d), which confirmed 
their fate.13 
figure 1. Characterization of cell types based on cell surface expression and cell morphology. (a) Flow 
cytometry results from bone marrow-derived mononuclear cells (MN) and (b) bone marrow-derived mesen-
chymal cells (MSC). Green lines represent isotype controls. (c) After prolonged non-passaged culture, skeletal 
myoblasts (SkMb) change morphologically (100x Bright-field Hoffman modulated contrast image, bar repre-
sents 40μm). (d) SkMb form longitudinal myotubes, confirming myoblast phenotype (400x Bright-field Hoffman 
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firefly luciferase (fluc) expression. After culturing for 6 passages, cells were processed for ex 
vivo BLI. Cell number correlated well with BLI signal in all groups (MN: r2=0.98, SkMb: r2=0.94, 
MSC: r2=0.94, Fibro: r2=0.93), indicating that BLI is a valid tool to assess cell viability. However, 
Fluc expression level differed per cell type, as MN showed poor ex vivo signal compared to 
other cell groups (figure 2a-b). We hypothesized this was a consequence of the Ficoll selection 
in the MN group, which may have accounted for hibernation of the cells due to the hostile en-
vironment, thereby preventing proper D-Luciferin uptake. In order to test this hypothesis, we 
lysed the cells and measured intracellular Fluc enzyme. Our in vitro luminometry results indeed 
showed that the Fluc enzyme was present in all cell types and correlated well with cell number 
(MN: r2=0.99, SkMb: r2=0.95, MSC: r2=1.00, Fibro: r2=0.93) (figure 2c). It also correlated well with 
the ex vivo BLI findings (MN: r2=0.99, SkMb: r2=0.98, MSC: r2=0.90, Fibro: r2=0.95; figure 2d). 
Thus, BLI is a reliable tool to measure viable cell numbers ex vivo and can be used instead of in 
vitro luminometry. 
figure 2. optical bioluminescence imaging (bli) signal from firefly luciferase (fluc) expression reflects 
viable cell number. (a) BLI of varying numbers of cells in 24-well plates with increasing signals. Scale bars 
represent peak signal in photons/s/cm2/sr. Cell numbers from all cell types showed robust correlation with (b) 
Fluc signal on ex vivo BLI and (c) in vitro Fluc enzyme on luminometry. (d) Both assays (BLI and luminometry) also 
correlated well with each other.
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In vivo kinetics and biodistribution of transplanted cells. In our study, increasing BLI signals 
in the MN group suggested a growing number of cells from day 2 to week 2 post-transplant. 
Moreover, presence of extra-cardiac signals was consistent with migration to other organs 
such as the femur, spleen, and liver (figure 3a). In contrast, for SkMB, MSC, and Fibro, BLI signals 
decreased acutely from day 2 to week 2. By week 4, the BLI signals equaled background level 
(figure 3b-e). Interestingly, robust signals were seen at day 2 to day 4 in the lungs, suggesting 
leakage of SkMb, MSC, and Fibro with subsequent intracappillary retention. This might have 
accounted for the higher rates of acute-phase mortality in these groups (data not shown). In 
order to assess the effects of myocardial milieu on MN survival, we also compared infarct ver-
sus peri-infarct targeted injection. Similarly, we observed significant donor cell death after an 
initial increase in BLI signal and no major differences in the cell survival pattern between the 
two modes of injection after 4 weeks (figure 4). 
 
figure 3. longitudinal in vivo optical biolumines-
cence imaging (bli) of transplanted cell survival. 
(a) Images from the same representative animal from 
each group reveal cell proliferation, death, and migra-
tion. MN show retention in the heart, and furthermore 
can home in on the femur, spleen, and liver (yellow ar-
rows). BLI images from animals 2 days after injection 
of SkMb, MSC, and Fibro show retention not only in 
the heart, but also in the lungs (red arrows). Decrea-
sing signal intensity over time is indicative of acute 
donor cell death in these groups. Scale bars represent 
BLI signal in photons/s/cm2/sr. (b) Quantification of BLI 
signals on fixed regions of interest (ROI) over the heart 
reveal an early increase in signal from day 2 until day 
7 in the MN group, while signal intensity in the SkMb 
(c), MSC (d), and Fibro (e) groups clearly decreases until 
background signal (black bars) at week 3 to 4. Bars re-
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figure 4. Cardiac injection site does not affect mn survival. (a) Pictures of representative animals injected 
with MN at the infarct versus peri-infarct zone. Note the acute proliferation phase from day 2 to day 7 followed 
by cell death from day 7 to day 28. Scale bars represent BLI signal in photons/s/cm2/sr. (b) Graphic representation 
of quantified BLI signals on fixed regions of interest (ROI) over the heart showing similar cell survival patterns in 
both groups. 
Ex vivo quantitative analysis of transplanted cells. Previously, Muller-Ehmsen and col- 
leagues have shown that post-mortem TaqMan PCR, which is based on the quantification of 
the Sry locus on the donor Y chromosome in the female recipient tissue, can be used to quan-
tify cell survival in the heart.17 To confirm increasing MN number during the first week, we 
explanted representative hearts on day 4 and 7, on which we performed ex vivo quantitative 
TaqMan PCR. Using a standard curve of cell number versus TaqMan cycle (data not shown), we 
were able to estimate the number of surviving cells. Indeed, this assay confirmed an increase in 
MN (2167±113 vs. 4408±544 cells, P<0.01) as shown in figure 5a. Next we performed TaqMan 
PCR on hearts injected with MN, SkMB, MSC, and Fibro at week 6 (n=6 per group). Similar to 
BLI data, the Taqman data confirmed the superior cell survival of MN (1853±568), which was 
significantly better than SkMb (97±62, P=0.001), MSC (341±192, P=0.005) and Fibro (no de-
tectable cells, P<0.001, ANOVA) (figure 5b). Taken together, these ex vivo quantitative assays 
validate the in vivo BLI technique, suggesting that the latter can be used to follow cell fate in 
living subjects and may provide valuable insights into cell migration, proliferation, and death.
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figure 5. Ex vivo quantitative Taqman PCR confirms bli findings. (a) To confirm that the increase of MN 
signals actually represented increased MN in the hearts, ex vivo TaqMan PCR on extracted DNA from explanted 
hearts was conducted on day 4 and 7 (n=2 on both time points). TaqMan PCR cycle number was recalculated 
to absolute cell number using a simultaneously ran standard curve. Bars represent mean ± SEM. * represents 
P<0.05. (b) At week 6, significantly more MN cells were present in the recipient hearts compared to SkMB, MSC, 
and Fibro (n=6 per group). Bars represent mean ± SEM. * indicates MN vs. other groups: P<0.05.
functional effects of cell transplantation. Echocardiographic measurements of cardiac per-
formance were conducted 4 and 6 weeks after cell transplantation (figure 6a). At 6 weeks, 
LVFS for MN (37.1±2.5%) was significantly higher than PBS (30.2±1.9%, P<0.001) and Fibro 
(30.1±2.8%, P=0.004) groups. LVFS in the SkMb (35.2±1.8%) group was also significantly better 
than the PBS group (P=0.001), while MSC (32.4±2.1%) had no significant preservative effects 
compared to Fibro and PBS groups (repeated measurements ANOVA) (figure 6b). The LVFS 
in the PBS group was comparable with the literature.18 Previously, it has been reported that 
cell transplantation accounted only for short-term preservation of cardiac function after MI.19 
In the present study, all cell groups showed decreased LVFS on week 6 compared to week 4. 
These findings suggest that the beneficial effects of cell transplantation may last only for the 
acute post MI period.
validation of non-invasive measurements of left ventricular dimensions. Echocardio-
graphy readings from week 6 indicated that MN preserved both left-ventricular end-systolic 
(LVsd) and end-diastolic (LVdd) diameters (data not shown). To validate these findings, we per-
formed invasive hemodynamic measurements. As expected, the left-ventricular end-systolic 
volume (Ves) 6 weeks after MN injection (42.6±2.0 µL) was significantly less than MSC (58.9±3.4 
µL, P=0.002) and Fibro (65.1±2.7 µL, P<0.001), while the Ves after SkMb injection (49.7±2.7µL) 
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diastolic volume (Ved) in the MN group (49.7±3.1 µL) was lower than all other groups and 
significantly decreased compared to Fibro (70.7±2.5 µL, P<0.001). No significant changes were 
observed in the SkMb (61.5±3.8 µL) and MSC (63.3±3.9 µL) groups (ANOVA). Importantly, these 
findings match the echocardiography results as mean values of LVsd vs. Ves and LVdd vs. Ved 
correlated robustly (r2=0.99 and r2=0.88, respectively, figures 6c-d). 
figure 6. measurements of functional consequences of cell transplantation into the infarcted mouse heart. 
(a) Representative M-mode traced picture taken at the level of the papillary muscle whereby left ventricular dia-
meters can be measured. Scale bar is included on the left side. (b) Quantification of LVFS at 4 weeks (black) and 
6 weeks (grey) after myocardial infarction and cell transplantation. MN appear to have the greatest functional 
protective effect compared to other groups. However, there is a general trend toward decreasing cardiac perfor-
mance at 6 weeks instead. Immediately after echocardiography at week 6, invasive three-dimensional steady-
state measurements of ventricular volumes at end-systole (Ves) and end-diastole (Ved) were conducted. Non-
invasive echocardiography and invasive hemodynamic measurements correlate robustly between (c) Ves vs. LVsd 
(r2=0.99) and (d) Ved vs. LVdd (r2=0.88). Bars represent mean±SEM. MN (*) or SkMb (†) vs. indicated groups: P<0.05. 
Transdifferentiation does not account for better cardiac performance. In our study, GFP-
expressing MN could easily be found, confirming engraftment and BLI results (figure 7). How-
ever, histological samples showed no overlay of donor-specific GFP, nucleus-specific DAPI, and 
cardiac specific troponin I and connexin 43 markers two weeks after transplantation. Thus, con-
cordant with earlier findings15, 20, we have not observed MN-derived cardiomyocyte formation. 
Furthermore, we had difficulty identifying GFP-expressing SkMb, MSC, or Fibro, indicating that 
only very low counts of these cells were present in the heart (data not shown).
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figure 7. immunohistochemical staining reveals no evidence of mn transdifferentiation into cardiomyo-
cytes. (a) Representative figure with staining for (b-c) troponin I and DAPI. Although GFP-expressing MN can be 
found in the myocardium (arrow), there is no cell population with overlay of GFP, DAPI and troponin I to suggest 
transdifferentiation of MN to cardiomyocytes. (d) Representative figure with staining for (e-f ) connexin 43 and 
DAPI. Although GFP-expressing MN can be found in the myocardium (arrow), there is no cell population with 







ADUlT sTEm CEll TyPEs foR TREATmEnT of myoCARDiAl isCHEmiA   |  101
DISCUSSION
This study is the first to evaluate the efficacy of three different clinical cell candidates for the 
treatment of myocardial infarction, as compared to a cellular control (Fibro) and non-cellular 
control (PBS). Our major findings are as follow: (1) molecular imaging using the Fluc reporter 
gene is a reliable tool for monitoring donor cell survival, proliferation and migration in vivo; 
(2) compared to SkMb, MSC and Fibro, MN show the most favorable survival pattern after in-
jection into the infarcted heart; (3) MN injection leads to a better, but transient, preservation 
of cardiac function; and (4) this preservation is probably not due to substantial repopulation 
of the infarcted myocardium (as most cells die by imaging and TaqMan analysis) nor transdif-
ferentiation into MN-derived cardiomyocytes.
Most animal studies assessing the therapeutic potential of cell therapy have used conventio-
nal, post-mortem histological or RT-PCR techniques to gain insight in donor cell location and 
count.2 However, these techniques cannot monitor the kinetics of cell migration or cell survival 
in the same subject in vivo. In this respect, studies have shown the possibility of labeling donor 
cells with iron particles or radioactive probes to image cell location in vivo. Unfortunately, iron 
particles are non-specific, as they can be ingested by macrophages following transplanted cell 
death21, and the relatively short half-lives of radioactive probes hamper long-term imaging 
of the cells.9 By contrast, the current study demonstrates that molecular imaging of the Fluc 
reporter gene can provide longitudinal in vivo imaging of donor cell survival, proliferation, and 
migration and is in those aspects superior to the aforementioned imaging techniques. These 
advantages are a result of the stable genetic integration of the reporter gene (Fluc) in the do-
nor cells, which are also equally transferred to progeny cells. As long as the donor/progeny 
cells are viable, transcription will lead to reporter gene mRNA followed by translation into re-
porter protein. Following systemic introduction, the reporter probe (D-Luciferin) will be cata-
lyzed by all cells that have the reporter protein, leading to a signal which can be detected by a 
sensitive CCD camera.22 However, due to the use of low-energy photons (2-3 eV), BLI is limited 
by photon attenuation and photon scattering within deep tissues. At present, this technique is 
not suitable for large animal or human studies.23 Current studies in our laboratory are therefore 
aiming to combine multi-fusion reporter gene constructs (thereby enabling PET and BLI ima-
ging) and iron labeling (for MRI).
Using in vivo BLI, ex vivo TaqMan PCR, and ex vivo histology, we have shown superior engraft-
ment of MN compared to SkMB, MSC, and Fibro. Until now, little data exist on survival of trans-
planted cells in the infarcted heart. Müller-Ehmsen and colleagues used conventional PCR 
techniques to show that MN and MSC gradually died off until 6 weeks after transplantation of 
1x105 cells, with the percentage of engrafted MN being as low as ∼2%. Moreover, the authors 
102  |   PART ii: ADUlT sTEm CElls - CHAPTER 6 ADUlT sTEm CEll TyPEs foR TREATmEnT of myoCARDiAl isCHEmiA   |  103
found evidence of MN migration to spleen and liver.24 Splenic and hepatic homing of MN, as 
also observed in this study, is most likely due to leakage from the initial injection. This has been 
shown earlier using RT-PCR in mice24, SPECT imaging in large animal models25, and PET ima-
ging in humans.26 In fact, the BLI findings of MN homing resemble leukocyte scans, showing 
white blood cells are effectively attracted by the liver and spleen.27 The mechanism by which 
these organs retain circulating MN may be attributed to chemoattractant properties of the tis-
sue or the biological role that these organs have. For example, the liver expresses high levels of 
stromal derived factor-1 (SDF-1), which is a developmental and postnatal chemoattractant for 
stem cells.28 This has been extrapolated to cardiac stem cell therapy by exogenous myocardial 
SDF-1 over-expression, which improved the rate of c-kit+ cell homing and improved LV func-
tion in hearts with post-infarction LV remodeling.29 
In addition, increasing in vivo BLI signal during the first 2 weeks showed that MN were capa-
ble of either proliferation or homing in on the ischemic myocardium after an initial washout 
during this period of time, which was independent of injection site (infarct or peri-infarct). Al-
though the survival pattern of MN was superior compared to other cell types, it must be stated 
that the cell number by TaqMan PCR at week 6 equaled ∼1,800 cells, representing only ∼0.4% 
of the initially injected cell number. For MSC, we found the in vivo imaging signals to decrease 
dramatically within one week. This pattern concurs with the findings from others who found 
drastic MSC death between day 3 and 7 after myocardial delivery.30
To date, there is intense investigative effort to uncover the mechanism by which stem cells may 
preserve the function of damaged hearts. Based on our current findings, the preservation of 
cardiac function by MN transplantation is not attributable to repopulation or transdifferentia-
tion. Rather, the functional benefits of MN transplantation might be due to an augmentation 
of the natural process of myocardial healing by paracrine signaling and promoting neovascu-
larization, among other factors. It has recently been shown that mice over-expressing MCP-1, 
which leads to an increased influx of MN into the damaged myocardium after infarction, had 
decreased infarcted areas and scar formation, and yielded better left ventricular function com-
pared to wild-type mice.31 Moreover, in the infarcted myocardium, CD11b+ macrophages are 
an important source of cytokines and growth factors32 and potential regulators of the extra-
cellular matrix synthesis.33 Specifically, transplantation of activated macrophages into the in-
farcted rat heart has been shown to accelerate vascularization and tissue repair and to improve 
cardiac remodeling and function.34 Regarding paracrine signaling, bone marrow stem cells can 
secrete vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angio-
poetin-1 (Ang-1), and monocyte chemoattractant protein-1 (MCP-1), leading to an increase in 






ADUlT sTEm CEll TyPEs foR TREATmEnT of myoCARDiAl isCHEmiA   |  103
results from the Doppler substudy of the REPAIR-AMI trial have recently shown clinical proof of 
restored microvascular function associated with an improved maximal vascular conductance 
capacity.37
The clinical relevance of this study is significant. Different clinical trials have been conducted 
with divergent results that raise questions about which optimal cell type to use.8 Although 
each cell type has its own advantages and limitations, our study is the first to detect a clear sur-
vival and modest functional benefit of MN compared to other clinical cellular candidates. How-
ever, questions remain regarding which portion of MN is responsible for the benefit, whether 
this benefit is transient, and whether a significant difference in cardiac function could translate 
into a clinical difference. These issues need to be addressed in future studies. Nevertheless, by 
using multi-modality evaluation, this study has demonstrated that MN confer a survival pat-
tern in the infarcted mouse heart superior to those of SkMb and MSC. Moreover, MN exhibited 
a modest but transient preservation of cardiac function compared to cellular and non-cellular 
controls. Finally, our findings highlight the importance of being able to track stem cells in vivo 
and should be an impetus for further research on the development of clinically applicable 
molecular imaging techniques to closely follow stem cell fate in humans. 
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ABSTRACT
background: Mesenchymal stem cells hold promise for cardiovascular regenerative therapy. 
Derivation of these cells from the adipose tissue might be easier compared to bone marrow. 
However, the in vivo fate and function of adipose stromal cells (ASC) in the infarcted heart has 
never been compared directly to bone marrow derived mesenchymal cells (MSC).
methods: ASC and MSC were isolated from transgenic FVB mice with b-actin promoter dri-
ving firefly luciferase and green fluorescent protein (Fluc-GFP) double fusion reporter gene, 
and were characterized using flow cytometry, microscopy, bioluminescence imaging (BLI) and 
luminometry. FVB mice (n=8/group) underwent myocardial infarction followed by intramyo-
cardial injection of 5x105 ASC, MSC, fibroblasts (Fibro, positive control), or saline (negative con-
trol). Cell survival was measured using BLI for 6 weeks and cardiac function was monitored by 
echocardiography and pressure-volume (PV) analysis. Ventricular morphology was assessed 
using histology.
Results: ASC and MSC were CD34-, CD45-, c-Kit-, CD90+, Sca-1+, shared similar morphology, and 
had a population doubling time of ∼2 days. Cells expressed Fluc reporter genes in a number-
dependent fashion, as confirmed by luminometry. After cardiac transplantation, both cell ty-
pes showed drastic donor cell death within 4-5 weeks. Furthermore, transplantation of either 
cell type was not capable of preserving ventricular function and dimensions, as confirmed by 
PV-loops and histology. 
Conclusion: This is the first study comparing the in vivo behavior of both cell types in the in-
farcted heart. ASC and MSC do not tolerate well in the cardiac environment, resulting in acute 
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INTRODUCTION
Almost 80 million Americans suffer from cardiovascular disease (CVD), and with an average 
of one death every 36 seconds, CVD is the number one killer of Americans. Despite a wide 
range of therapeutic options to prevent progression of heart failure, end-stage disease can 
only be treated by heart transplantation which is, in turn, hampered by a lack of suitable donor 
organs.1 Bone marrow mononuclear stem cells (BMSC) have raised hope as a new therapeutic 
modality as they were believed to differentiate into cardiomyocytes when transplanted into 
the infarcted murine myocardium.2 Although this observation is subject to controversy3, BM-
SC-mediated cardiac repair has recently been introduced into clinical medicine4. A small stro-
mal subset of BMSC, called mesenchymal stem cells (MSC), is capable of proliferation in vitro5 
and therefore gains popularity as a candidate to replace the infarcted myocardium. MSC have 
been proposed to improve cardiac function after myocardial infarction in both animals6 and 
humans7, and might even have an immunomodulating effect.8 However, the process of bone 
marrow harvesting can be painful and is limited in the quantity of aspirate. 
Recently, stromal cells have been isolated from the adipose tissue9, which would be an ideal 
source regarding procurement procedure (e.g., elective abdominoplasty) and yield. These adi-
pose stromal cells (ASC) largely express the same surface markers as MSC10 and have shown 
to preserve cardiac function after infarction.11 Although the in vitro properties of ASC and MSC 
have been compared before12-14, there are no reports evaluating the cellular behavior and func-
tional effects of either cell type when transplanted into the ischemic myocardium. Here, we 
present the first report using a molecular imaging technique to unveil and compare the in vivo 
behaviors and functional effects of ASC and MSC following transplantation into the infarcted 
heart. 
METHODS
Animals. All animal study protocols were approved by the Stanford Animal Research Com-
mittee. The donor group consisted of male L2G mice (n=4, 8 weeks old), which were bred on 
FVB background and ubiquitously express green fluorescent protein (GFP) and firefly luciferase 
(Fluc) reporter genes driven by a β-actin promoter as previously described 15. Recipient animals 
(n=37) consisted of syngeneic, female FVB mice (8 weeks old, Jackson Laboratories, Bar Harbor, 
ME). Animals were randomized into 4 recipient groups (n=8/ group): (1) adipose tissue-derived 
stromal cells (ASC), (2) bone-marrow-derived mesenchymal cells (MSC), (3) fibroblasts (Fibro) 
as cellular control group, and (4) phosphate buffered saline (PBS) as non-cellular control group. 
Cell culture of fibro, AsC, and msC. Donor mice were sacrificed by cervical dislocation after 
ample anesthesia with isoflurane, and were placed in 70% ethanol for 5 minutes. (A) For the 
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isolation of Fibro, skin biopsies were taken from the tail and ears, minced and incubated over-
night in collagenase type II (400 U/mL, Gibco-Invitrogen, Carlsbad, CA), dissolved in DMEM 
(Gibco, NY) supplemented with 20% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, 
UT), 1% antibiotics/antimycotic solution (Penicillin/Streptomycin, Gibco-Invitrogen, Carlsbad, 
CA) at 37°C and 5% CO2 in air as described 
16. The next day, cells were dislodged from digested 
tissue by repeated pipetting and were passed through 70 μm sterile netting into sterile 15-ml 
centrifuge tubes. The samples were centrifuged for 5 minutes at 1200 rounds per minute (rpm), 
and the cell pellet was resuspended in DMEM/20% FBS/1%Penicillin-Streptomycin to be plated 
in a 25 cm2 tissue flask at 37°C/5%CO2. (b) For the isolation of ASC, the adipose tissue was iso-
lated from the inguinal and abdominal region as described before.17 In brief, the adipose tissue 
was washed in PBS and digested using 5 mL 0.075% collagenase (type I, Gibco-Invitrogen, 
Carlsbad, CA) in PBS for 30 minutes, followed by deactivation by DMEM/20% FBS/1%Penicillin-
Streptomycin. After centrifuging for 5 minutes at 1200 rpm, the cell pellet was resuspended 
and incubated for 10 minutes in ACK lysing buffer to eliminate red blood cells. The suspension 
was centrifuged, resuspended in DMEM/ 20% FBS/1%Penicillin-Streptomycin, filtered through 
a 70 μm mesh, and plated in a 25 cm2 tissue flask at 37°C/ 5%CO2 to grow ASC. (C) For the iso-
lation of MSC, the long bones were explanted, washed and flushed with PBS using a 25-Gauge 
needle to collect bone marrow. After passing through a 70 μm strainer, the isolate was centri-
fuged at 1200 rpm for 5 minutes, washed and resuspended into DMEM/20%FBS/1%Penicillin/
Streptomycin medium to grow MSC as described.5 
flow cytometry. At passage 8-10, the cells were labeled using specific FITC-conjugated anti-
bodies against CD34, CD45, C-kit, Sca-1, CD90, and CD106 and processed through a FACSCali-
bur system (BD, San Jose, CA) according to the manufacturer’s protocol. Results were compa-
red to appropriate isotype controls. 
 
In vitro firefly luciferase (fluc) assays. Cells were dislodged from culture flasks to be resus-
pended in PBS. Cell suspensions were divided into a 6-well plate in known concentrations. 
After administration of D-Luciferin (Xenogen, Alameda, CA, 4.5ug/mL), peak signal (photons/
second/square centimeter/steridian or p/s/cm2/sr) was measured using a charged coupled de-
vice (CCD) camera (IVS200, Xenogen, Alameda, CA). Same amounts of dislodged cells were 
lysed using 200 µL of 10X Passive Lysis Buffer (Promega, Madison, WI) and centrifuged at maxi-
mum speed for 2 minutes at 4°C. For every sample, 20 µL of supernatant was added to 100 
µL of Luciferase Assay Reagent (LAR-II, Promega, Madison, WI) and luminosity in relative light 
units (RLU) was measured on a 20/20n luminometer (Turner Biosystems, Sunnyvale, CA). All 
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surgical model. Female FVB mice (8 weeks old) were intubated with a 20-gauge angiocath 
(Ethicon Endo-Surgery, Inc. Cincinnati, OH) and were placed under general anesthesia with 
isoflurane (2%). Myocardial infarction (MI) was created by ligation of the mid-left anterior des-
cending (LAD) artery with 8-0 Ethilon suture through a left anterolateral thoracotomy. After 
approximately 10 minutes, the infarct region was injected with 5x105 cells or PBS respective of 
group randomization using a Hamilton syringe with a 29-gauge needle. The chest was closed 
in 4 layers with 5-0 vicryl suture. All surgical procedures were performed in a blinded fashion 
by one micro-surgeon (G.H.) with several years of experience with this model. 
Echocardiography. Echocardiography studies were performed 2, 4 and 6 weeks postope-
ratively. Three independent two-dimensional transversal-targeted M-mode traces were ob-
tained at the level of the papillary muscles using a 14.7-MHz transducer on a Sequoia C512 
Echocardiography system (Siemens, Malvern, PA). Using the enclosed software, left ventricular 
end-diastolic and end-systolic posterior and anterior dimensions were measured by a blinded 
member of our group (A.Y.S.) and processed to calculate left ventricular fractional shortening 
(LVFS).
In vivo optical bioluminescence imaging (bli). BLI was performed using the IVIS200 
(Xenogen, Alameda, CA) system. Recipient mice were anesthetized with isoflurane, shaved and 
placed in the imaging chamber. After acquisition of a baseline image, mice were intraperito-
neally injected with D-Luciferin (400 mg/kg body weight; Xenogen, CA). Mice were imaged on 
postoperative day 2, 4, 7, 10, and at week 2, 4, 5, and 6. Peak signal (p/s/cm2/sr) from a fixed 
region of interest (ROI) was evaluated using Living Image 2.50.1 software (Xenogen, CA). 
invasive hemodynamics. Invasive hemodynamic measurements were conducted by closed-
chest pressure-volume (PV) loop analysis prior to sacrifice at week 6. The animal was placed 
under general anesthesia as described above. After midline neck incision, a 1.4 F conductance 
catheter (Millar Instruments, Houston, TX) was retrogradely advanced through the right caro-
tid artery into the left ventricle. The measurements of segmental conductance were recorded 
which allowed extrapolation of the left ventricular volume, which was coupled with pressure. 
These data were analyzed in a blinded fashion using PVAN 3.4 Software (Millar Instruments, 
Houston, TX) and Chart/Scope Software (AD Instruments, Colorado Springs, CO). 
Postmortem histology. Hearts (n=3/group at week 6) were flushed with saline and placed 
in 2% paraformaldehyde for 2 hours at room temperature followed by 12-24 hours in 30% 
sucrose at 4°C. The tissue was embedded in Optical Cutting Temperature (OCT) Compound 
(Tissue-Tek. Sakura Finetek USA Inc., Torrance, CA) and snap frozen on dry ice. Five-micron sec-
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tions were cut in both the proximal and apical regions of the infarct zone. Slides were stained 
for H&E. Stained tissue was examined by Leica DMRB fluorescent microscope. 
Ex vivo Taqman PCR. Animals were sacrificed and hearts were explanted, followed by mincing 
and homogenization in 2 mL DNAzol (Invitrogen, Carlsbad, CA, USA). DNA was isolated accor-
ding to the manufacturer’s protocol. The DNA was quantified on a ND-1000 spectrophotome-
ter (NanoDrop Technologies, Wilmington, DE, USA) and 500 ng DNA was processed for TaqMan 
PCR using primers specific for the Sry locus selectively found on the Y chromosome in the male 
donor cells. RT-PCR reactions were conducted in iCylcer IQ Real-Time Detection Systems (Bio-
Rad, Hercules, CA, USA). Lower cycle numbers represent higher donor cell counts.18 Samples 
were conducted in triplets.
Effects of gender mismatch, myocardial ischemia, and green fluorescent protein (GfP) on 
cell survival. To investigate the effect of our gender mismatch model, we injected 5x105 male 
and female cells into the hindlimbs of male FVB mice (n=5). To assess the effects of myocardial 
milieus (ischemia vs. non-ischemia) on cell survival, 5x105 MSC were injected into non-infarct-
ed hearts from female FVB recipients (n=3). To evaluate whether GFP could have an effect on 
transplanted cell survival, 5x105 GFP+-Fluc+ cells were injected into the hindlimbs of female 
FVB mice that previously received intramyocardial GFP-Fluc plasmid injection 3 months prior 
(n=3). As control, 5x105 GFP+-Fluc+ were similarly injected in non-manipulated FVB mice (n=3). 
In these experiments, cell survival was measured using in vivo optical bioluminescence ima-
ging as described above.
statistics. Statistics were calculated using SPSS 15.0 (SPSS Inc., Chicago, IL). Descriptive statis-
tics included mean and standard error. Comparison between groups was performed using a 
one-way between groups ANOVA, or, when compared over time, one-way repeated measures 
ANOVA, both with Bonferroni correction. A logarithmic transformation of values was perfor-
med when needed to ensure normal distribution within each group and significance was as-
sumed when P<0.05. 
RESULTS
Characterization of AsC, msC, and fibro. After culturing for approximately 8 passages, he-
matopoietic cells were eliminated from both ASC and MSC cultures. This was confirmed by 
flow cytometry showing absent CD34, CD45, and C-kit markers. Moreover, both populations 
were Sca-1+, CD90+, and CD106+ (MSC) or CD106- (ASC) (figure 1), consistent with prior litera-
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figure 1. In vitro assessment of cell surface marker expression. (a) After 8-10 passages, flow cytometry sho-
wed that the ASC population was depleted from hematopoietic cells. Moreover, these cells tested negative for 
CD106, but positive for the stem cell antigen (Sca-1). (b) MSC also showed negative hematopoietic expression, 
but differed from their adipose tissue-derived counterparts regarding a positive expression for CD106. Dotted, 
light grey areas represent isotype controls. (c) Both ASC and MSC expressed the mesenchymal-specific marker 
CD90 (Black areas represent isotype controls).
On microscopy, both cell types showed spindle-shaped morphology (figure 2a). Following 
isolation, MSC have slower population doubling time compared to ASC and Fibro before even-
tually growing like ASC and Fibro with an average population doubling time of approximately 
2 days at passage 7 (figure 2b). All populations were furthermore tested for the expression of 
the reporter gene firefly luciferase (Fluc) (figure 2c). In all groups, cell number and Fluc signal 
correlated robustly with r2 values of 0.95 (ASC), 0.80 (MSC), and 0.97 (Fibro). Moreover, the as-
say of Fluc enzyme activity by luminometry also showed good correlation with cell number 
(ASC: r2=0.95, MSC: r2=0.85, Fibro: r2=0.98, figure 2d). 
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figure 2. In vitro characterization of morphology, expansion time, and reporter gene expression. (a) When 
kept into culture, all cell types shared a spindle-shaped morphology (Bright-field Hoffman modulated contrast 
image, bar represents 20μm). (b) After an initial period of relatively slower in vitro growth of MSC, all cell types 
had mutual doubling times of approximately 2 days at passage 9. Bars represent mean ± SEM. (c) In vitro optical 
bioluminescence imaging (BLI) signal from firefly luciferase (Fluc) expression of increasing numbers of cells in 
24-well plates show a correlative increase in signal intensity. Scale bars represent peak signal in photons/s/cm2/
sr. (d) Lysates from the cell populations shown in figure 2c also showed robust correlation of cell number with 
Fluc enzyme on conventional luminometry. 
Importantly, Fluc enzyme activity correlated well with the previous BLI findings (ASC: r2=0.86, 
MSC: r2=0.75, Fibro: r2=0.95). Taken together, these data suggest that BLI is a reliable tool for 
measuring viable cell numbers and can be used instead of luminometry. Moreover, we found 
a robust correlation between in vivo BLI signals and ex vivo TaqMan PCR cycle counts of Sry 
expression, indicating that cardiac BLI signal is representative of the presence of male donor 
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figure 3. In vivo optical bioluminescence signals parallel ex vivo male donor cell sry expression on Taq-
man PCR. Facilitated by the male-to-female transplant model, in vivo BLI signals were controlled by TaqMan PCR-
assessment of Sry expression of the male donor cells in the female hearts. (a,b) The hearts of 2 mice (MSC 1,2) 
with different BLI signals were explanted, the DNA was extracted, and TaqMan PCR was performed on 3 samples 
from each heart. (c) Higher BLI signal in MSC 1 correspond to lower PCR cycle counts, indicating higher Sry ex-
pression caused by increased donor cell count. (d) Correlation plot of BLI signals vs. TaqMan PCR cycle (r2=0.79).
kinetics of cell survival by longitudinal bioluminescence imaging. Previously, several 
groups have used RT-PCR or histological techniques and observed radical cell death after MSC 
transplantation into the ischemic myocardium.18, 19 However, these techniques do not allow for 
longitudinal imaging of cellular kinetics. Our BLI data showed that 2 days after intramyocardial 
transplantation, all cell types exhibited robust signals from the cardiac region, thereby confir-
ming successful transplantation.20 However, in the following days, all three cell types experi-
enced significant donor cell death (figure 4a). Quantitative analysis shows decreased signals 
at day 7-10 as compared to day 2, which reached background levels by week 4-5 (figure 4b-d). 
When normalized to the signal of day 2, there were no significant differences between ASC, 
MSC, and the Fibro control group (figure 4e, P=NS, repeated measurements ANOVA). 
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figure 4. longitudinal in vivo optical bioluminescence imaging (bli) of intramyocardially transplanted 
cells in living mice. (a) Representative figures of animals within each group show that, after an initial strong 
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weeks. Scale bars represent BLI signal in photons/s/cm2/sr. (b-d) Graphic representation of decreasing signals 
in the (b) ASC, (c) MSC, and (d) Fibro groups which are indicative of cell death. Background signals (dotted line) 
were reached between week 3 (Fibro) to week 5 (MSC) (n>7 in all groups, * indicates P<0.05 compared to the 
signal on day 2, ANOVA). (e) Normalized graph of reporter gene signals from transplanted cells showing that, 
when compared over time and controlled for initial differences in signal between cell types, there were no signi-
ficant differences between ASC, MSC, and cellular control groups (Bars represent mean ± SEM, p=NS, repeated 
measurements ANOVA). 
influence of gender mismatch, myocardial milieus, and GfP expression on in vivo trans-
planted cell survival. To enable ex vivo validation of our in vivo BLI study, we performed a 
gender mismatch model with male donors and female recipients followed by TaqMan PCR 
of male Sry gene. From studies with organ transplant patients, it has been noticed that male 
patients receiving female grafts have decreased graft survival and require more immunosup-
pressant drugs 21. Although this effect was generally less apparent in male-female transplants 
21, we set out to investigate the role of gender mismatch by transplanting equal numbers of 
male and female ASC into hindlimbs of male mice. As shown in figure 5, there were no signi-
ficant differences in cell survival between the cell types from both genders. After two weeks, 
BLI signals were 6.3x104±0.8x104 p/s/cm2/sr for male ASC and 5.7x104±1.3 x104 p/s/cm2/sr for 
female ASC (P=NS). 
figure 5. Effect of donor-recipient gender mismatch on in vivo cell survival. To assess whether gender mis-
match had influenced cell survival, both 5x105 male and female ASC were transplanted into male mice. (a, b) 
Imaging signals from either cell type were comparable without any significant differences. Scale bars represent 
BLI signal in photons/s/cm2/sr (Bars represent means ± SEM, n=5, p=NS, ANOVA). 
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In our study, it is also possible that GFP can elicit an immune response 22, which may have led 
to a decreased survival in our cardiac experiments. In order to differentiate between the effects 
of ischemic versus normal cardiac tissue on stem cell survival, MSC were also transplanted into 
non-infarcted hearts. While acute survival was observed in the non-ischemia group, the cells 
were still not capable of surviving for a prolonged period (figure 6). 
figure 6. Effect of ischemia on in vivo cell survival. In order to differentiate between the effects of ischemic 
versus normal cardiac tissue on stem cell survival, 5x105 MSC were transplanted into both infarcted and non-
infarcted hearts. No significant differences in cell survival were observed in a 3-week period. Scale bar represents 
BLI signal in photons/s/cm2/sr (n=3/group, p=NS, ANOVA).
In order to explore the influence of GFP-expression on cell survival, we transplanted GFP+-
Fluc+ into the hindlimbs of naïve FVB mice or FVB mice that were pre-sensitized by means of 
previous Fluc-GFP plasmid injection. By comparison of cell survival pattern, again there were 
no significant differences between BLI signals from both animals (figure 7). In summary, while 
both gene mismatch and GFP immunogenicity could have affected cell survival, our direct 
comparison studies suggest that they were not the main contributing factors for the loss of 
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figure 7. Effect of donor GfP-expression on in vivo cell survival. Both (a) ASC (b) and MSC expressed GFP (in 
vitro fluorescence microscopy pictures), which might have influenced cell survival by possible immunogenicity. Ho-
wever, after transplantation of 5x105 GFP+-Fluc+ MSC into pre-sensitized and naïve FVB mice, (c) longitudinal BLI and 
(d) quantification of signal intensity revealed no significant differences between imaging signals from day 0 to day 
28. Scale bars represent BLI signal in photons/s/cm2/sr (Bars represent means ± SEM, n=3/group, p=NS, ANOVA).
Assessment of cardiac contractility by echocardiography. Previously, it has been observed 
that ASC11 and MSC23 preserved left ventricular dimensions and fractional shortening after 
infarction. However, there is no comparative functional data available between both cell ty-
pes, after prolonged time in culture. In the current study, measurements of left ventricular 
dimensions revealed a gradual increase in diameters in both diastole and systole, suggesting 
negative remodeling in all groups without any significant benefits of cell transplantation when 
evaluated at weeks 2, 4, and 6 (figure 8a-c). For the cell groups (ASC, MSC, Fibro), after an 
initial non-significant increase in left ventricular fractional shortening (LVFS) compared to the 
PBS group at week 2, the increasing ventricular dilatation resulted in a declining LVFS over 
time (figure 8d). By week 6 after cell transplantation, there was a trend toward improved LVFS 
in the ASC (33.1±1.0%) and MSC (33.0±3.5%) groups compared to the Fibro (31.3±2.2%) and 
PBS (32.0±1.8%) control groups, of which the latter (figure 8d, P =NS, repeated measurements 
ANOVA) had similar values compared to the literature 24. For complete echocardiography re-
sults, please refer to table 1.
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figure 8. In vivo measurements of cardiac function over time. (a) Representative M-mode traced two-dimen-
sional picture taken at the level of the papillary muscle whereby left ventricular diastolic and systolic diameters 
can be measured. (b,c) Cell transplantation after myocardial infarction was not capable of preventing an increase 
in left ventricular diastolic (LVdd, b) or systolic diameters (LVsd, c). (d) Left ventricular performance, as measured 
by left ventricular fractional shortening (LVFS), was preserved only in the short term after cell transplantation. 
The dotted line represents the mean pre-operative fractional shortening of all operated animals. Six weeks af-
ter transplantation, there was a comparable LVFS in the ASC and MSC groups. Although cardiac function was 
slightly better than control groups, there was no significant difference when controlled for the trend over time 
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Time (days)  AsC  msC  fibro  Pbs
LVFS (%) 14 38.2 ± 3.5 35.2 ± 3.2 38.6 ± 3.2 33.2 ± 2.0
LVFS (%) 28 35.9 ± 1.7 32.5 ± 2.4 35.2 ± 2.8 34.2 ± 3.4
LVFS (%) 42 33.1 ± 1.0 33.0 ± 3.5 31.3 ± 2.2 32.0 ± 1.8
LVdd (mm) 14 3.9 ± 0.3 3.7 ± 0.2 3.4 ± 0.2 3.5 ± 0.6
LVdd (mm) 28 4.0 ± 0.3 4.0 ± 0.2 3.7 ± 0.1 3.4 ± 0.1
LVdd (mm) 42 3.8 ± 0.1 4.0 ± 0.2 3.9 ± 0.1 3.5 ± 0.1
LVsd (mm) 14 2.4 ± 0.1 2.4 ± 0.2 2.1 ± 0.2 2.3 ± 0.1
LVsd (mm) 28 2.6 ± 0.2 2.8 ± 0.2 2.4 ± 0.1 2.4 ± 0.1
LVsd (mm) 42 2.5 ± 0.1 2.7 ± 0.3 2.7 ± 0.1 2.4 ± 0.1
Table 1. non-invasive echocardiography measurements. Values are reported in mean ± SEM. No symbols 
indicate P=NS (Repeated measurements ANOVA).
Hemodynamic measurements using pressure-volume (Pv) loops. Recently, it has been 
shown that MSC were capable of preserving myocardial compliance, as measured by inva-
sive hemodynamic measurements.25 Thus, to validate the echocardiography measurements of 
ventricular dimensions, invasive steady-state hemodynamic measurements of left ventricular 
diastolic and systolic volumes were conducted immediately after echocardiography at week 
6. When plotted versus each other, mean diastolic and systolic volumes and diameters from 
each group correlated with r2 values of 0.88 and 0.70, respectively (figure 9a-c). Stroke work 
and cardiac output, important parameters of ventricular performance26, did not differ among 
cellular groups but was slightly better than the PBS control group (figure 9d,e, P=NS, ANO-
VA). Ventricular contraction was not different between groups, but there was a trend towards 
an improved ventricular relaxation, as measured by the minimum ∆P/∆t, in the ASC and MSC 
groups (figure 9f, g, P=NS, ANOVA). Furthermore, an increase in arterial elastance, suggestive 
of higher afterload caused either by arterial stiffening or increased peripheral resistance27, was 
seen in the PBS group but this was not significantly different from the ASC and MSC group and 
the Fibro controls (figure 9d, P=NS, ANOVA). 
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figure 9. invasive steady-state pressure-volume measurements of cardiac performance. (a,b) Pressure-
volume recordings of (a) a normal, non-operated animal, and (b) PBS control animal 6 weeks after infarction 
with typical right shift. (c) Mean values of left ventricular volumes, as measured by pressure-volume loops, were 
correlative with the earlier acquired left ventricular diameters, as measured by echocardiography (dots repre-
sent mean measured values from each group). (d, e) Although transplantation of ASC and MSC resulted in a 
similar trend of preservation of (d) stroke work and (e) cardiac output compared to the PBS group, there was no 
significant difference compared to the cellular control. (f ) Although maximum dP/dt was not different among 
groups, there was a (g) trend towards better minimum dP/dt, which is indicative of better ventricular relaxation. 
(h) Similarly, there was a trend towards lower afterload, as shown by lower arterial elastance, in all cellular groups 
compared to the PBS group (Bars represent means ± SEM, n>6 in every group, p=NS, ANOVA).
Post-mortem histology. Immediately after PV-analysis, the animals were euthanized after 
which the hearts were explanted. Gross morphology showed that ventricular dilatation and fi-
brous scar formation had not been prevented by cell transplantation (figure 10). As suggested 
by the BLI, echocardiography, and PV findings, transplantation of both ASC and MSC did not re-






ADiPosE TissUE- AnD bonE mARRow-DERivED msC in THE infARCTED HEART   |  125
figure 10. macroscopic pictures of representative explanted hearts show no prevention of cardiac remo-
deling after cell transplantation. 6 weeks after transplantation of (a) ASC, (b) MSC, and (c) Fibro there are no 
gross signs of tissue preservation compared to (d) PBS (H&E stained slides of representative hearts).
DISCUSSION
This study has evaluated for the first time the in vivo behavior and functional effects of both 
adipose tissue-derived stromal cells (ASC) and bone marrow-derived mesenchymal stem cells 
(MSC) after injection into the ischemic myocardium, as compared to a cellular (Fibro), and non-
cellular (PBS) control group. The major findings are as follows: (1) molecular imaging using the 
Fluc reporter gene is a reliable tool for repetitively monitoring donor cell survival in vivo; (2) 
similar to the Fibro control group, ASC and MSC rapidly die off after injection into the infarcted 
heart; and (3) ASC and MSC were not capable of significantly preventing left ventricular remo-
deling and subsequent loss of cardiac function.
Until now, ASC and MSC studies have been largely based on in vitro studies10 or investigations 
that monitored cell location and quantity by post-mortem histological analysis28 or PCR tech-
niques.18 To study the true in vivo behavior of stem cells, one needs to be able to repetitively 
image cell location and count in a non-invasive fashion. One such approach would be the la-
beling of stem cells with iron particles which would enable imaging by MRI.29 However, this 
technique does not provide insight into cell number since the same amount of iron particles 
are divided among daughter cells during cell proliferation or ingested by macrophages in case 
of cell death.30 By contrast, the current study demonstrates that molecular imaging of the Fluc 
reporter gene with the D-Luciferin reporter probe can provide repetitive, longitudinal in vivo 
imaging of donor cell survival in the infarcted heart of the same animal, thereby preventing 
sampling biases that can occur with the use of multiple animals that need to be sacrificed on 
different time points to perform conventional histological staining.31 
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The clinical relevance of this study is significant. MSC have been suggested as potential 
treatments for a wide variety of diseases including graft versus host disease, osteogenesis im-
perfecta, rheumatoid arthritis, multiple sclerosis, and myocardial infarction32. Since the ASC 
and MSC appear to be comparable cells with also similar in vivo behavior, it would be possible 
to yield stromal cells from fat instead of bone marrow. Not only would this provide a less re-
stricting source regarding yield, it would also be a more patient friendly isolation procedure. In 
fact, it has even been proposed that human ASC are superior to MSC with regard to their para-
crine and angiogenic potential in response to ischemia.33 Despite these reported advantages, 
an important finding from our study is that both MSC and ASC do not survive for longer term 
following transplantation into the infarcted heart. Based on our quantitative measurements of 
BLI signals, all cells have died by week 6. This is in concordance with earlier PCR findings from 
Muller-Ehmsen et al., who noticed robust cell death after transplantation with less than 2% of 
the initially transplanted MSC being present at 6 weeks after cardiac transplantation.18 Simi-
larly, Nakamura and colleagues were only able to find 4.4% engraftment of MSC19 1 week after 
intramyocardial transplantation, while Amsalem et al. were unable to find any MSC 4 weeks 
after transplantation.23 Moreover, Mangi and colleagues observed robust cell death early after 
transplantation, which was mitigated by transfecting the MSC with the pro-survival gene Akt-
1.34 Thus, although prolonged survival of MSC and ASC has been proven possible in different 
models35, 36, the environment in the heart proves hostile to these cells, resulting in decreased 
cell survival. 
There have been several studies reporting preservation of cardiac function after myocardial 
infarction and subsequent ASC11 and MSC37 transplantation. On the contrary, in this study we 
did not observe any functional benefit from ASC or MSC after transplantation into the infarcted 
heart. In fact, after an initial preservation, we have observed decreasing fractional shortening 
in both ASC and MSC groups from week 2 to week 6. Although these differences could be 
a consequence of differences in the experimental animal and surgical models, the observed 
short-term effect of cell transplantation is in concordance with findings from a growing body 
of experimental studies. Ultra-sensitive small animal MRI has recently been used to show that 
MSC fail to repair the ischemic heart and do not have any beneficial effect on cardiac function 
after infarction.38 This non-beneficial effect corresponds to other studies, which show that non-
transduced MSC do not ameliorate functional heart failure after transplantation.39 In addition, 
Dai and colleagues observed no long-term functional effect after an initial significant benefit 1 
month after transplantation of MSC in infarcted rat hearts.28 In combination with the BLI data of 
the current study and as suggested in a recent review40, the dismal cell survival of ASC and MSC 
might underlie this short term effect. This poor survival pattern makes robust repopulation 
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fect has been shown to be of crucial importance in MSC function.34, 41 By transfecting MSC with 
Akt-1, researchers have observed not only a better cell survival under hypoxic conditions, but 
also a robust increase in paracrine factors which resulted in a preservation of morphology and 
function of the infarcted heart34, 41, effects that were also shown using MSC transfected with the 
pro-survival gene Bcl-2.39 Thus, further research is needed to identify the factors responsible 
for the acute donor cell death in the heart (both infarcted and non-infarcted). Improving stem 
cell survival may offer a sustained paracrine effect which could lead to protective effects on 
resident cardiomyocytes from apoptosis and a subsequent preservation of cardiac function. 
Several limitations of this study can be raised. First, we used Fluc- and GFP-expressing cells in 
order to be able to investigate cellular fate in case of robust cell survival after 6 weeks. It has 
been suggested that GFP could impair actin-myosin interactions in muscle cells42 which might 
have influenced cardiac function. However, the lack of functional benefit of transplantation of 
either cell type in this study is also in concordance with other studies using non-GFP-labeled 
MSC.28, 38 Second, we chose to use longer-term cultured cells because this generally increases 
purity and also because the ability to culture these cells underlies a crucial advantage which 
is important for its off-the-shelf clinical potential. However, it has been shown that higher pas-
sage MSC had decreased  growth factor release under hypoxic conditions and that passage 
number of MSC was inversely correlated to the protective effect on infarcted hearts.43 Thus, it is 
possible that the lack of functional benefit is a consequence of dismal cell survival, diminished 
paracrine signaling, and high passage of the cells. 
In conclusion, we have reported that the stromal population from the adipose tissue has close 
in vitro resemblance with its counterpart from the bone marrow. Importantly, using non-inva-
sive molecular imaging techniques, this study has shown for the first time that these cells also 
have similar in vivo behavior in the infarcted heart. Finally, we did not observe a clear func-
tional benefit after transplantation of both cell types. These results should be a stimulus for 
further research regarding improvement of cellular behavior to ultimately be able to restore 
cardiac function after myocardial infarction by transplanting long-term cultured, off-the-shelf 
adipose tissue-derived stromal cells.
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LETTER TO THE EDITOR
It can hardly be argued that cardiac imaging methodologies targeting small animal models 
have been crucial for rapidly transitioning therapies from the bench to bedside. The adapta-
tion of ultrasound for imaging murine hearts, for example, has allowed characterization of the 
developing and adult rodent heart, making it an essential tool for the study of developmental 
biology and cardiovascular disease. Nevertheless, additional imaging tools may prove useful 
adjuncts and/or alternatives to such established traditional modalities.
 Ideally, a cardiovascular imaging modality should provide structural-functional quantitation, 
and be non-invasive, fast, cost-effective, precise, and accurate. While the combination of echo-
cardiography and small animal cardiac MRI has proven to meet several of these criteria, there is 
certainly room for other modalities to be employed as well. At our institution, experimentation 
with a Micro-CT scanner eventually produced contrast-enhanced, high-resolution 3-dimen-
sional imaging of the murine heart and associated structures. Indeed, early success with CT 
imaging of murine hearts has also been described in limited detail by other investigators 1, 2 but 
to our knowledge, a validation of this technique by direct comparison to multiple established 
methodologies has not been described. Hence, we present the first study aimed to directly 
compare this novel imaging modality with both conventional echocardiography and conduc-
tance catheter (CC) measurement techniques using an established murine model of ischemic 
heart disease. Specifically, we have tested the hypothesis that Micro-CT can provide reliable 
information about ventricular structure and function following surgical LAD-ligation induced 
myocardial infarction (MI) in mice.
We randomized adult (8-10 weeks old) female FVB mice (n=19) to surgical LAD ligation or sham 
procedure. Dual cardiac and respiratory gated, IV contrast enhanced (20 µL/g Fenestra VC; ART 
Inc., Montreal, Canada) CT scans were performed pre-operatively and at 4, 8, and 12 weeks 
post-procedure using the eXplore Locus RS150 MicroCT (GE Healthcare, Fairfield, CT). Scans 
were performed with a 70 kVp, 40 mAmp x-ray source, acquiring 286 views over 200°, avera-
ging two frames per view, 4x4 binning on the CCD detector. The heart was centered in a 46.25 
mm axial field of view (84.7 mm trans-axial FOV), and sub-regions of the scanned data were 
reconstructed at an isotropic resolution of 97.3 µm. End-diastolic and end-systolic images were 
prospectively acquired with a temporal resolution of 15 milliseconds (ms) by gating on ECG P- 
and S’-waves, respectively (see figure 1a-b for animal set-up and gating reference). Continual 
imaging of the cardiac cycle (at 10-15 ms intervals) was also conducted of a representative 
animal at each time point (figure 2 demonstrates continuous imaging of control animal). Post-
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figure 1. outline of image acquisition and processing by micro-CT. (a) Mouse positioned on CT scanner 
bed with 3 lead ECG. (b) Screen shot of ECG (top) and respiratory (bottom) tracings. Red squares occurring at 
the same time in both ECG and respiratory tracings indicate image acquisition points during maximum LV con-
traction (S’) and inspiration. (c) Region of interest (orange dots) created around heart chamber (LV shown). (d) 
Histogram used to isolate voxels representing chamber volume. (e) Rendered surface of blood within chamber 
(LV). (f ) Representative composite image of cardiac chambers and great vessels. 
All operators obtaining and analyzing the CT scans were able to obtain measurements with 
minimal variability (±0.5-4.0%, data not shown). Echocardiography was performed by obtai-
ning three independent two-dimensional transversal-targeted M-mode traces at the level of 
the papillary muscles using a 14.7-MHz transducer on a Sequoia C512 Echocardiography sys-
tem (Siemens, Malvern, PA, USA). Using the Siemens proprietary software, left ventricular end-
diastolic and end-systolic posterior and anterior dimensions were measured and processed 
to calculate left ventricular fractional shortening (LVFS). Invasive, steady-state hemodynamic 
measurements were conducted by closed-chest pressure-volume (PV) loop analysis using a 
1.4-F conductance catheter (Millar Instruments, Houston, TX, USA) at week 12. These data were 
analyzed using PVAN 3.4 Software (Millar Instruments, Houston, TX, USA) and Chart/Scope 
Software (AD Instruments, Colorado Springs, CO, USA). 
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Mean left ventricular diastolic (LVDV) and systolic (LVSV) volumes were not significantly diffe-
rent between the sham and MI groups at baseline (37.2±2.0 μL vs. 39.7±1.8 μL in diastole and 
11.2±0.6 μL vs. 11.4±0.8 μL in systole, respectively, P=NS). However, these volumes gradually 
increased in the MI group, finally reaching a mean diastolic value of 133.2±21.2 μL, compared 
to 55.4±1.0 μL in the sham operated group at 12 weeks post-operation (P=0.002, figure 3a-c).
Similarly, LVSV increased to 100.1±19.6 μL as compared to 19.9±1.2 μL in the sham group 
(P=0.002, figure 3d). This MI-induced increase in volumes mirrored functional failure, with de-
teriorating LVEF from an initial 70.6±2.5% to 26.2±2.8% after 12 weeks. By contrast, LVEF in the 
sham group remained around baseline (68.6±2.6%, P<0.0005, figure 3e).
figure 2. Quantification of cardiac chamber volumes by micro-CT. Representative reconstruction of cardiac 
chamber volumes in (a) end-systole and (b) end-diastole allowed for extrapolation of chamber volumes and 
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As shown in figure 4, volumes measured by Micro-CT correlated well with dimensions ac-
quired from echocardiography in both diastole (r2=0.73) and systole (r2=0.82). Similarly, volu-
mes derived from the conductance catheter (CC)-based approach showed a correlative trend 
with those from the Micro-CT (r2=0.83 in systole and r2=0.81 in diastole). When volumes and 
dimensions were processed to calculate functional measurements of ventricular contraction, 
Micro-CT proved to correlate well with echocardiography (r2=0.72, figures 4d). These obser-
vations suggest that Micro-CT imaging can provide reliable volumetric assessment of cardiac 
chambers and ventricular function. For detailed echocardiography, CC, histological results, and 
representative images, please refer to figures 5-7.
figure 3: Gated micro-CT provides insight into myocardial infarction-induced cardiac remodeling. (a) End 
diastolic (top row) and end systolic (bottom row) images of a normal mouse heart with chambers labeled in yel-
low. From left to right: rendered surface of blood volume, sagittal, axial, and coronal views. (b) Similar series of 
images from the same animal 12 weeks following LAD ligation (scale bar=5mm in both panels), showing clear 
signs of negative remodeling. (c) Graphic representation of increasing left ventricular diastolic volume (LVDV) 
over time following myocardial infarction as compared to relatively stable volumes in the sham-operated group. 
(d) Similarly, left ventricular systolic volume (LVSV) increased due to loss of cardiac muscle after infarction. (e) 
Myocardial infarction led to dilated cardiomyopathy with a significant loss of left ventricular ejection fraction 
(LVEF) as early as one month following LAD ligation (Bars represent mean±SE. *P<0.05 compared to sham group 
by repeated measurements ANOVA).
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figure 4. micro-CT findings correlate robustly with established methods of measuring murine cardiac 
function. (a,b) Volumes derived from Micro-CT image analysis correlate well with dimensions measured using 
echocardiography and volumes assessed with the conductance catheter (CC) in both systole and diastole. (c) 
Echocardiography measurements of chamber length correlated well with volumes derived from CC measure-
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figure 5. Echocardiographic m-mode traced measurements of ventricular diameters and calculated left 
ventricular fractional shortening (lvfs). (a) Representative M-mode traced picture taken at the level of the 
papillary muscle of a pre-operative heart whereby left ventricular diameters can be measured. Scale bar re-
presents 5 mm. (b) The same heart as in (a) shows extensive dilatation at 12 weeks post-MI. (c-e) A gradual MI-
induced increase in ventricular diameters in diastole (LVDD, c), and systole (LVSD, d) translated in a significantly 
compromised LVFS over a period of 12 weeks as compared to the sham group (Bars represent mean±SE. * repre-
sents P<0.05 compared to sham group by repeated measurements ANOVA). 
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figure 6. Conductance catheter (CC) based assessment of cardiovascular function. (a) Representative 
pressure-volume loops of sham (left) and MI (right) animals at 12 weeks post-MI, showing typical right shift 
indicating increased ventricular dilatation and volumes compared to pre-operative assessment. (b,c) Confirming 
findings by Micro-CT and echocardiography, extrapolation of pressure-volume loops showed significantly incre-
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as well as stroke work (SW) were both significantly diminished as well. (f ) As a confirmatory measure of CHF, the 
arterial elastance (AE) was also significantly increased at the 12-week post-MI time point. (g) Finally, significantly 
decompensated MI-induced heart failure was illustrated by a markedly decreased maximum power generated 
by the left ventricle (Bars represent mean±SE. * represents P<0.05 compared to sham group by Student’s t-test).
figure 7. Post-mortem histological analysis confirms in vivo micro-CT images. (a,b) Representative heart 12 
weeks following sham procedure appears both grossly and histologically normal, corresponding to the in vivo 
images acquired by Micro-CT immediately prior to CC-measurements and sacrifice. (c) By contrast, a representa-
tive fixed heart 12 weeks post-infarction shows an aneurysmal, infarcted region and fibrosis on Masson-Trichro-
me staining (black arrows). (d) Corresponding in vivo Micro-CT images from the same heart with the infarcted 
area marked by yellow arrows clearly resembles the post-mortem images from (c). Scale bars represent 5 mm.
Over the past decade, cardiac CT has become an important clinical imaging modality for the characterization of 
cardiac structure and function, as well as coronary artery pathology 3, 4. However, cardiac CT imaging has long 
been inapplicable to pre-clinical, small animal models due to the high spatial and temporal resolution required 
to visualize mouse hearts with rates of over 400 beats a minute. Recent advances in technology have allowed 
adaptation of CT imaging to the small animal laboratory, adding a valuable asset to the pre-clinical research tool 
chest. As shown in the present study, Micro-CT can provide accurate and precise measurements of the murine 
heart, and can serve as a useful adjunct to established measurements of cardiac function. Further refinements 
of this emerging technology are ongoing, and we predict that Micro-CT scanning will continue to be used in the 
small animal laboratory with increasing frequency.
142  |   PART ii: ADUlT sTEm CElls - CHAPTER 9
REFERENCES:
1. Nahrendorf M, Badea C, Hedlund LW, Figueiredo JL, Sosnovik DE, Johnson GA, Weissleder 
R. High-resolution imaging of murine myocardial infarction with delayed-enhancement 
cine micro-CT. Am J Physiol Heart Circ Physiol. 2007;292(6):H3172-3178.
2. Detombe SA, Ford NL, Xiang F, Lu X, Feng Q, Drangova M. Longitudinal follow-up of 
cardiac structure and functional changes in an infarct mouse model using retrospectively 
gated micro-computed tomography. Invest Radiol. 2008;43(7):520-529.
3. Pouleur AC, le Polain de Waroux JB, Kefer J, Pasquet A, Vanoverschelde JL, Gerber BL. 
Direct comparison of whole-heart navigator-gated magnetic resonance coronary 
angiography and 40- and 64-slice multidetector row computed tomography to detect 
the coronary artery stenosis in patients scheduled for conventional coronary angiograp-
hy. Circ Cardiovasc Imaging. 2008;1(2):114-121.
4. Ruzsics B, Lee H, Powers ER, Flohr TG, Costello P, Schoepf UJ. Images in cardiovascular 
medicine. Myocardial ischemia diagnosed by dual-energy computed tomography: 
correlation with single-photon emission computed tomography. Circulation. 
2008;117(9):1244-1245.
CHAPTER 9
molecular imaging of bone marrow mononuclear Cell 
survival and Homing in a murine model 
of Peripheral Artery Disease
Koen E.A. van der Bogt1,2*, Alwine A. Hellingman2*, 
Maarten A. Lijkwan1,2, Ernst Jan Bos1,2, Margreet R. de Vries3, 
Michael P. Fischbein1, Paul H. Quax2,3, Robert C. Robbins1, 
Jaap F. Hamming2 and Joseph C. Wu4
Submitted
* Both authors contributed equally to this study.
144  |   PART ii: ADUlT sTEm CElls - CHAPTER 9 bonE mARRow mononUClEAR CEll TRAnsPlAnTATion foR PAD   |  145
ABSTRACT
introduction: Bone marrow mononuclear stem cell (MNC) therapy is a promising treatment 
for peripheral artery disease (PAD). This study aims to provide insight into cellular kinetics 
using molecular imaging following different transplantation methods.
methods and Results: MNCs were isolated from F6 transgenic mice (FVB background) that 
express firefly luciferase (Fluc) and green fluorescence protein (GFP). Male FVB mice (n=38) 
underwent femoral artery ligation and were randomized into 3 groups receiving: (1) single 
intramuscular (i.m.) injection of 2x106 MNC; (2) weekly i.m. injection of 5x105 MNC; and (3) i.m. 
injection of PBS. To assess the biodistribution following system delivery, we also injected (1) 
5x106 MNCs intravenously (i.v.) and (2) PBS i.v. as control (n=10/group). Cellular kinetics, mea-
sured by in vivo bioluminescence imaging (BLI), revealed near-complete donor cell death 4 
weeks after i.m. transplantation. Following i.v. transplantation, BLI monitored cells homed on 
the injured area in the limb, to liver, spleen, and bone marrow. Ex vivo BLI showed presence of 
MNCs in the scar tissue as well the adductor muscle. However, no significant effects on neovas-
cularization were observed, as monitored by Laser-Doppler-Perfusion-Imaging and histology. 
Conclusion: This is the first detailed study to assess the kinetics of transplanted MNCs in PAD 
using in vivo molecular imaging. MNC survival after i.m. transplantation is short-lived and 
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INTRODUCTION
Peripheral artery disease (PAD) currently affects over 27 million people in North America and 
Europe and is associated with impaired leg function and decreased quality of life, leading to 
significant morbidity and mortality.1, 2 Despite a variety of treatment options, including per-
cutaneous transluminal angioplasty, stenting, and bypass surgery, a cluster of patients do not 
respond to therapy, leaving no other option than amputation in one third of patients within 
this group.3 
Recently, stem cell therapy has emerged from bench to bedside as a treatment for end-stage 
PAD, potentially offering a last option for revascularization of the ischemic limb. While results 
from pre-clinical experiments using bone marrow-derived mononuclear cells (MNC) appear 
hopeful, outcomes from clinical studies are mixed4, raising questions about transplanted stem 
cell behavior and mechanisms of action involved in the benefits of stem cell transplantation. 
As to cell behavior, two major issues are the lack of donor cell survival after introduction into 
ischemic target tissue and the absence of cell homing to the injured area following systemic 
administration.5 Donor cell death would hamper three mechanisms believed to be of impor-
tance for the beneficial effects seen after cell transplantation: a lasting scaffolding effect, trans-
planted cell-derived neovascularization, and the secretion of protective paracrine factors by 
the transplanted cells. 
To study stem cell behavior, one must be capable of monitoring cell location, migration, pro-
liferation, and death. Recent proof-of-principle studies have demonstrated the ability to track 
cell fate following cardiac injections.5, 6 In the present study, we monitor by molecular imaging 
the presence of MNC after transplantation in mice with induced hind limb ischemia. These 
experiments are designed to answer critical questions regarding cell survival and homing pat-
terns to the affected leg, as well as functional consequences of different transplantation stra-
tegies. 
METHODS
Experimental animals. Animal study protocols were approved by the Animal Research Com-
mittees from both institutions (Stanford University and Leiden University). The donor group 
for imaging experiments consisted of 8-week old male F6 mice (n=10), which were bred on 
FVB background and ubiquitously express green fluorescent protein (GFP) and firefly luciferase 
(Fluc) reporter genes driven by a β-actin promoter as previously described.7 Recipient animals 
(n=60) for these experiments consisted of syngeneic, male FVB mice (10-12 weeks old, Jackson 
Laboratories). To compare the efficacy of a single versus repeated injection with cells, animals 
were randomized into 3 groups: (1) single intramuscular (i.m.) injection of 2x106 MNCs, (2) four 
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repeated injections of 5x105 MNCs, and (3) i.m. injection of phosphate buffered saline (PBS) 
injection as control. To compare the efficacy of local versus system delivery, animals were also 
injected with (1) single intravenous (i.v.) injection of 2x106 MNCs and (2) PBS i.v. as control.
Preparation and characterization of bone marrow mononuclear cells (mnC). The long 
bones were explanted, washed, and flushed with PBS using a 25-gauge needle to collect bone 
marrow. After passing through a 70 μm strainer, the isolate was centrifuged at 1200 rpm for 5 
minutes, washed, and resuspended into PBS. To acquire the MNC fraction, the bone marrow 
isolate was centrifuged for 40 minutes at 1600 rpm using a 14 mL tube with 3 mL Ficoll-Paque 
Premium (GE Healthcare, Piscataway, NJ, USA) gradient and 4 mL cell/saline suspension, as 
described.5 MNCs were prepared freshly before application.
Characterization of cells by flow cytometry. Cells were incubated in 2% FBS/PBS at 4°C for 
30 min with 1 μL of APC-conjugated anti-CD31 (eBioscience), anti-CD45 (BD Biosciences), and 
anti-Gr-1 (BD Biosciences), or PE-conjugated anti-CD34 (eBioscience), anti-CD11b (BD Biosci-
ences), anti-Flk-1, anti-Sca-1 (both eBioscience), and anti-NK1.1 (BD Biosciences), and pro-
cessed through a FACSCalibur system (BD, San Jose, CA, USA) according to the manufacturer’s 
protocol.
In vivo optical bioluminescence imaging (bli). BLI was performed on the IVIS 200 (Xenogen, 
Alameda, CA, USA) system. For in vitro characterization of luciferase expression, cells were sus-
pended in different quantities in 1 mL PBS. Following administration of 10 μL (43.5 μg/mL) D-
Luciferin, peak signals (photons/s/cm2/sr) from a fixed region of interest (ROI) were evaluated 
and plotted versus cell number. For in vivo experiments, recipient mice were anesthetized with 
isoflurane, shaved, and placed in the imaging chamber. After acquisition of a baseline image, 
mice were intraperitoneally injected with D-Luciferin (400 mg/kg body weight). Mice were 
imaged on days 1, 3, 6, 9, 13, 20, and 27 post-injection. Peak signals (photons/s/cm2/sr) from 
a fixed region of interest (ROI) were evaluated as described.7 For ex vivo experiments, animals 
were euthanized immediately following the moment when peak signals were achieved. The 
organs were rapidly explanted and imaged according to the protocol described above.
surgical model for hind limb ischemia and cell injections. Mice were placed under general 
anesthesia with either isoflurane (2%) or ketamine/xylazine combination. Ischemia was cre-
ated by left sided electro-coagulation of the femoral artery just proximally to the superficial 
epigastric artery. One day postoperatively, 40 μL of cell/PBS injections were given into the ad-
ductor muscle, or 100 μL of cell/PBS solution into the tail vein using a 28-gauge syringe. Subse-
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of PAD, male C57BL/6 mice (n=20, Charles River) underwent left sided electro-coagulation of 
both common iliac and femoral arteries. Afterwards, animals were randomized to receive intra-
venous injection of 5x106 MNCs or injection or PBS as control (n=10/group). 
laser Doppler Perfusion imaging (lDPi). Neovascularization was monitored by measure-
ments of perfusion of the hind limbs at the level of the paws and was performed in the mouse 
hind limb before and directly after the surgical procedure with Laser Doppler Perfusion Imaging 
(LDPI) (Moor Instruments) at weekly interval over 4 weeks. Eventually, perfusion was expressed 
as a ratio of the left (ischemic) to right (non-ischemic) paw. Before LDPI, mice were anesthetized 
with an intraperitoneal injection of Midazolam (5 mg/kg, Roche) and Medetomidine (0.5 mg/
kg, Orion).
Ex vivo ElisA for apoptosis on digested muscle. The selected muscle was explanted, diges-
ted using a stator-rotator homogenizer, and lysed. ELISA was performed directly on the super-
natant to quantify histone-associated DNA fragments (mono- and oligonucleosomes), mar-
king early apoptotic cells (Cell Death Detection ELISA, Roche Applied Science, Indianapolis, IN).
Ex vivo assays of reporter gene expression. To validate in vivo BLI findings, the bone mar-
row was collected as described above and assayed for GFP expression by flow cytometry as 
described above.
Post-mortem immunohistochemistry. Immunohistochemistry was performed to visualize 
smooth muscle cell layers of collateral arteries with an antibody against smooth muscle actin. 
Furthermore, with an antibody against GFP, GFP+ MNCs were traced in the ischemic skeletal 
muscle. Five µm-thick paraffin-embedded sections of skeletal muscle fixed with 4% formal-
dehyde were used. These were re-hydrated and endogenous peroxidase activity was blocked 
for 20 minutes in methanol containing 0.3% hydrogen peroxide. Skeletal muscle slides were 
stained with monoclonal anti-α smooth muscle actin (mouse anti-human, DAKO, dilution 
1:800) or polyclonal anti-GFP (rabbit anti-mouse, Invitrogen, dilution 1:4000). Antigen retrie-
val was not necessary and sections were incubated overnight with primary antibody. Rabbit 
anti-mouse HRP (DAKO, dilution 1:300) or goat anti-rabbit biotin (DAKO, dilution 1:300) were 
used as secondary antibodies respectively. Negative controls were performed by using isotype 
controls instead of the primary antibody. For both stainings, the signal was detected using 
NovaRED substrate kit (Vector laboratories) and sections were counterstained with hematoxy-
lin. Stainings were quantified from randomly photographed sections using image analysis 
(ImageJ). 
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statistical analysis. Statistics were calculated using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). 
Descriptive statistics included mean and standard error. Comparison between groups was 
performed using a one-way between groups ANOVA, or one-way repeated measures ANOVA 
when compared over time, and significance was assumed according to the LSD procedure. 
RESULTS
Cell characterization. Following isolation and Ficoll selection, the MNC population showed 
subpopulations of CD31+, CD34+, CD45+, and Sca-1+, but Flk-1- cells, representing hematopoie-
tic but not early endothelial progenitors cells. Moreover, strong expression of CD11b, Gr-1, 
and NK 1.1, representative of macrophages, granulocytes, and natural killer cells, indicated the 
largely inflammatory character of this donor cell population (figure 1a).
Reporter gene characterization. To be able to follow cells in an in vivo fashion by biolumines-
cence imaging (BLI), we first set out to characterize the expression of the reporter gene Fluc in 
vitro. As suggested in figure 1b, luciferase expression intensity increased with increasing cell 
numbers. When maximum expression per well was plotted versus the number of cells, a robust 
correlation was observed with an r2 value equaling 0.97 (figure 1c). Thus, BLI signal intensity is 
closely representative of the number of living cells carrying the luciferase reporter gene. More-
over, the robust activity of GFP in the donor-specific Fluc-GFP double-fusion reporter gene 
construct was confirmed by in vitro fluorescence microscopy (figure 1d). 
figure 1. bone marrow mononuclear cell (mnC) characterization. (a) Flow cytometric analysis following 
Ficoll-selection of MNCs indicates low numbers of stem/endothelial progenitor cells (Sca-1, flk-1) and high num-
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present counts). (b) In vitro BLI signals from various numbers of Fluc+ MNCs show (c) robust correlation with cell 
numbers (r2=0.97). Scale bars represent BLI signal in photons/s/cm2/sr. (d) In vitro fluorescence microscopy con-
firms the expression of GFP by the donor cells. 
monitoring kinetics of transplanted mnCs by in vivo bioluminescence imaging (bli). In 
the current study, MNCs were injected into the left adductor muscles one day following crea-
tion of ischemia by left femoral artery occlusion. By doing so, it is possible to study the efficacy 
of MNCs in stimulating arteriogenesis (the process of collateral artery formation4), instead of 
studying the angiogenic effect which is less influential on restoration in blood flow.8 To com-
pare the efficacy of a single versus repeated injection with cells, animals were randomized into 
3 groups: (1) single MNC injection, (2) repeated MNC injection, and (3) PBS injection. Following 
single transplantation of 2x106 MNCs, a short-term post-transplant increase in BLI signal from 
6.6±1.5x104 at day 1 to 8.9±2.5x104 p/s/cm2/sr at day 3 (P=NS), suggesting an increase in cells in 
the adductor muscle region during the initial days. Thereafter, however, cell death resulted in a 
rapid decrease in signal intensity, reaching background levels after 4 weeks (figure 2). In order 
to overcome the problem of poor long-term cell survival, a modified transplantation technique 
was analyzed in which a similar cumulative dose, but divided in 4 weekly doses of 5x105 MNCs, 
was transplanted. This lead to a relatively stable presence of donor cells, although there was no 
statistically significant difference after 4 weeks (5.1±0.8x103 in single vs 5.7±0.3x103 p/s/cm2/sr 













figure 2. mnC survival following intramuscular injection into the adductor muscles of fvb mice after 
femoral artery ligation. (a) In vivo BLI pictures of mice that received either a total of 2x106 MNC by single injec-
tion (upper panel) or by weekly injections (lower panel) show MNC survival is short-lived as most of the signal 
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intensity died off at 4 weeks post-transplant. (b) Quantification of signals showed a somewhat more stable level 
of MNC presence following repeated injections although the difference did not reach statistical significance. 
Scale bars represent BLI signal in photons/s/cm2/sr.
Ex vivo, postmortem localization of GfP+ mnCs in the ischemic adductor muscles. The 
distribution of GFP+ MNCs was assessed in the post-ischemic adductor muscle of mice treated 
with a single injection of 2x106 MNCs and weekly injections of 5x105 MNCs. As shown in figure 
3, skeletal muscles were harvested 28 days after the induction of ischemia. Low numbers of en-
grafted GFP+ MNCs were observed in the adductor muscle of mice that received weekly injec-
tions of MNCs, concordant with in vivo BLI signals. These GFP+ MNCs surrounded vessels within
the muscle tissue, suggesting a potential role of these cells in inducing neovascularization. 
In contrast, GFP+ MNCs were not observed in the adductor muscles of mice receiving a single 
injection of MNCs at week 4, and corresponding to BLI results. 
figure 3. immunohistochemistry of GfP+ mnCs within the post-ischemic adductor muscle. Representative 
pictures of anti-GFP muscle staining of (a) positive control slide (magnification 20x), (b) adductor muscle of 
mouse receiving four weekly 5x105 MNC-injections, showing 2 GFP+ cells near a blood vessel (magnification 80x).
laser Doppler Perfusion imaging (lDPi) of blood flow restoration following mnC trans-
plantation in fvb mice. For the experiments described above, we used FVB mice to perform a 
syngeneic transplantation model with our transgenic FVB mice constitutively expressing Fluc+/
GFP+ reporter genes. In these mice, femoral artery ligation resulted in a significant decrease in 
paw perfusion when compared to the healthy right hind limb (P<0.001 for all groups, figure 4). 
Three days following MNC transplantation, a trend was observed towards better flow recovery 
with increased MNC number, as the ligated/healthy paw perfusion ratios in the 2x106 MNC and 
5x105 groups were 0.75±0.07 and 0.67±0.07, respectively, as compared to 0.62±0.07 in the PBS 
group (P=NS). However, no significant differences were observed during the prolonged follow 
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figure 4. laser Doppler Perfusion imaging (lDPi) of ischemic hind limbs following intramuscular mnC 
therapy. (a) Graphic representation and (b) quantification of paw perfusion by LDPI show a significantly decre-
ased perfusion in the affected left hind limbs as compared to the healthy paw. While a dose-dependent trend 
towards faster recovery can be observed 3 days after ligation, no significant differences were measured over a 
total time period of 28 days (Repeated measurements ANOVA, * indicates P<0.05).
Histological confirmation of short-term lDPi findings. To investigate whether in vivo LDPI 
matched the actual presence of collaterals, post-mortem histological staining for α-smooth 
muscle actin was performed. As shown in figure 5, no significant differences in collateral den-
sity and collateral size in the post-ischemic adductor muscle were found after a single MNC 
injection, repeated MNC injections, and saline (PBS) injection at week 4, further confirming the 
lack of functional improvement seen in LDPI results. 
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figure 5. immunohistochemistry analysis of arteriogenesis within the post-ischemic adductor muscle. 
Representative pictures of anti-α smooth muscle staining of (a) single 2x106 MNC-injection, (b) weekly 5x105 
MNC-injection, and (c) PBS treated mice. Quantification of (d) mean number of collaterals and (e) mean collateral 
size showed no significant differences among different study groups four weeks after surgery(P=NS, ANOVA).
Confirmation of short-term lDPi findings. To further explore the observed short-term effect 
of cell therapy on paw perfusion, we performed an apoptosis specific ELISA on the affected 
gastrocnemius muscles. We hypothesized that increased monocytic cell numbers may have 
beneficial effects on ischemia-induced apoptosis in the muscular tissue. Thus, to investigate 
if higher perfusion ratios lead to tissue preservation, gastrocnemius muscles were assayed for 
DNA fragments in mono- and oligonucleosomes. As shown in figure 6, treatment with both 
single 2x106 MNCs and weekly 5x105 MNCs led to significantly (P=0.03 and P=0.02, respectively, 
ANOVA) decreased amount of fragmented DNA (mirroring apoptosis) as compared to the PBS 
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figure 6. Quantification of short-term apoptotic rates in gastrocnemius muscles of mnC treated animals. 
ELISA for histone-associated DNA fragments in mono- and oligonucleosomes of digested gastrocnemius mus-
cles revealed an almost 3-fold increase in apoptosis following left femoral artery ligation and PBS treatment as 
compared to the healthy contralateral muscle as well as compared to MNC treated animals (*P<0.05, ANOVA).
In vivo molecular imaging of mnC homing. To date, most clinical trials have used a trans-
plantation approach that is based on direct delivery into the affected muscle.9 Others have 
chosen strategies that rely on stimulation of natural homing of progenitor cells to the affected 
area.10 While the current studies with intramuscular injections of MNC suggest that low cell 
survival might underlie a lack of functional effect, there is no such data available for systemic 
injection of MNC. Therefore, FVB mice were injected i.v. with 5x106 MNC 1 day following ische-
mia and were imaged by BLI until day 14. As shown in figure 7, the initial BLI signals on day 0 (1 
hour after transplantation) equaled background levels, thus confirming the cells were spread 
out through the circulatory system, without signs of retention in the pulmonary capillaries as 
observed in previous studies with larger size cell types such as mesenchymal stem cells.11 Over 
time, however, signal intensity to the injured area increased. In addition, signals arose from 
the bone marrow, spleen, and liver, which indicate homing patterns that mimic endogenous 
myelomonocytic pathways.12 
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figure 7. In vivo visualization of systemically injected mnC by bli. (a,b) One day after left femoral artery 
ligation, 5x106 MNCs were injected via tail vein injection and monitored for 10 days. In vivo BLI pictures and signal 
quantification on multiple time points show that after an initial low signal period due to scattered MNCs throug-
hout the body, cells then travelled to the injured area but also showed preference for the liver, bone marrow, and 
spleen. Scale bars represent BLI signal in photons/s/cm2/sr (P=NS, ANOVA).
Ex vivo confirmation of in vivo patterns of cellular kinetics. To validate and further spe-
cify the observed in vivo findings, organs were procured immediately following euthanization. 
As shown in figure 8a, BLI following dissection of the skin showed in situ signals from liver, 
spleen, and the long bones similar to in vivo results. However, the signals that were previously 
observed from the injured area in vivo were now largely concentrated in the subcutaneous fat 
pad as well as in the femoral bone. Indeed, when the different tissues were explanted, it be-
came clear that there was only a low signal from the adductor muscle, while equally strong sig-
nals were observed from the scarred skin, the subcutaneous fat pad, and the bone marrow in 
the femoral bone. Thus, this ex vivo imaging confirmed the in vivo signals from liver and spleen. 
Moreover, the presence of GFP+ donor MNCs in the bone marrow was validated with flow cyto-
metry (figure 8b). Taken together, these experiments showed that BLI is a reliable method to 
monitor MNC trafficking in an in vivo fashion. Homing to the injured area was not limited to the 
adductor muscle, but also occurred to other areas of injury as well as more natural biological 
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figure 8. Ex vivo confirmation of in vivo mnC distribution patterns. (a) Graphic in vivo representation of MNC 
retention in liver, spleen, and bone marrow. Surprisingly, removal of the skin leads to a remarkable reduction of 
signal intensity from the scarred area. After explantation of various organs and ex vivo BLI, the signal that was 
previously observed from the injured area during in vivo experiments appeared to be a cumulative signal from 
MNC retention from skin, subcutaneous tissue, and muscle. Scale bars represent BLI signal in photons/s/cm2/sr.
(b) To confirm the BLI signals from the bone marrow, the marrow was flushed from the bone and processed 
through flow cytometry for GFP+ donor cells. The flow cytometry results correlated with the BLI results, as the 
recipient bone marrow indeed contained Fluc+/GFP+ donor MNCs.
monitoring effects of intravenously injected mnC therapy in severe PAD. The PAD mo-
del as described above has been used and validated multiple times in C57BL/6 mice.13 The 
reason for using FVB mice in the previous experiments was to establish a clinically equivalent 
model of autologous cell transplantation as our F6 transgenic donor mice were bred on FVB 
background. However, we observed a robust endogenous recovery of arteriogenic response 
following ischemia by 4 weeks (see the PBS injection group in Figure 4B), which can be speci-
fic for FVB mice.14 Therefore, to investigate the functional effects of intravenous injection and 
subsequent MNC homing to the ischemic environment, another strain of C57BL/6 mice under-
went electro-coagulation of both the common iliac and femoral artery to ensure profound and 
more durable ischemia. One day post-operation, 5x106 MNCs or PBS as control were injected 
(n=10 per group), and paw perfusion was again measured by LDPI. As shown in figure 9, the 
ischemic/non-ischemic paw perfusion ratio decreased dramatically from an overall mean of 
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1.04±0.04 pre-operation to 0.04±0.01 post-operation (P<0.0001). Indeed, the current surgical 
model resulted in sustained loss of perfusion over 4 weeks. However, intravenous injection 
of MNCs was still incapable of restoring paw perfusion in a significant matter, with ratios of 
0.60±0.07 in the cell group compared to 0.57±0.08 in the PBS group (P=NS) 4 weeks after ope-
ration. 
figure 9. functional results following systemic mnC injection after severe hind limb ischemia. (a) Follo-
wing ligation of both the femoral and iliac arteries, markedly decreased paw perfusion was observed for a pro-
longed period. (b) Quantification of paw perfusion revealed systemic MNC injection was not capable of restoring 
paw perfusion significantly better than PBS treatment during. (P=NS, Repeated measurements ANOVA).
DISCUSSION
This is the first study to evaluate post-transplant MNC behavior in a murine model of PAD using 
in vivo molecular imaging techniques. The major findings can be summarized as follows: (1) BLI 
is a valid tool to monitor MNC survival, proliferation, and migration; (2) MNC survival following 
a single intramuscular injection is short-lived; (3) repeated MNC injections do not provide sig-
nificantly prolonged cell survival; (4) homing of MNCs following intravenous injection is not 
limited to the area of injury; and (5) neither intramuscular nor intravenous injection of MNC 
results in an increased paw perfusion.
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Yuyama and colleagues9, over 25 clinical trials have been registered on www.clinicaltrials.gov, 
using either intramuscular or systemic injections into the ischemic leg. Although the findings 
from this first study were hopeful, so far these results have not been confirmed by large rando-
mized clinical trials. The initial thought behind the use of progenitors cells in regenerative me-
dicine was that it could truly regenerate the damaged tissue by forming new blood vessels15, 
skeletal muscle16, or even myocardium.17 However, since the true regenerative capacity has 
been questioned18, and considering the poor survival capacity of MNC and other progenitor 
cells in this and other studies thus far5, a more plausible explanation for a possible beneficial 
effect would be the secretion of protective cytokines as suggested before.19 Indeed, it has re-
cently been shown that a more profound angiogenic response can be achieved in ischemic 
muscle by transplanting progenitor cells overexpressing both VEGF and SDF-1.20 Alternatively, 
to achieve true regeneration, one could switch to more specialized cell types rather than whole 
MNCs. In this respect, it has recently been shown that embryonic stem cell-derived endothelial 
cells can improve perfusion due to the favorable effect of engraftment and biological acti-
vity.21 Thus, in the future, it might be a feasible approach to use a set of growth factors by gene 
therapy, increase survival of specialized cells (e.g., embryonic stem cell or induced pluripotent 
stem cell derivatives), or use a combination of these two.
Previous studies have assessed MNC function and mechanism following transplantation into 
the ischemic leg largely using post-mortem histological techniques.22 However, this requires 
euthanizing the animal, thereby increasing inter-animal variance and preventing longitudinal 
studies of the same subject. Moreover, the search for scant donor cells on histological slides 
from all organs is extremely difficult and time consuming. As a consequence, these techniques 
are less suitable for studying the kinetics of cells through the body over time. In contrast, in 
this study we have used our molecular imaging platform based on the double-fusion reporter 
construct carrying Fluc+/GFP+, to yield valuable insight into longitudinal cell fate. By doing so, 
we were able to track the spatiotemporal kinetics of MNC homing, retention, and survival in a 
murine model of PAD. 
Interestingly, we observed a relatively limited cell survival after intramuscular injection in the 
adductor muscle. After a short-term post MNC transplantation increase in BLI signal until day 
3, a rapid decrease in BLI-signal intensity to background levels after four weeks was observed. 
The limited cell survival was confirmed by the immunohistochemical staining against GFP+ 
cells. One week after the fourth transplantation of 5x105 MNCs, low numbers of these cells 
could be found near blood vessels, suggesting a role in neovascularization, or indicating these 
cells prefer the adjacency of oxygenated blood. The poor survival in the adductor muscle, ho-
wever, is interesting since femoral artery ligation results in less profound ischemia in the ad-
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ductor muscle as compared to the gastrocnemic muscle. This suggests that even in a normoxic 
niche, MNCs require more biologically attractive environments to be capable of robust survi-
val. This once again stresses the need for development of cell survival augmenting approaches 
such as scaffolds or transduction of cells with pro-survival factors.
Results from this study show that, following systemic injection, MNCs migrate extensively to 
the bone marrow, spleen, and liver. This pattern indicates MNCs travel to their natural biologi-
cal niches as all of these organs play a role in intra- and extramedullary hematopoiesis. Confir-
ming this observation, our BLI findings are concordant with previous leukocyte scans showing 
retention in the liver and spleen.23 Apparently, the chemoattractant properties of these organs 
are stronger than the ischemic environment in the affected muscle. For future experiments, it 
is important to improve homing to the ischemic muscles which may increase arteriogenic re-
sponse as measured by LDPI. This can be realized in two ways: 1) improving the attractiveness 
of the target environment with, for example, the MNC mobilizer stromal-derived factor-1 (SDF-
1)24; or 2) manipulating the cells to become more specifically guided. In this respect, it might be 
a better approach to isolate a subset of the mononuclear fraction such as the CD14+ expressing 
cells that are expected to play a more active role in the restorative process after ischemia.25 
Taken together, this is the first study to monitor the kinetics of MNCs in PAD in an in vivo fashion 
using molecular imaging techniques. Results from this study highlight caution should be exer-
cised when interpreting results from experimental and clinical studies. The poor survival and 
homing patterns warrant further research toward better retention and increased biological 
activity of the cells in the injured area. By doing so, cell therapy might develop as a valuable 
option for treating end-stage PAD.
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INTRODUCTION
Over the past years, stem cell therapy has raised tremendous enthusiasm as a potential treat-
ment for cardiovascular diseases. However, questions remain about the in vivo behavior of the 
cells after transplantation and the mechanism of action with which the cells could potentially 
alleviate disease symptoms. The objective of the research described in this thesis was to visu-
alize the survival, proliferation, and migration of both embryonic and adult stem cells using 
non-invasive molecular imaging techniques in small animal models of cardiovascular diseases. 
The major findings can be described as follows: (1) Non-invasive bioluminescence imaging 
is a validated tool to monitor donor cell survival, proliferation, migration, and misbehavior; 
(2) Embryonic stem cells (ESC) are a potential source for a true regenerative therapy; (3) ESC 
form teratomas; (4) Adult stem cell survival is short-lived, but of all adult stem cells currently 
used in the clinic, mononuclear cells show the most prolonged survival; (5) Transplantation of 
mononuclear cells can preserve cardiac function in the short term after myocardial infarction 
in mice; (6) Compared to other measurements of cardiac function in mice, Micro-CT is a supe-
rior, three-dimensional, non-invasive method to assess cardiac geometry and function; and (7) 
Transplantation of mononuclear cells in peripheral artery disease is hampered by dismal cell 
survival and homing.
MONITORINg EMBRyONIC STEM CELL THERApy
In this thesis we have provided, largely for the first time, insight in the in vivo cellular behavior 
of adult and ESC. In Chapter 2, we have shown that ESC transplantation results in superior pre-
servation of cardiac function in the short term compared to fibroblasts, as measured by small 
animal MRI that was confirmed by invasive hemodynamic measurements. However, novel bio-
luminescence imaging of the GFP+/Fluc+ ESC revealed a robust increase in BLI signal as early 
as two days post-transplant. After having shown that increasing BLI signal is in fact representa-
tive of an increase in cell number in vitro by BLI and that in vivo BLI signals correlated well with 
ex vivo TaqMan PCR, the increasing signal in vivo was clearly a consequence of cell proliferation. 
This early, in vivo suggestion of teratoma formation was supported by gross histology showing 
intense accumulation of donor cells. 
As a follow-up study, Chapter 3 nicely outlined the importance of using BLI to monitor cell fate 
after ESC transplantation. Indicative of the sensitivity of this technique, we observed increa-
sing signals, implying teratoma formation, as early as one week after subcutaneous transplan-
tation of as little as 1000 ESC. Correlating with the BLI results, teratoma formation was indeed 
confirmed by post-mortem histology showing differentiation of ESC to progeny from all three 
germ layers. The chapter also showed the importance of being able to perform whole-body 
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were easily identified by BLI. Finally, the stable integration of the GFP/Fluc construct in the 
donor ESC and the persistence of cell retention in the heart was illustrated by experiments 
showing follow-up of intramyocardially transplanted ESC in vivo as long as 10 months. These 
above mentioned advantages of using molecular imaging techniques to monitor ESC trans-
plantation were summarized and related to the great potential of ESC to treat a wide variety 
of diseases in Chapter 4. Chapter 5, on the other hand, focused on the potential of ESC to 
differentiate into cardiomyocytes while indicating some of the hurdles that need to be over-
come before ESC-derived-cardiomyocyte therapy will face the clinic. Next to the possibility of 
teratoma formation following inefficient pre-differentiation and subsequent transplantation 
of a heterogeneous population, this chapter also discussed the problems of immunogenicity 
and stable integration within the host myocardium.
MONITORINg ADULT STEM CELL THERApy
Chapter 6 was designed to answer the basic question: Which adult stem cell already clinically 
used in heart failure trials in humans can best preserve cardiac function after myocardial in-
farction in mice? To monitor cell fate after transplantation, all cells were isolated from donor 
mice that transgenically expressed both GFP and Fluc. After multimodality in vitro validation of 
reporter gene expression in all cell types, in vivo BLI results showed extensive donor cell death 
from skeletal myoblasts (SkMb), mesenchymal stem cells (MSC), and fibroblasts (Fibro, a cel-
lular control) within three to four weeks after transplantation. Mononuclear cells (MN), on the 
other hand, were still present after 6 weeks, although in low numbers. Interestingly, these cells 
proliferated during the inflammatory phase (first ten days) after infarction, while some cells 
that had leaked into the circulation homed to the spleen, liver, and bone marrow later on. Our 
echocardiography studies, validated by invasive hemodynamic measurements, showed signifi-
cantly improved cardiac function in mice that had received mononuclear cells as compared to 
negative (saline injection) and cellular (fibroblast injection) controls, while skeletal myoblasts 
were only significantly better than the negative controls. On the contrary, mesenchymal stem 
cells had no significant functional effect. Interestingly, however, deterioration of cardiac func-
tion was observed between 4 and 6 weeks in all cellular groups without such an effect in the 
saline control group, suggesting that the preservation lasts only for a short time. However, this 
can only be confirmed by future long-term studies. 
In addition to the findings described in the previous chapter, Chapter 7 provided for the first 
time in vivo information on the cellular kinetics of adipose tissue-derived stromal cells when 
transplanted into the infarcted mouse heart. This recently discovered cell population is be-
lieved to be similar to mesenchymal stem cells from the bone marrow. Indeed, these cell types 
shared similar morphology, cell surface expression patterns, and in vitro behavior. Unfortu-
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nately, however, neither cell type was capable of surviving the ischemic environment of the 
infarcted heart and cell death ensued within 4 weeks of transplantation. Moreover, we did not 
observe any functional effect by echocardiography and pressure-volume loops.
In the studies described above, echocardiography proved to be an easy-to-use, quick moda-
lity to measure cardiac function in mice, and acquired diameters were generally correlative 
to ventricular volumes measured by conductance catheters. However, echocardiography is 
limited by means of its two-dimensionality while performing pressure-volume loops with a 
conductance catheter is a terminal procedure. In Chapter 8, we therefore introduced a novel, 
three-dimensional, in vivo modality to our inventory. The model of murine myocardial ische-
mia was used to show good correlations between Micro-CT and the more conventional ima-
ging modalities. However, Micro-CT proved to gain the most detailed, precise measurements 
of systolic and diastolic cardiac geometry and subsequent functional parameters. Moreover, 
in vivo images acquired with Micro-CT resembled ex vivo post-mortem histological pictures of 
ventricular morphology.
Finally, Chapter 9 provided insight into the kinetics of mononuclear cells (MN) after intra-
muscular and intravenous transplantation into a mouse model of peripheral artery occlusive 
disease. Intramuscular injection, either by single or repeated dosages, resulted in dismal cell 
survival without any effects on restoration of perfusion as measured by Laser-Doppler Perfusion 
Imaging. Following intravenous injection, regular in vivo BLI revealed homing to the injured 
area, although not exclusively. Signals were also observed from liver, spleen, and bone marrow. 
Moreover, ex vivo BLI showed that signals from the injured area were predominantly the result of 
homing to the scarred skin and the manipulated subcutaneous fat pad rather than the ischemic 
muscle. These findings translated into a lack of functional effect on paw perfusion.
NON-INvASIvE MOLECULAR IMAgINg: kEEpINg AN EyE ON TRANSpLANTED 
CELL SURvIvAL, pROLIFERATION, MIgRATION, AND MISBEHAvIOR.
The common technique used in the studies described in this thesis was non-invasive biolu-
minescence imaging. The double-fusion reporter construct carrying GFP and Fluc, on which 
this imaging technique was based, proved to be stably integrated into the donor cell’s DNA as 
confirmed by in vitro BLI and luminometry. Moreover, in vivo BLI signals were validated by ex 
vivo quantitative PCR techniques as well as post-mortem histology and flow-cytometry with 
staining for GFP. Thus, BLI is a validated tool to image cell quantity as its signal is representative 
of cell number due to the equal transmission of the reporter genes to daughter cells. Subse-
quently, the adult stem cell studies have shown this technique to be suitable to image cell sur-
vival and migration. The fact that dead cells lack the transcriptional and translational process of 
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Furthermore, the ESC studies have emphasized the excellent value of BLI to monitor cell loca-
tion, proliferation, and misbehavior. Taken together, BLI is an indispensible tool for imaging the 
effects and safety of cell therapy. However, BLI uses low-energy 2-3 eV photons, which leads 
to photon attenuation and scattering within deep tissues.1 Moreover, at present the imaging 
system containing the ultrasensitive CCD camera is unavailable for large animals or humans. 
These factors make this technique currently unsuitable for large animal or clinical safety stu-
dies. Instead, clinical molecular imaging techniques are currently based upon the utilization 
of Positron Emission Tomography (PET) with its associated reporter construct herpes simplex 
virus thymidine kinase (HSV-tk). Following injection of a radiolabeled thymidine analog (e.g. 
[18F]fluoro-3-hydroxymethylbutylguanine or [18F]-FHBG), the donor cells carrying HSV-tk will 
phosphorilate and subsequently trap the probe inside the cell, producing a signal consisting of 
high-energy photons strong enough for deep tissue imaging. This HSV-tk reporter gene con-
struct has been used in small2 and large animal3 studies as well as in human trials.4 Due to the 
fact that every imaging modality has its advantages and drawbacks, it is important to develop 
reporter gene constructs that combine different techniques. In this respect, we have shown 
the promise of the double fusion construct carrying Fluc and GFP for BLI and immunohistoche-
mistry (IHC) in the studies described, respectively. Moreover, our group has developed a triple 
fusion construct containing Fluc, red fluorescent protein (RFP), and tk, thereby enabling BLI, 
IHC, and PET imaging.5 Additionally, reporter gene imaging can be combined with magnetic 
labeling to enable superior imaging of acute localization of transplanted cells by MRI.6
CLINICAL UpDATE
To date, over 250 and almost 30 clinical trials are registered for heart disease and peripheral 
artery occlusive disease, respectively (http://clinicaltrials.gov/), illustrating the huge enthusi-
asm for cell therapy among doctors, patients, and media. As to cardiac cell therapy, studies 
greatly differ in patient population (acute vs. chronic ischemia), cell type and the administered 
quantity, method and timing of delivery, and duration of follow-up. Moreover, the majority of 
results comes from non-blinded trials. 
So far, two meta-analyses have been published, both of which analyzed the efficacy of cell the-
rapy for acute ischemic heart disease. Abdel-Latif and colleagues analyzed 18 controlled stu-
dies and generally, cell injection showed no increase in adverse events. Improvements in car-
diac function with cell transplantation included a significant 3.66% increase in left ventricular 
ejection fraction and a significant 5.49% reduction in infarct size.7 A second meta-analysis was 
performed by Lipinski and colleagues. After analysis of 10 studies, intracoronary cell therapy 
showed a significant decrease in recurrent myocardial infarction, but no difference in morta-
lity risk and rehospitalization. Cell therapy resulted in a 2.97% increase in ejection fraction, 
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decreased end-systolic volume, and a 5.28% reduction in perfusion defect size.8 Despite the 
statistically significant numbers from both meta-analyses, these studies do not clearly provide 
information whether these numbers translated into clinically relevant improvements in quality 
of life.
A recent Cochrane systematic review by Martin-Rendon and colleagues described 13 rando-
mized controlled trials with a cumulative of 880 patients that received percutaneous intra-
coronary infusion of cells following acute ischemia. This review modestly concluded that cell 
therapy for acute myocardial infarction may be safe and moderately beneficial. However, the 
trials included were too small to demonstrate whether this therapy may have an effect on the 
incidence of mortality and morbidity.9
Regarding cell therapy for peripheral artery occlusive disease, the data are still rather preli-
minary, as most studies do not provide adequate patient numbers for definitive conclusions. 
Although small studies such as the initial TACT investigation show promising results inclu-
ding a 4-week increased ankle-brachial index, decreased rest pain and increased pain-free 
walking time,10, 11 these observations require large, multicenter randomized trials to confirm 
the ability of cell therapy for relieving symptoms and improving quality of life in peripheral 
artery occlusive disease. 
         
fUTURE DiRECTions 
This thesis has shown that there are certain advantages and drawbacks of stem cell therapy for 
cardiovascular diseases. On adult stem cells, a functional benefit, if present, may be the result 
of paracrine signaling protecting host cells from dying, attracting native stem cells, attenuating 
remodeling, and inducing arterio-/ angiogenesis. However, this activity may be limited by poor 
cell survival which may explain short-term effects in our studies and some large clinical trials.12 
Therefore, one major goal should be to develop strategies that improve cell survival or increase 
the downstream effects as described above. In this regard, it may be of significant benefit to 
stimulate the cells using specific growth factors. Overexpression of certain factors might both 
increase survival as well as augment the biological function of adult stem cells. Supporting this 
hypothesis, researchers have shown that transfection of mesenchymal stem cells with the pro-
survival gene Akt not only increased cell survival, but also augmented the functional effect on 
the infarcted heart.13 More research will nevertheless be needed to discover the optimal com-
bination of transcriptional factors needed to establish a significant, clinically relevant benefit 
of cell therapy. However, one must keep in mind the mechanism that might lead to this objec-
tive. If the stem cells do not have the capacity to become cells of the target tissue (cardiomyo-
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artery disease) the question remains whether prolonged survival is necessary. If the effect of 
adult stem cells is merely a consequence of paracrine signaling, an approach whereby a slow-
release cocktail of cytokines is infused might be just as effective. Alternatively, a gene therapy 
approach whereby the host tissue is modified to express pro-angiogenic or pro-survival genes 
could still be very promising. Taken together, in the case of cardiovascular disease, adult stem 
cell therapy seems to be more of a preservative therapy rather than a true regenerative therapy 
and has yet to be optimalized on the basis of more mechanistic studies.
ESC, on the other hand, have shown to be capable of really rebuilding the heart muscle, as we 
have observed that they form cardiomyocytes in vivo. Even if the frequency of this rare event 
can be increased or if ESC-derived cardiomyocytes can be purely grown in culture and subse-
quently transplanted, it remains questionable if these cells can truly integrate with native tis-
sue and, importantly, will contract synchronously and respond effectively to the natural pacing 
of the heart. This problem has an extra dimension because ESC-derived cardiomyocytes ap-
pear to consist of both atrial and ventricular types that may react differently upon pacing. This 
illustrates the great caution warranted when using these cells for transplantation. Two other 
major problems we have visualized or addressed in this thesis concern tumorigenicity and 
immunogenicity. The development of more efficient pre-differentiation systems may make it 
possible to obtain 100% pure populations of a desired cell type from undifferentiated ESC cul-
tures, thus limiting the possibility of present undifferentiated, potentially tumorigenic cells. Ac-
cordingly, it should be stressed that imaging cell therapy is indispensible as malignant events 
should be detected at an early stage. In this respect, one major advantage of using reporter 
gene imaging with the HSV-tk construct is the possibility to use this construct as a suicide gene 
as it is responsive to gancyclovir treatment. As such, the donor cells can be targeted when 
imaging reveals misbehavior, possibly preventing teratoma formation.5
One other ESC-related problem involves immunorejection. Great progress has recently been 
made by our group to characterize the immunogenic pattern of ESC. Similar to organ trans-
plants, the rejection of embryonic stem cell grafts is CD4-mediated which can be largely over-
come by treatment with immunosuppressive drugs.14 Although these findings illustrate the 
increased understanding of ESC biology and development, consequently embryonic stem cell 
therapy will pose the patient to a life-long treatment to immunosuppressive drugs including 
the associated complications. Lastly, and very important, are the ethical issues that are associ-
ated to the derivation of cells from embryonic tissue. However, a great breakthrough has been 
established that has changed the field of stem cell research dramatically.
Recently, a Japanese group has published a report showing the possibility of using transcrip-
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tion factors to reprogram adult stem cells (fibroblasts) to less differentiated states, where af-
ter these cells regain capability to differentiate into all germ layers.15 These observations may 
redefine the differentiation patterns as described in the introduction of this thesis, now sho-
wing that, by in vitro manipulation, germ layer- or tissue lineage boundary limitations can be 
overcome. These so-called induced pluripotent stem cells (iPSc) seem to resemble ESC, but 
circumvent ethical and immunogenicity problems, offering the possibility to develop patient- 
and disease specific stem cells. Not only could this lead to new cell replacement therapies 
for tissue otherwise incapable of endogenous regeneration, but iPSc can also serve as in vitro 
surrogates for testing drug efficacy and toxicity specific to a disease or patient. While the op-
portunities seem innumerable, iPSc remain to be characterized more thoroughly regarding, 
among others, differentiation capacity and energy metabolism.
One last modality that will likely regain significant interest is gene therapy. As the effect of cell 
therapy may largely depend on the paracrine action of the cells rather than their structural, 
long lasting support, it would perhaps make more sense to ‘train’ the host cells to exhibit the 
paracrine character needed to stimulate, for example, angiogenesis. In order to provide a signi-
ficant beneficial effect, it is yet to be investigated which factor is a key modulator of the process 
of angiogenesis, and create a vector that is non-immunogenic and grants an efficient, long 
lasting transfection. Ultimately, reporter gene imaging can be combined with gene therapy, 
allowing for in vivo monitoring of gene expression and dosing. Combining knowledge from 
imaging, cell therapy, and angiogenesis studies, we are currently moving forward in achieving 
these characteristics and hope to provide a novel gene therapy agent for cardiovascular disea-
ses in the near future. 
FINAL REMARkS
The field of adult stem cell therapy for cardiovascular disease has provoked an enormous 
amount of enthusiasm, leading to a clinical translation of experimental findings with unpre-
cedented rapidity. Such transitions cannot solely be based on findings in experimental rodent 
models, as the results from the studies described in this thesis are not always concordant to 
findings from clinical studies. This emphasizes the current gap that exists between animal mo-
dels and human disease and justifies extensive investigations in large animals or even primates 
before proceeding to any kind of clinical trial with cardiomyocytes. Regarding ESC or iPSc, it is 
of main importance to characterize these cells, explore the way they differentiate, and portray 
their genomic and proteomic patterns. Luckily, research in this field has been given a boost by 
recent developments since president Obama issued Executive Order 13505 entitled “Remo-
ving Barriers to Responsible Scientific Research Involving Human Stem Cells” (http://stemcells.
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tutes of Health was restored after being strongly limited for eight years under the previous 
administration. Hopefully, this will lead to a better understanding of developmental biology, 
disease, and therapeutic targets for the large range of diseases that can benefit from new tre-
atments, not at the least for cardiovascular diseases (figure 1). In all these settings, molecular 
imaging should and will indisputably form an important tool in assessing the efficacy in both 













figure 1. Promises and directions of stem cell research (www.nih.gov)
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STAMCELLEN vOOR HART- EN vAATzIEkTEN
Hart- en vaatziekten zijn de belangrijkste doodsoorzaak in de westerse wereld en kostten de 
Nederlandse samenleving in 2005 5.5 miljard euro aan ziektekosten (8% van het totaal). Met 
de huidige trend naar een verouderende en adipeuzere samenleving zullen deze getallen naar 
verwachting de komende jaren nog flink toenemen.
Ondanks een variëteit aan behandelingen is er nog een grote groep patiënten die niet goed 
reageert op bestaande therapie en zodoende aangewezen is op harttransplantatie in het ge-
val van hartfalen of amputatie van een been wanneer het perifeer arterieel vaatlijden (PAV, ver-
gevorderde aderverkalking in ledematen) betreft. Echter, harttransplantatie is, onder andere 
door een schrijnend tekort aan donororganen, slechts in een select aantal gevallen mogelijk 
en zodoende is er behoefte aan nieuwe therapeutische opties.
Stamceltherapie heeft de afgelopen jaren veel enthousiaste en hoopvolle reacties teweeg ge-
bracht. Een stamcel is een cel die aan het begin van de ontwikkeling staat en kan uitgroeien 
tot verschillende soorten meer gespecialiseerde celtypen. Bovendien heeft een stamcel de ca-
paciteit om zichzelf te vermenigvuldigen. Door deze twee eigenschappen biedt een stamcel 
theoretisch de mogelijkheid voor het kweken van een onuitputbare hoeveelheid weefsel-spe-
cifieke cellen om bijvoorbeeld cardiomyocyten (hartspiercellen) te vervangen of bloedvaten te 
vernieuwen. Omdat het lichaam dat aan hart- en vaatziekten lijdt zelf niet of zeer beperkt de 
mogelijk heeft tot regeneratie van deze weefsels, zou het inspuiten van stamcellen een oplos-
sing kunnen zijn voor een groot maatschappelijk gezondheidsprobleem. 
Er zijn verschillende soorten stamcellen, die grofweg verdeeld kunnen worden in drie soor-
ten: Embryonale stamcellen (ESC), volwassen stamcellen en de recent ontdekte geïnduceerd-
pluripotente stamcellen. De studies in dit proefschrift zijn gericht op de eerste twee groepen.
ESC vormen de binnenste celmassa van de blastocyst, het embryo in een zeer vroeg ontwikke-
lingsstadium 5 dagen na bevruchting. Na isolatie kunnen ESC onder strikt gehandhaafde con-
dities op een onderlaag van bindweefselcellen oneindig delen. ESC zijn pluripotent en kunnen 
zich differentiëren naar alle kiemlagen (endo-, ecto-, en mesoderm, een soort tussenstation in 
celdeling) en verder naar iedere cel van het menselijk lichaam. 
In tegenstelling tot ESC zijn volwassen stamcellen multipotente cellen. Dat wil zeggen dat zij 
al een stap in de ontwikkeling hebben ondergaan en zich reeds in een bepaalde kiemlaag be-
vinden. Volwassen stamcellen kunnen zich nog wel verder specialiseren naar een variëteit aan 
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aanwezig in het volgroeide menselijk lichaam in onder andere het beenmerg, de huid, en de 
darm en zijn verantwoordelijk voor de constante vernieuwing van deze weefsels. 
Sinds wetenschappers aan het begin van dit millennium beschreven dat beenmergcellen na 
het inspuiten in de beschadigde hartspier differentiëren naar cardiomyocyten is het veld van 
stamceltherapie voor hart- en vaatziekten in een stroomversnelling geraakt. Ondanks het feit 
dat deze observatie controversieel is gebleken, werden binnen afzienbare tijd klinische trials 
gestart waarin de effectiviteit van beenmergcellen voor de behandeling van myocardinfarct 
en PAV werd onderzocht. De resultaten van deze trials zijn wisselend positief maar vertonen 
onderling verschillende uitkomsten. Dit onderstreept het gebrek aan kennis over wat er met 
de cellen gebeurt na transplantatie en op welke manier deze cellen al dan niet bijdragen aan 
herstel of preservatie van hart- of spierfunctie.
In vIvo MOLECULAR IMAgINg vAN gETRANSpLANTEERDE STAMCELLEN
Om het mechanisme te bestuderen waarmee getransplanteerde cellen wel of niet aan func-
tioneel herstel bijdragen is het van groot belang om inzicht te verkrijgen in het gedrag van 
stamcellen na transplantatie. Dit wordt meestal gedaan door in experimentele modellen de 
stamcellen te markeren met conventionele reportergenen zoals Green Fluorescent Protein 
(GFP). GFP wordt geïsoleerd uit lichtgevende kwallen. Om GFP (en daarmee de gemarkeerde 
stamcellen) in beeld te brengen is het nodig om met een uitwendige lichtbron de GFP van 
energie te voorzien. Dit heeft tot gevolg dat er een hoog achtergrondsignaal ontstaat. Boven-
dien wordt een deel van het signaal geabsorbeerd door het omliggende weefsel waardoor het 
moeilijk is gemarkeerde stamcellen in dieper gelegen locaties te identificeren wat deze me-
thode minder geschikt maakt voor beeldvorming in een levend dier (in vivo). Om deze reden 
wordt GFP beeldvorming meestal verricht op geëxplanteerde plakjes weefsel met behulp van 
histologie. Omdat dit het opofferen van het proefdier vergt ontstaat er met histologie echter 
slechts een beeld van een bepaald moment in plaats van een serie van gebeurtenissen over 
een langere periode. Echter, om het ware gedrag van getransplanteerde stamcellen in beeld 
te brengen is het van belang om de cellen herhaaldelijk over een langere periode, in vivo te 
kunnen volgen. Om dit te bewerkstelligen heeft onze onderzoeksgroep nieuwe, moleculaire 
beeldvormingtechnieken ontwikkeld.
Molecular Imaging wordt gedefinieerd als de in vivo karakterisatie van cellulaire en moleculaire 
processen. Dit staat of valt bij het ontwerpen van een geschikt reporter construct, dat bestaat 
uit een reporter gen gelinkt aan een promoter. Deze promoter kan altijd “aan” staan, geïndu-
ceerd ingeschakeld worden, of weefselspecifiek zijn. In de studies die in dit proefschrift wor-
den bechreven is bioluminescence imaging (BLI) met het reporter gen Firefly Luciferase (Fluc, 
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dat geisoleerd wordt uit vuurvliegjes) gebruikt achter een ß-actine promoter die in iedere cel 
tot expressie komt. Na het inbouwen van het reporter construct in de cel leidt transcriptie en 
translatie tot de productie van intracellulair Fluc eiwit. Op het moment dat de cellen in beeld 
gebracht dienen te worden wordt er een reporter probe (luciferin) in het proefdier gespoten, 
dat reageert met het reporter eiwit en een signaal afgeeft dat met een gevoelige CCD-camera 
opgevangen kan worden. 
Bovengenoemde methode heeft een aantal voordelen: Ten eerste blijft het proefdier leven wat 
het mogelijk maakt een situatie op meerdere tijdstippen te bekijken; ten tweede zal het Fluc 
eiwit slechts geproduceerd worden door levende cellen waardoor een beeld ontstaat van de 
celoverleving; Ten derde is het een methode waarbij het gehele dier in beeld komt zodat de 
celdistributie duidelijk wordt; en ten slotte is het niet nodig extrensiek excitatielicht te gebrui-
ken zodat er relatief weinig achtergrondsignaal ontstaat. 
BEELDvORMINg vAN EMBRyONALE STAMCELTHERApIE vOOR HART- EN vAAT-
zIEkTEN
Het doel van dit proefschrift was om duidelijkheid te verkrijgen op het gebied van stamcel-
overleving, -groei, en -migratie, en onbedoelde bijwerkingen van stamceltherapie.
Het eerste deel van het proefschrift is gericht op de voor- en nadelen van ESC therapie. In 
hoofdstuk 2 werd onderzocht wat er gebeurt als ongedifferentieerde ESC in het geïnfarc-
teerde muizenhart worden ingespoten. De functionele effecten op de korte termijn werden 
gevolgd met MRI en getest met invasieve drukmetingen. Er leek een functioneel voordeel te 
bestaan van het gebruik van ESC ten opzichte van de controletherapiën. Het belang van ge-
voelige in vivo beeldvorming van ESC werd onderstreept door snel stijgende signalen in de 
eerste week na transplantatie. Deze stijgende signalen bleken representatief voor groei van tu-
moren die uit verschillende soorten cellen bestonden (teratomen) met dezelfde achtergrond 
(ESC). Post-mortem histologie bevestigde de aanwezigheid van tumor en liet daarnaast zien 
dat een klein deel van de ESC daadwerkelijk hartcellen vormde.
Om meer inzicht te verkrijgen in de kwaadaardige aspecten van ESC therapie werd de stu-
die uit hoofdstuk 3 uitgevoerd. De experimenten illustreren de voordelen van BLI en laten 
zien dat slechts 100-1000 ongedifferentieerde ESC met BLI al zichtbaar zijn en dat diezelfde 
hoeveelheid al genoeg is om teratomen te vormen. Bovendien werd het belang van beeldvor-
ming van het gehele dier duidelijk omdat er niet alleen tumoren ontstonden ter plaatse van 
de injectie, maar ook op afstand in andere organen. Ten slotte konden ESC in het hart tot 10 
maanden gevolgd worden en werd zo duidelijk dat de integratie en expressie van de reporter 
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Hoofdstuk 4 biedt een overzicht van de voor- en nadelen van verschillende beeldvormingtech-
nieken voor het volgen van ESC therapie. Bovendien beschrijft dit hoofdstuk de grote variëteit 
aan ziekten waar ESC therapie mogelijk een nieuwe behandeling voor kan vormen. Hoofdstuk 
5 richt zich vervolgens meer specifiek op de mogelijkheid van het kweken van hartcellen uit 
ESC. Bovendien wordt hier bediscussieerd wat er gedaan dient te worden voordat ESC thera-
pie veilig in klinische studies gebruikt kunnen worden. Het gevaar van teratoomvorming blijft 
aanwezig indien de ESC voor transplantatie niet voldoende uitgekweekt worden naar meer 
gespecialiseerde celtypen en ontdaan worden van ongedifferentieerde cellen. Bovendien zijn 
ESC nooit van de patiënt zelf en leidt ESC transplantatie, net als orgaantransplantatie, onher-
roepelijk tot een afstotingsreactie. Tenslotte bestaat er het probleem dat getransplanteerde 
ESC wellicht niet goed integreren in het hartweefsel en op een andere manier reageren op 
signalen waardoor de getransplanteerde cellen mogelijk een ander ritme aannemen dan het 
omliggende spierweefsel.
BEELDvORMINg vAN vOLwASSEN STAMCELTHERApIE vOOR HART- EN vAAT-
zIEkTEN
Een belangrijke vraag die uit de grote hoeveelheid studies met verschillende soorten volwassen 
stamcellen naar voren kwam is: Welke volwassen stamcel kan de functie van het beschadigde 
hart het beste beschermen of verbeteren? Hoofdstuk 6 geeft hierop voor het eerst een ant-
woord. Verschillende soorten stamcellen werden geïsoleerd uit het beenmerg (mononucleaire 
cellen –MN- en mesenchymale cellen –MSC-), de spieren (skeletmyoblasten –SkMb-), en de huid 
(fibroblasten –Fibro-) van muizen die in iedere cel van hun lichaam de traceerbare, lichtgevende 
reportergenen Fluc en GFP tot expressie brachten. Na uitvoerige in vitro karakterisatie van repor-
tergenexpressie werden de cellen ingespoten in de hartspier van ongemodificeerde wild-type 
muizen die een hartinfarct hadden ondergaan. In vivo BLI liet vervolgens zien dat van alle cel-
typen, MN het langst overleefden waarbij er na zes weken nog een marginaal signaal aanwezig 
was in vergelijking tot maximaal 4 weken in de andere groepen. In overeenstemming met dit 
overlevingsvoordeel lieten de functionele testen (echocardiografie en invasieve hemodynami-
sche metingen) een significant voordeel van MN transplantatie zien ten opzichte van de con-
trolegroepen. Hierbij moet aangetekend worden dat in alle groepen die celtherapie ontvingen 
er een trend bestond van een verslechtering van hartfunctie tussen de vierde en zesde week 
na transplantatie, terwijl de hartfunctie in de controlegroep die slechts zoutoplossing ontving 
stabiel was. Deze bevinding suggereert dat het effect van celtransplantatie van korte duur is, 
hetgeen ook uit sommige klinische studies kan worden geconcludeerd. 
Een nieuwe groep stamcellen binnen het palet van klinische celkandidaten is aanwezig in het 
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vet. Er was veel enthousiasme rondom deze adipose-derived stromale cellen (ASC) omdat ze 
zouden lijken op MSC uit het beenmerg maar makkelijker te isoleren zijn. Na een in vitro evalu-
atie bood Hoofdstuk 7 voor het eerst een vergelijking van de in vivo kinetica en de functionele 
gevolgen op de beschadigde hartspier van beide celpopulaties. ASC en MSC deelden dezelfde 
morfolgische en groeieigenschappen en lieten een vergelijkbaar patroon van celexpressie 
zien. Ook in vivo gedroegen de cellen zich op eenzelfde manier wat helaas betekende dat zo-
wel ASC als MSC binnen vier weken afstierven. Bovendien was er met echocardiografie en inva-
sieve hemodynamische metingen geen functioneel voordeel te meten van celtransplantatie.
In de bovengenoemde studies werd de hartfunctie in vivo gemeten met echocardiografie. De 
metingen waren over het algemeen vergelijkbaar met de invasieve hemodynamische metin-
gen maar het tweedimensionale karakter maakt echocardiografie toch beperkt. In hoofdstuk 
8 werd daarom onderzocht of er wellicht ruimte was voor Micro-CT beeldvorming van het hart. 
Het muismodel van hartfalen werd gebruikt om te laten zien dat Micro-CT een betrouwbare 
manier is om in vivo de hartdimensies en –functie te meten op een driedimensionale manier. 
De resultaten van de Micro-CT correleerden met meer conventionele methoden maar bleken 
preciezer met betrekking tot geometrie en functionele uitkomst. Bovendien bood Micro-CT in 
vivo beelden die vergelijkbaar waren met post-mortem histologie.
Ten slotte maakt hoofdstuk 9 de overstap van hartziekten naar PAV. Er werd onderzocht wat 
er met getransplanteerde MN gebeurde na injectie in de bovenbeenspier of na systemische 
introductie bij muizen waarbij de bovenbeenslagader was onderbonden. Na injectie in de 
spier, zowel eenmalig als herhaald, waren de uitkomsten vergelijkbaar met de resultaten van 
de eerdere studies in het hart waarbij er marginale celoverleving was zonder effect op de door-
bloeding van het ischemische been zoals gemeten met Laser-Doppler Perfusion Imaging. Na 
intraveneuze injectie gevolgd door regelmatige BLI werd duidelijk dat een deel van de MN 
naar het aangedane gebied migreert, maar dat een minstens zo groot deel naar de lever, de 
milt, en het beenmerg afreist. Ex vivo BLI liet vervolgens zien dat het signaal uit het aangedane 
gebied met name het resultaat was van retentie van de MN in de beschadigde huid en het 
onderhuidse vet aldaar, meer dan daadwerkelijk in de aangedane spier. Dit migratiepatroon 
resulteerde in een gebrek aan functioneel effect.
CONCLUSIE
Dit proefschrift beschrijft het gedrag van zowel embryonale als volwassen stamcellen in mo-
dellen van hart- en vaatziekten. Terwijl ESC therapie daadwerkelijk regeneratief kan zijn en 
het beschadigde weefsel zou kunnen vervangen, heeft het de nadelen dat er gevaar is voor 
teratogeniciteit en dat de cellen bovendien een afstotingsreactie uitlokken. Deze gevaren be-
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aangedane gebied en lijken in de gebruikte modellen een marginaal functioneel effect te heb-
ben. Toekomstige studies dienen gericht te zijn op het minimaliseren van de gevaren van ESC 
transplantatie, de verbetering van celoverleving en functionaliteit van volwassen stamcellen, 
en de verdere karakterisatie van geïnduceerd-pluripotente stamcellen. Verdere ontwikkeling 
is nodig om stamceltherapie een waardevolle toevoeging te maken in het arsenaal van behan-
delingen voor hart- en vaatziekten. 
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